<SEC-DOCUMENT>0001193805-25-000757.txt : 20250530
<SEC-HEADER>0001193805-25-000757.hdr.sgml : 20250530
<ACCEPTANCE-DATETIME>20250530164433
ACCESSION NUMBER:		0001193805-25-000757
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250528
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250530
DATE AS OF CHANGE:		20250530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		251011726

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e664551_8k-immunicpricing.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:IMUX="http://imux.com/20250528">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_IMUX_imux.com_20250528 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250528_20250528 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001280776 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000004" name="dei:EntityCentralIndexKey">0001280776</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imux-20250528.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-28</xbrli:startDate>
        <xbrli:endDate>2025-05-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_905_edei--DocumentType_c20250528__20250528_zOpRTtdNLWBa"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT<br/>
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):&#160;<span id="xdx_901_edei--DocumentPeriodEndDate_c20250528__20250528_z5h5hcwPg6V4"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May
28, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20250528__20250528_zCYUeGcc6TY9"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000011" name="dei:EntityRegistrantName">IMMUNIC, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20250528__20250528_zcnN2RgBKoK4"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20250528__20250528_zEKsTGLqMbca"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000013" name="dei:EntityFileNumber">001-36201</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20250528__20250528_zXVCru2A7Jr9"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000014" name="dei:EntityTaxIdentificationNumber">56-2358443</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction<br/>
of incorporation)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(IRS Employer Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20250528__20250528_ztRc0gLpI3Ci"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000015" name="dei:EntityAddressAddressLine1">1200 Avenue of the Americas</ix:nonNumeric></span>,<span id="xdx_90B_edei--EntityAddressAddressLine2_c20250528__20250528_zf7Zui5bGap8"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000016" name="dei:EntityAddressAddressLine2">&#160;Suite 200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20250528__20250528_z8yj11ByvDDg"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000017" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>,&#160;<span id="xdx_903_edei--EntityAddressStateOrProvince_c20250528__20250528_zVfz7pAJ8c7f"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000018" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span>&#160;<span id="xdx_900_edei--EntityAddressPostalZipCode_c20250528__20250528_zM9DZDbQfMxd"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000019" name="dei:EntityAddressPostalZipCode">10036</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCountry_c20250528__20250528_zh3EXwZAsefj"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt-sec:countrynameen" id="Fact000020" name="dei:EntityAddressCountry">USA</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code:&#160;<span id="xdx_906_edei--CityAreaCode_c20250528__20250528_zBCckMw2wlZ8"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000021" name="dei:CityAreaCode">(332)</ix:nonNumeric></span>&#160;<span id="xdx_907_edei--LocalPhoneNumber_c20250528__20250528_zgLRUBAB8Gy"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000022" name="dei:LocalPhoneNumber">255-9818</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20250528__20250528_zCFLdbClg4Ad"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 95%"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--SolicitingMaterial_c20250528__20250528_zKUPYpdDSzGk"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20250528__20250528_zIdecwAwIKM2"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20250528__20250528_z1pxvFFU98jf"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 36%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font-size: 10pt">Name of exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20250528__20250528_zfQkcphfSZm9"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20250528__20250528_znCvgqTHuDi6"><ix:nonNumeric contextRef="AsOf2025-05-28" id="Fact000028" name="dei:TradingSymbol">IMUX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20250528__20250528_z3G0LMspIn05"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167; 240.12b2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20250528__20250528_zJVYNWSd4y58"><ix:nonNumeric contextRef="AsOf2025-05-28" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes &#9744;&#160;No&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 100%"><span style="font-size: 10pt"><b>Item 1.01. Entry Into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">On May 28, 2025, Immunic, Inc. (the &#8220;Company&#8221;) entered
into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink Partners LLC, as representative of the underwriters
named in Schedule A thereto, relating to the offering, issuance and sale of (i) pre-funded warrants to purchase an aggregate of 86,666,667
shares of common stock, par value $0.0001 (&#8220;Common Stock&#8221;) of the Company (the &#8220;Pre-Funded Warrants&#8221;), (ii) accompanying
series A warrants to purchase an aggregate of 86,666,667 shares of Common Stock of the Company (or Pre-Funded Warrants) (the &#8220;Series
A Warrants&#8221;), and (iii) accompanying series B warrants to purchase an aggregate of 86,666,667 shares of Common Stock of the Company
(or Pre-Funded Warrants) (the &#8220;Series B Warrants&#8221;) (the &#8220;Offering&#8221;). The combined public offering price per Pre-Funded
Warrant and accompanying Series A Warrant and Series B Warrant, which are being sold together but are immediately separable, is $0.7499.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Each Pre-Funded Warrant is immediately exercisable for
one share of Common Stock at an exercise price of $0.0001 per share and will expire when exercised in full. Each Series A Warrant is
immediately exercisable for one share of Common Stock at an exercise price of $0.75 per share and will expire on December 31, 2025.
Each Series B Warrant is exercisable on the earlier of (i) October 1, 2025, (ii) the first day following any five trading days
during which the volume weighted average price for the Common Stock of the Company during such five trading day period is $1.25 or
greater (the &#8220;VWAP Target&#8221;), or (iii) immediately prior to the consummation of a Fundamental Transaction (as defined in
the Series B Warrants) for one share of Common Stock at an exercise price of $0.75 per share and will expire five years from the
date of issuance. Each Series A Warrant and Series B Warrant will immediately expire in proportion to the extent that the
corresponding Pre-Funded Warrant is exercised prior to September 30, 2025; provided that this term will not apply to the Series B
Warrants immediately as of the date of achievement of the VWAP Target. The holder of the&#160;Pre-Funded&#160;Warrants and Series B
Warrants may also satisfy its obligation to pay the exercise price through a &#8220;cashless exercise,&#8221; in which the holder
receives the net value of such warrant in shares of Common Stock determined according to the formula set forth in
the&#160;applicable warrant. <span style="background-color: white">Holders of Series A Warrants may, provided there is no effective
registration statement or prospectus available which covers the warrants and shares of Common Stock issuable upon exercise of the
Series A Warrants, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment
of the aggregate exercise price, elect instead to receive upon such exercise (either in whole or in part) the net number of shares
of Common Stock determined according to a formula set forth in the Series A Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Company is prohibited from effecting an exercise of any Pre-Funded
Warrants, Series A Warrants or Series B Warrants to the extent that such exercise would result in the number of shares of Common Stock
beneficially owned by such holder and its affiliates exceeding 4.99% (or 9.99% at election of the holder) of the total number of shares
of Common Stock outstanding immediately after giving effect to the exercise (the &#8220;Beneficial Ownership Limitation&#8221;), which
percentage may be increased or decreased at the holder&#8217;s election, not to exceed 19.99%. Any increase to the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. If a holder is not permitted to exercise
a Series A Warrant or a Series B Warrant for Common Stock due to the Beneficial Ownership Limitation, then the holder may exercise such
Series A Warrant or Series B Warrant for an equivalent number of Pre-Funded Warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The aggregate proceeds from the Offering are expected to
be approximately $65 million before deducting underwriting discounts and commissions and offering expenses payable by the Company in connection
with the Offering. The Company may receive up to an aggregate of $130 million of additional gross proceeds if the Series A Warrants and
Series B Warrants are exercised in full for cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Offering is being made pursuant to an effective registration statement
on Form S-3 (Registration Statement No. 333-275717), as amended, previously filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
on November 22, 2023, and declared effective by the SEC on May 31, 2024, as supplemented by the preliminary prospectus supplement, dated
May 28, 2025, and a final prospectus supplement (the &#8220;Prospectus Supplement&#8221;) filed with the SEC pursuant to Rule 424(b) under
the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), on May 30, 2025. The closing of the offering is expected to
take place on or about June 3, 2025, subject to the satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the terms of the Underwriting Agreement, the
Company and its executive officers and directors have agreed, subject to certain customary exceptions, to certain restrictions on the
issuance and sale of its Common Stock and securities convertible into shares of Common Stock during the 90 day period following the closing
of the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Underwriting Agreement contains customary representations,
warranties and agreements by the Company, conditions to closing, indemnification obligations of the Company and the underwriters, including
for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties
and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely
for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The foregoing descriptions of the Underwriting
Agreement, the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants are not complete, and are qualified in their
entirety by reference to the full text of each of the Underwriting Agreement, and the forms of the Pre-Funded Warrant, the Series A
Warrant and the Series B Warrant, which are attached hereto as Exhibit 1.1, 4.1, 4.2 and 4.3, respectively, and which are
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="background-color: white">A
copy of the legal opinion and consent of Dentons US LLP relating to the&#160;Pre-Funded&#160;Warrants, the Series A Warrants, the Series
B Warrants and the shares of Common Stock underlying such warrants is attached as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>Item 7.01. Regulation FD Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">On May 29, 2025, the Company issued a press release announcing the
pricing of the Offering (the &#8220;Pricing Press Release&#8221;). A copy of the Pricing Press Release is furnished hereto as Exhibit
99.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The information in this Current Report on Form 8-K under
Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the SEC and shall not be deemed to be &#8220;filed&#8221;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or
the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Caution Concerning Forward Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;plans,&#8221; and &#8220;future&#8221; or similar expressions
are intended to identify forward-looking statements. Forward-looking statements include statements concerning the offering, such as the
expected gross proceeds (including the anticipated gross proceeds from the exercise of the Series A Warrants and Series B Warrants in
full for cash) and the anticipated closing date. Forward-looking statements are based on management&#8217;s current expectations and are
subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or
implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance,
and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company&#8217;s business are
described in detail in its SEC filings, including in the Company&#8217;s Annual Report on Form 10-K for the full-year ended December 31,
2024, filed with the SEC on March 31, 2025, and in the Company's subsequent filings with the SEC, which are available on the SEC&#8217;s
website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the
SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements
except as may be required by law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 46%"><span style="font-size: 10pt"><b>Item 9.01. Financial Statements and Exhibits.</b></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: white 1pt solid; white-space: nowrap">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No. </b></p></td>
    <td style="border-bottom: white 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: white">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="e664551_ex1-1.htm">Underwriting Agreement, dated as of May 28, 2025, by and between Immunic, Inc. and Leerink Partners LLC</a></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex4-1.htm">Form of Pre-Funded Warrant</a></span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex4-2.htm">Form of Series A Warrant</a> &#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex4-3.htm">Form of Series B Warrant</a> </span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">5.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex5-1.htm">Opinion of Dentons US LLP</a></span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex5-1.htm">Consent of Dentons US LLP (contained in Exhibit 5.1)</a></span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664551_ex99-1.htm">Pricing Press Release</a></span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page to this Current Report on Form 8-K in Inline XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: May 30, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>Immunic, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Daniel Vitt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Daniel Vitt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi53Wn0WXFhWxSikibkcbZbCdlMxY9Uje0mmLGAIhee/LE2Ik1rTSFTKcFkUGB6ybSjmEAq/IaC7oHelmm4CfBd60dayM69cfmJJn0DPzsTz7e+9stcUyATkLJzKMZyCniZSQ70TQ6SmZqy7ROK0qUKaEnKlhjU7xe/hwUC8yVL/7pCOy1WQSiMZykD8QyyiGPbXqSXy3kGWpCEZ9BWLN9Gi8a/lyaDoSlhXWPs4O9L+DL8X+SlM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>e664551_ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMMUNIC, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pre-Funded Warrants to Purchase 86,666,667 Shares
of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Series A Warrants to Purchase 86,666,667 Shares
of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Series B Warrants to Purchase 86,666,667 Shares
of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">May 28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1301 Avenue of the Americas, 5th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immunic, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement with Leerink Partners LLC (&ldquo;<U>Leerink Partners</U>&rdquo;)
and each of the other Underwriters named in <U>Schedule&nbsp;A</U> hereto (collectively, the &ldquo;<U>Underwriters</U>,&rdquo; which
term shall also include any underwriter substituted as hereinafter provided in Section&nbsp; 10 hereof), for which Leerink Partners is
acting as representative (in such capacity, the &ldquo;<U>Representative</U>&rdquo;), with respect to the sale by the Company and the
purchase by the Underwriters, acting severally and not jointly, of the respective numbers of (i) pre-funded warrants, substantially in
the form of <U>Annex A</U> hereto, to purchase an aggregate of 86,666,667 shares of common stock, par value $0.0001 per share, of the
Company (the &ldquo;<U>Common Stock</U>&rdquo;), with an exercise price of $0.0001 per share (&ldquo;<U>Pre-Funded Warrants</U>&rdquo;),
(ii) Series A Common Stock Warrants, substantially in the form of <U>Annex B</U> hereto, to purchase an aggregate of 86,666,667 shares
of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrants) with an exercise price equal to $0.75 per share (&ldquo;<U>Series A
Warrants</U>&rdquo;) and (iii) Series B Common Stock Warrants, substantially in the form of <U>Annex C</U> hereto, to purchase an aggregate
of 86,666,667 shares of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrants) with an exercise price of $0.75 per share (&ldquo;<U>Series
B Warrants</U>&rdquo; and, together with the Series A Warrants, the &ldquo;<U>Common Warrants</U>&rdquo;; and the Common Warrants, together
with the Pre-Funded Warrants, the &ldquo;<U>Securities</U>&rdquo;) set forth in <U>Schedule&nbsp;A</U> hereto. As used herein, &ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company understands that
the Underwriters propose to make a public offering of the Securities as soon as the Representative deems advisable after this Underwriting
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) has been executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed with
the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a shelf registration statement on Form&nbsp;S-3 (No. 333-275717),
as amended, covering the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as
amended (the &ldquo;<U>Securities Act</U>&rdquo;), and the rules and regulations of the Commission promulgated thereunder (the &ldquo;Securities
Act Regulations&rdquo;), which shelf registration statement was declared effective on May 31, 2024. Such registration statement, as of
any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and
any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant
to Item 12 of Form S-3 under the Securities Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule
430B under the Securities Act Regulations (&ldquo;<U>Rule 430B</U>&rdquo;), is referred to herein as the &ldquo;Registration Statement;&rdquo;
provided, however, that the &ldquo;Registration Statement&rdquo; without reference to a time means such registration statement as amended
by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered
the &ldquo;new effective date&rdquo; of such registration statement with respect to the Securities within the meaning of paragraph (f)(2)
of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference
therein at such time pursuant to Item 12 of Form S-3 under the Securities Act and the documents otherwise deemed to be a part thereof
as of such time pursuant to the Rule 430B. Any registration statement filed pursuant to Rule 462(b) of the Securities Act Regulations
is herein called the &ldquo;Rule 462(b) Registration Statement&rdquo; and, after such filing, the term &ldquo;<U>Registration Statement</U>&rdquo;
shall include the Rule 462(b) Registration Statement. Each preliminary prospectus used in connection with the offering of the Securities,
including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities
Act, are collectively referred to herein as a &ldquo;preliminary prospectus.&rdquo; Promptly after execution and delivery of this Agreement,
the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under
the Securities Act Regulations (&ldquo;<U>Rule 424(b)</U>&rdquo;). The final prospectus, in the form first furnished or made available
to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated
by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, are collectively referred to herein as the &ldquo;<U>Prospectus</U>.&rdquo;
For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment
or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval system (or any successor system)(&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Applicable
Time&rdquo; means 6:40 P.M., New York City time, on May 28, 2025 or such other time as agreed by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;General Disclosure
Package&rdquo; means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary
prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and
the information included on <U>Schedule&nbsp;B-1</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer Free
Writing Prospectus&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act Regulations
(&ldquo;<U>Rule 433</U>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the
Securities Act Regulations (&ldquo;<U>Rule 405</U>&rdquo;)) relating to the Securities that is (i) required to be filed with the Commission
by the Company, (ii) a &ldquo;road show for an offering that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i),
whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form
filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records
pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer General
Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors
(other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433 (a &ldquo;<U>Bona Fide Electronic Road Show</U>&rdquo;)),
as evidenced by its being specified in <U>Schedule&nbsp;B-2</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer Limited
Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Testing-the-Waters
Communication&rdquo; means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Written Testing-the-Waters
Communication&rdquo; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
(or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include
all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration
Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and
all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus
shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (collectively, the &ldquo;<U>Exchange Act</U>&rdquo;), incorporated or deemed to be incorporated by reference in
the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Representations and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof,
the Applicable Time, the Closing Time (as defined below) and agrees with each Underwriter, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company meets the requirements for use of Form S-3 under the Securities Act. Each of the Registration Statement and any amendment
thereto has become effective under the Securities Act. No stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued by the Commission under the Securities Act, no order preventing or suspending the use
of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been
instituted by the Commission or are pending or, to the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied
with each request (if any) from the Commission for additional information. Each of the Registration Statement and any post-effective amendment
thereto, at the time it became effective and at each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2)
under the Securities Act Regulations, complied in all material respects with the requirements of the Securities Act and the Securities
Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with
the Commission, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each
preliminary prospectus delivered to the Underwriters for use in connection with the offering and the Prospectus was or will be identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation
S-T. The Registration Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary
prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement
has been duly executed pursuant to such authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp; </FONT>Neither
the Registration Statement nor any amendment thereto, at its effective time or at the Closing Time, contained, contains or will
contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading. As of the Applicable Time, none of (A) the General Disclosure Package,
(B) any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package, nor (C)
any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the
Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any
filing with the Commission pursuant to Rule 424(b), or at the Closing Time, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The representations and warranties in this subsection shall
not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package
or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity
with written information furnished to the Company by any Underwriter through the Representative expressly for use therein. For
purposes of this Agreement, the only information so furnished shall be the information in the first and second sentences of the
fifth paragraph and the second sentence of the twelfth paragraph under the caption &ldquo;Underwriting&rdquo; in each case contained
in the General Disclosure Package and the Prospectus (collectively, the &ldquo;<U>Underwriter Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>Each issuer free writing prospectus, as of its issue date and as of the Applicable Time, did not, does not and will not include
any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the General
Disclosure Package or the Prospectus, including any document incorporated by reference and deemed to be a part thereof that has not been
superseded or modified. Each issuer free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433 or
that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent
of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or
institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (B) has not authorized anyone other
than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been authorized
to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communications other than those listed on <U>Schedule B-3</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being
used as the determination date for purposes of this clause ii)), the Company was not and is not an &ldquo;ineligible issuer&rdquo; (as
defined in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that
the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has
been prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d)
of the Exchange Act. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on the Nasdaq Global Select
Market (&ldquo;<U>Nasdaq</U>&rdquo;), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any
notification that the Commission or Nasdaq is contemplating terminating such registration or listing. The Company is in compliance with
the current listing standards of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>No person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) has the right to act as
an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Securities hereunder, whether as
a result of the filing or effectiveness of the Registration Statement or the sale of the Securities as contemplated hereby or otherwise.
Except for the Underwriters, there is no broker, finder or other party that is entitled to receive from the Company or any of its Subsidiaries
(as defined below) any brokerage or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware,
with full corporate power and authority to acquire, own, lease and operate its properties, and to lease the same to others, and to conduct
its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform
its obligations under this Agreement. The Company is duly qualified to transact business as a foreign corporation and is in good standing
in the State of California and under the laws of each other jurisdiction that requires such qualification, whether by reason of the ownership
or leasing of property or the conduct of business, except to the extent that the failure to be so qualified or in good standing could
not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise),
earnings, results of operations, business, properties, operations, assets, liabilities or prospects of the Company and its Subsidiaries,
taken as a whole, whether or not arising from transactions in the ordinary course of business (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>Each of the Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of this Agreement, as defined in Rule 405 under the Securities
Act) (each, a &ldquo;<U>Subsidiary</U>&rdquo; and collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;) has been duly organized and is
validly existing in good standing (where such concept exists) under the laws of the jurisdiction of its organization and has full power
and authority to acquire, own, lease and operate its properties, and to conduct its business as described in the Registration Statement,
the General Disclosure Package and the Prospectus. Each Subsidiary is duly qualified to transact business and is in good standing (where
such concept exists) under the laws of each jurisdiction that requires such qualification, whether by reason of the ownership or leasing
of property or the conduct of business, except to the extent that the failure to be so qualified or in good standing could not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Effect. All of the issued and outstanding share capital or other
equity or ownership interests of each Subsidiary has been duly authorized and validly issued, is fully paid and nonassessable, has been
issued in compliance with federal state and securities laws and is owned by the Company, directly or through other wholly owned Subsidiaries,
free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly
or indirectly, any corporation, association or other entity, other than the Subsidiaries listed on Exhibit 21.1 to the Company&rsquo;s
most recent Annual Report on Form 10-K filed with the Commission. No Subsidiary is prohibited or restricted, directly or indirectly, from
paying dividends to the Company, from making any other distribution with respect to such Subsidiary&rsquo;s equity securities, from repaying
to the Company or any other Subsidiary any amounts that may from time to time become due under any loans or advances to such Subsidiary
from the Company or from transferring any property or assets to the Company or to any other Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company has the authorized and outstanding capitalization as set forth in the Company&rsquo;s most recent periodic report on
Form 10-K or Form 10-Q, as the case may be, as of the dates referred to therein (subject, in each case, to the issuance of Securities
under this Agreement, the issuance of shares of Common Stock upon exercise of share options and warrants disclosed as outstanding as of
the date hereof in the Registration Statement, the General Disclosure Package and the Prospectus and the grant of options under existing
share option plans described in the Registration Statement, the General Disclosure Package and the Prospectus). The Securities and Warrant
Shares conform in all material respects to the description thereof contained in the Registration Statement, the General Disclosure Package
and the Prospectus and such description conforms, in all material respects, to the rights set forth in the instruments defining the same.
All of the issued and outstanding share capital or other equity or ownership interest of the Company (including the Common Stock) has
been duly authorized and validly issued and is fully paid and nonassessable, has been issued in compliance with all federal, state and
local securities laws and is free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the
outstanding shares of capital stock of the Company were issued in violation of any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive
rights, rights of first refusal or other rights to purchase or subscribe for, or equity or debt securities convertible into or exchangeable
or exercisable for, any share capital of the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is
a party or by which any of them may be bound. The descriptions of the Company&rsquo;s equity incentive plan, stock option plans and other
stock plans or arrangements described in the General Disclosure Package and the Prospectus and in effect as of the date hereof (collectively,
the &ldquo;<U>Stock Plans</U>&rdquo;) and the options or other rights granted thereunder, set forth in the Registration Statement, the
General Disclosure Package and the Prospectus accurately and fairly present the information required to be shown with respect to such
Stock Plans and the options or other rights granted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters
pursuant to this Agreement and, when executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable
against the Company in accordance with their respective terms, except as the enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable
principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants in a number sufficient
to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Securities in accordance
therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant Shares is not subject to any preemptive
or similar rights. The issuance and sale of the Securities as contemplated hereby will not cause any holder of any share capital, securities
convertible into or exchangeable or exercisable for share capital or options, warrants or other rights to purchase share capital or any
other securities of the Company to have any right to acquire any preferred shares of the Company. There are no restrictions upon the voting
or transfer of the Common Stock under the Company&rsquo;s amended and restated certificate of incorporation or amended and restated bylaws
or any agreement or other instrument to which the Company is a party or otherwise filed as an exhibit to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>There is no statute, regulation, contract, agreement or other document required to be described in the Registration Statement,
the General Disclosure Package or the Prospectus, or to be filed as an exhibit to the Registration Statement or any document incorporated
by reference therein which is not described or filed as required. The statements set forth or incorporated by reference in the General
Disclosure Package or Prospectus, insofar as they purport to constitute summaries of the terms of the statutes, regulations, contracts,
agreements or other documents described and filed, constitute accurate summaries of the terms thereof in all material respects. The statements
set forth or incorporated by reference in the General Disclosure Package and the Prospectus under the headings &ldquo;Risk Factors,&rdquo;
&ldquo;Business&mdash;Product Candidates,&rdquo; &ldquo;Business&mdash;Government Regulation - All Products&rdquo; and &ldquo;Description
of Capital Stock We May Offer&rdquo; and under the sub-headings &ldquo;Vidofludimus Calcium Intellectual Property, Licenses and Royalties,&rdquo;
and &ldquo;IMU-856 Intellectual Property, Licenses and Royalties,&rdquo; insofar as such statements summarize legal matters, agreements,
documents or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents or proceedings.
Neither the Company nor any of its Subsidiaries has sent or received any communication regarding termination of, or intent not to renew
or render performance under, any of the contracts or agreements referred to or described in the General Disclosure Package, the Prospectus
or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, or any document
incorporated by reference, and no such termination or non-renewal has been threatened by the Company or any of its Subsidiaries or, to
the Company&rsquo;s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been
rescinded as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>This Agreement has been duly and validly authorized, executed and delivered by the Company and constitutes a valid and legally
binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforceability, including rights
of indemnification, may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws
relating to or affecting creditors&rsquo; rights generally and by general principles of equity. This Agreement conforms in all material
respects to the descriptions thereof in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds thereof
as described in the Registration Statement, the General Disclosure Package and the Prospectus, or exercise of the Securities, will not
be an &ldquo;investment company&rdquo; as defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>No consent, approval, license, permit, qualification, authorization or other order or decree of, or registration or filing with,
any court or other governmental, taxing or regulatory authority or agency, is required for the Company&rsquo;s execution, delivery and
performance of this Agreement or the Securities or consummation of the transactions contemplated hereby or by the Registration Statement,
the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities hereunder), except such as have been
already obtained or made or as may be required under the Securities Act, applicable state securities or Blue Sky laws, applicable rules
of Nasdaq, or applicable rules of the Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Neither the execution and delivery by the Company of, nor the performance of the Company of its obligations under, this Agreement
or the Securities (including the issuance of the Warrant Shares) will conflict with, result in a breach or violation of, or result in
the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its Subsidiaries pursuant
to: (i) the certificate or articles of incorporation, charter, bylaws, articles of association, limited liability company agreement, certificate
or agreement of limited or general partnership or other similar organizational documents, as the case may be, of such entity, (ii) the
terms of any indenture, contract, license, lease, mortgage, deed of trust, note agreement, agreement or other instrument, obligation,
condition, covenant or instrument to which it is a party or bound or to which its property or assets is subject or (iii) any statute,
law, rule, regulation, judgment, order or decree applicable to the Company or any of its Subsidiaries of any court, regulatory body, administrative
agency, governmental body, arbitrator or other authority having jurisdiction over the Company, any of its Subsidiaries or any of their
respective properties or assets, as applicable, except, in the case of clauses (ii) and (iii) above, for any such conflict, breach, violation
or default that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure Package
and the Prospectus: (i) there has been no material adverse change, or any development that could reasonably be expected to result in a
material adverse change, in the condition (financial or otherwise), earnings, results of operations, business, properties, operations,
assets, liabilities or prospects of the Company and its Subsidiaries, taken as a whole, whether or not arising from transactions in the
ordinary course of business; (ii) neither the Company nor its Subsidiaries has (A) incurred any material liability or obligation, indirect,
direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes,
accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order
or decree, that are material, individually or in the aggregate, to the Company and its Subsidiaries, considered as one entity, (B) entered
into any material transactions not in the ordinary course of business or (C) issued or granted any shares of the Company&rsquo;s capital
stock or securities convertible into or exchangeable or exercisable for or that represent the right to receive shares of the Company&rsquo;s
capital stock other than under the Stock Plans; and (iii) there has not been any material decrease in the share capital or any material
increase in any short-term or long-term indebtedness of the Company or any of its Subsidiaries and there has been no dividend or distribution
of any kind declared, paid or made by the Company or, except for dividends paid to the Company or another Subsidiary, by any Subsidiary
on any class of shares, or any repurchase or redemption by the Company or any of its Subsidiaries of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>There are no persons (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) with registration
or other similar rights to have any equity or debt securities of the Company registered for sale under the Registration Statement or included
in the offering contemplated by this Agreement, except for such rights as have been duly waived in a writing previously furnished to the
Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The financial statements of the Company included or incorporated by reference in the Registration Statement, the General Disclosure
Package and the Prospectus, together with the related notes and schedules, present fairly the consolidated financial position of the Company
and the Subsidiaries as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders&rsquo;
equity of the Company and the Subsidiaries for the periods specified and have been prepared in compliance in all material respects with
the requirements of the Securities Act and Exchange Act and in conformity with United States generally accepted accounting principles
(&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent basis during the periods involved. To the extent applicable, any pro forma financial
statements, information or data included or incorporated by reference in the Registration Statement, the General Disclosure Package and
the Prospectus comply with the requirements of Regulation S-X of the Securities Act, including, without limitation,&nbsp;Article 11<B><I>&nbsp;</I></B>&nbsp;thereof,
fairly present the information set forth therein, and the assumptions used in the preparation of such pro forma financial statements and
data are reasonable, the pro forma adjustments used therein are appropriate to give effect to the circumstances referred to therein and
the pro forma adjustments have been properly applied to the historical amounts in the compilation of those statements and data. The other
financial data set forth or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus
is accurately and fairly presented in all material respects and prepared on a basis consistent with the financial statements and books
and records of the Company. There are no financial statements (historical or pro forma) that are required to be included or incorporated
by reference in the Registration Statement, the General Disclosure Package or the Prospectus that are not included or incorporated by
reference therein as required. The Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent
(including any off-balance sheet obligations or any &ldquo;variable interest entities&rdquo; as that term is used in Accounting Standards
Codification Paragraph 810-10-25-20), not disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.
All disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus that contain &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission) comply, in all material respects, with
Regulation G under the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The statistical,
industry-related and market-related data included or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus were obtained or derived from sources which the Company reasonably and in good faith believes are reliable and accurate,
such data agree with the sources from which they are derived, and the Company has obtained the written consent to the use of such data
from such sources to the extent required. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being associated
with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the Public
Company Accounting Oversight Board (&ldquo;<U>PCAOB</U>&rdquo;), has participated in or otherwise aided the preparation of, or audited,
the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement,
the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>There are no actions, suits, claims, investigations or proceedings pending or, to the Company&rsquo;s knowledge, threatened to
which the Company or any of the Subsidiaries is or would be a party, or of which any of the respective properties or assets of the Company
and the Subsidiaries is or would be subject, at law or in equity, before any court or arbitral body or by or before any federal, state,
local or foreign governmental or regulatory commission, board, body, authority or agency, that (i) are required to be described in the
Registration Statement, the General Disclosure Package or the Prospectus and are not so described, (ii) could reasonably be expected to
have a material adverse effect on the ability of the Company to perform its obligations under this Agreement or the Securities or on the
consummation of any of the transactions contemplated hereby or (iii) could reasonably be expected to have a Material Adverse Effect. The
aggregate of all pending legal or governmental proceedings to which the Company or any of its Subsidiaries is a party or of which any
of their respective properties or assets is the subject which are not described in the General Disclosure Package or the Prospectus, including
ordinary routine litigation incidental to the Company&rsquo;s business, could not reasonably be expected to (A) result in a Material Adverse
Effect or (B) have a material adverse effect on the ability of the Company to perform its obligations under this Agreement or the Securities
or the consummation of any of the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company owns or leases all such real properties as are necessary to the conduct of its operations as presently conducted in
all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Neither the Company nor any Subsidiary is in violation or default of (i) any provision of its certificate or articles of incorporation,
charter, bylaws, articles of association, limited liability company agreement, certificate or agreement of limited or general partnership,
or other similar organizational documents, as the case may be, of such entity; (ii) the terms of any indenture, contract, lease, mortgage,
deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which it is a party
or bound or to which its property or assets is subject; or (iii) any statute, law, rule, regulation, judgment, order or decree of any
court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company,
any of its Subsidiaries or any of their respective properties or assets, as applicable, except, in the case of clauses (ii) and (iii)
above, for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Baker Tilly US, LLP (&ldquo;<U>Baker Tilly</U>&rdquo;), whose report on the consolidated financial statements of the Company is
filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K filed with the Commission and incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus, is (i) an independent registered public
accounting firm as required by the Securities Act, the Exchange Act and the rules of the PCAOB, (ii) in compliance with the applicable
requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered
public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration
to be withdrawn. Baker Tilly has not been engaged by the Company to perform any &ldquo;prohibited activities&rdquo; or provided to the
Company any &ldquo;non-audit services&rdquo; (as defined in Section 10A of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>There are no transfer taxes or other similar fees or charges under federal law, the laws of any state, any foreign law, or any
political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by
the Company or sale by the Company of the Securities or the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>All United States federal income tax returns of the Company and its Subsidiaries required by law to be filed have been filed or
extensions thereof have been requested, and all taxes shown by such returns or otherwise assessed, which are due and payable, have been
paid, except assessments that are being contested in good faith and as to which adequate reserves have been provided under GAAP. The Company
has no knowledge of any material tax deficiency which has been or is likely to be threatened or asserted against the Company or its Subsidiaries.
Each of the Company and its Subsidiaries has filed all foreign, state, provincial, local or other tax returns that are required to have
been filed pursuant to applicable foreign, state, provincial, local or other law except insofar as the failure to file such returns would
not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and paid all taxes due pursuant
to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes, if any, as are being
contested in good faith and as to which adequate reserves have been provided and except for such taxes or assessments the nonpayment of
which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The charges, accruals
and reserves on the books of the Company and its Subsidiaries in respect of any income or other tax liability for any years not finally
determined are adequate to meet any assessments or re-assessments for additional tax for any years not finally determined, except to the
extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect. All material taxes which the Company
and its Subsidiaries are required by law to withhold or to collect for payment have been duly withheld and collected and have been paid
to the appropriate governmental authority or agency or have been accrued, reserved against and entered on the books of the Company and
its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company&rsquo;s knowledge, is threatened
or imminent, and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its or
any of its Subsidiaries&rsquo; principal suppliers, manufacturers, contractors or customers, in each case that would have a Material Adverse
Effect. None of the employees of the Company or any of its Subsidiaries is represented by a union and, to the knowledge of the Company,
no union organizing activities are taking place. Neither the Company nor any of its Subsidiaries has violated (or received notice of any
violation of) any federal, state or local law or foreign law relating to the discrimination in hiring, promotion or pay of employees,
nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous foreign laws and regulations, which would,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Each of the Company and its Subsidiaries are insured by recognized and reputable institutions with policies in such amounts and
with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited
to, policies covering real and personal property owned or leased by the Company and its Subsidiaries against theft, damage, destruction,
acts of vandalism and earthquakes and policies covering the Company and its Subsidiaries for clinical trial liability claims. The Company
has no reason to believe that it or any of its Subsidiaries will not be able (i) to renew its existing insurance coverage as and when
such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its
business as now conducted and at a cost that could not reasonably be expected to have a Material Adverse Effect. Neither the Company nor
any of its Subsidiaries has been denied any material insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and each of its Subsidiaries has good and marketable title in fee simple to all real property owned by them and good
and marketable title to all personal property owned by them that is material to their business (except with respect to intellectual property,
which is addressed exclusively in Section 1(a)(xli) Section 1(a)(lvi), in each case free and clear of all liens, encumbrances and defects
except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such
property by the Company or any Subsidiary; and any real property and buildings held under lease by the Company or any of its Subsidiaries
are held by them under valid, subsisting and enforceable leases (subject to the effects of (A) bankruptcy, insolvency, fraudulent conveyance,
fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights or remedies of creditors generally;
(B) the application of general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith
and fair dealing, regardless of whether enforcement is considered in proceedings at law or in equity); and (C) applicable law and public
policy with respect to rights to indemnity and contribution) with such exceptions as are not material and do not interfere with the use
made and proposed to be made of such property and buildings by the Company or such Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and its Subsidiaries possess and are operating in compliance in all material respects with such valid and current material
certificates, authorizations or permits required by United States federal, state or foreign regulatory agencies or bodies to conduct their
respective businesses as currently conducted and as described in the Registration Statement, the General Disclosure Package and the Prospectus
(collectively, &ldquo;<U>Permits</U>&rdquo;). Neither the Company nor any of its Subsidiaries is in violation of, or in default under,
any of the Permits or has received any written notice of proceedings relating to the revocation or modification of, or non-compliance
with, any such certificate, authorization or permit, which, individually or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company and each of its Subsidiaries make and keep accurate books and records and maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general
or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for
in all material respects and is prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and each of its Subsidiaries have established and maintain disclosure controls and procedures (as defined in Rules
13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including
its consolidated Subsidiaries, is made known to the Company&rsquo;s principal executive officer and its principal financial officer by
others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being
prepared; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company&rsquo;s most recent fiscal
quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the
Company&rsquo;s most recent audited fiscal year, there has been no material weakness in the Company&rsquo;s internal control over financial
reporting (whether or not remediated) and no change in the Company&rsquo;s internal control over financial reporting, including any corrective
actions with regard to significant deficiencies or material weaknesses. The Company is not aware of any change in its internal control
over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely
to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Neither the Company, nor any of its Subsidiaries, nor to the knowledge of the Company, any of its or their respective directors,
officers or controlling persons has taken, directly or indirectly, without giving effect to any actions taken by the Underwriters, (i)
any action designed to or that might constitute or reasonably be expected to cause or result in, under the Exchange Act or otherwise,
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or (ii) any
action designed to or that might constitute or reasonably be expected to cause or result in a violation of Regulation M under the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i) neither the
Company nor any of its Subsidiaries is in violation of any United States federal, state or local, or any foreign, statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial
or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation,
laws and regulations relating to the emissions, discharges, release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) or otherwise
related to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials
(collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), which violation includes, but is not limited to, noncompliance with any permits
or other governmental authorizations required for the operation of the business of the Company or any of its Subsidiaries under applicable
Environmental Laws, or noncompliance with the terms and conditions thereof, nor has the Company or any of its Subsidiaries received any
written communication, whether from a governmental authority, citizens group, employee or otherwise, that alleges that the Company or
any of its Subsidiaries is in violation of any Environmental Law; (ii) the Company and its Subsidiaries have all material permits, authorizations
and approvals required under any applicable Environmental Laws and are in compliance with their requirements; (iii) there are no pending
or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims,
liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any
of its Subsidiaries, or any investigation with respect to which the Company or any of its Subsidiaries has received written notice or
any written notice by any person or entity alleging potential liability for investigatory costs, cleanup costs, governmental responses
costs, natural resources damages, property damages, personal injuries, attorneys&rsquo; fees or penalties arising out of, based on or
resulting from the presence, or release into the environment, of any Hazardous Materials at any location owned, leased or operated by
the Company or any of its Subsidiaries, now or in the past; and (iv) to the Company&rsquo;s knowledge, there are no past or present actions,
activities, events, conditions, incidents or circumstances that might reasonably be expected to result in a violation of any Environmental
Law or form the basis of an order for clean-up or remediation, or an action, suit, investigation or proceeding by any private party or
governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security Act of 1974,
as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<U>ERISA</U>&rdquo;)) established or maintained
by the Company, or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects with ERISA. &ldquo;ERISA
Affiliates&rdquo; means, with respect to the Company, any member of any group of organizations described in Sections 414(b), (c), (m)
or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &ldquo;<U>Code</U>&rdquo;)
of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to
occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, or any of its ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee
benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither
the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with
respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the
Code. Each &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates that is intended
to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which
would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company is in compliance with, and there is and has been no failure on the part of the Company and, to the Company&rsquo;s
knowledge, any of the Company&rsquo;s directors or officers, in their capacities as such, to comply with, any applicable provision of
the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof (the &ldquo;<U>Sarbanes-Oxley
Act</U>&rdquo;) and the rules and regulations promulgated in connection therewith, including Section 402 relating to loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvii) Neither
the Company, any of its Subsidiaries, nor, to the knowledge of the Company, any of their respective directors, officers, agents, employees
or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of
the unlawful payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any &ldquo;government official&rdquo;
(including any officer or employee of a government or government-owned or controlled entity or of a public international organization,
or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office) to influence official action or secure an improper advantage; and the Company, each of its Subsidiaries and, to
the Company&rsquo;s knowledge, each of their respective affiliates have conducted their businesses in compliance with applicable anti-corruption
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>None of the Company, any Subsidiary, affiliate, director, officer or employee thereof or, to the best of the Company&rsquo;s knowledge,
any agent, representative or other person acting on behalf of the Company or any of its Subsidiaries or affiliates, is aware of or has
taken any action, directly or indirectly, that would result in a violation by such persons of any applicable anti-corruption laws, including
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &ldquo;<U>FCPA</U>&rdquo;), including,
without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer,
payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the
giving of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined in the FCPA) or any foreign political party
or official thereof or any candidate for foreign political office or otherwise took any action (or failed to fully disclose any action)
in contravention of the FCPA; and the Company, its Subsidiaries and each of their respective affiliates have conducted their businesses
in compliance with the FCPA and have instituted and maintain, and will continue to maintain, policies and procedures designed to ensure,
and which are reasonably expected to continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects
with applicable financial recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the &ldquo;<U>Money Laundering Laws</U>&rdquo;) and no action, suit, investigation or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws
is pending or, to the best of the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xl)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Neither the Company nor any of its Subsidiaries, nor any director or officer thereof, nor, to the Company&rsquo;s knowledge, any
employee, agent, affiliate or representative of the Company or any of its Subsidiaries, is currently or is owned or controlled by an individual
or entity that is subject to any sanctions administered or enforced by the United States government (including, without limitation, the
Office of Foreign Assets Control of the United States Department of the Treasury), the United Nations Security Council, the European Union,
His Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;) or is located, organized
or resident in a country or territory that is the subject or target of Sanctions; and the Company will not directly or indirectly use
the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, or any joint
venture partner or other person or entity, for the purpose of financing or facilitating the activities of or business of any person or
entity, or in any country or territory, that currently or at the time of such financing or facilitation is the subject of any Sanctions
or in any other manner that will result in a violation by any person or entity (including any person participating in the transactions
contemplated by this Agreement) of any Sanctions. For the past five years, the Company and its Subsidiaries have not knowingly engaged
in and are not now knowingly engaged in any dealings or transactions with any person or entity, or in any country or territory, that at
the time of the dealing or transaction is or was the subject of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xli)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and its Subsidiaries own or possess the right to use all inventions, patent applications, patents, trademarks, trade
names, service names, domain names, copyrights, trade secrets, know-how and other intellectual property (collectively, &ldquo;<U>Intellectual
Property</U>&rdquo;) as are (i) necessary or material for the conduct of their respective businesses as currently conducted or as currently
proposed to be conducted and as described in the Registration Statement, the General Disclosure Package and the Prospectus and (ii) necessary
or material for the commercialization of the products described in the Registration Statement, the General Disclosure Package and the
Prospectus as being under development. There is no pending or, to the Company&rsquo;s knowledge, threatened (i) action, suit, proceeding,
or claim by others challenging the rights of the Company or any of its Subsidiaries in or to any such Intellectual Property that, if decided
adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse Effect, and the Company is
unaware of any facts which would form a reasonable basis for any such claim; (ii) action, suit, proceeding, or claim by others that the
Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any Intellectual Property of others that, if decided
adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse Effect, and the Company is
unaware of any facts which would form a reasonable basis for any such claim; or (iii) action, suit, proceeding, or claim by others challenging
the validity, scope, or enforceability of any such Intellectual Property owned or licensed by the Company or its Subsidiaries and the
Company is unaware of any facts which would form a reasonable basis for any such claim. To the best of the Company&rsquo;s knowledge,
the operation of the business of the Company and its Subsidiaries as now conducted, and as described in the General Disclosure Package
and the Prospectus, and in connection with the development and commercialization of the products described in the General Disclosure Package
and the Prospectus does not infringe, misappropriate, conflict with or otherwise violate any claim of any patent or published patent application
of any other person or entity. There is no prior art of which the Company or any of its Subsidiaries is aware that may render any patent
owned or licensed by the Company or its Subsidiaries invalid or any patent application owned or licensed by the Company or its Subsidiaries
unpatentable which has not been disclosed to the applicable government patent office. The Company&rsquo;s granted or issued patents, registered
trademarks and registered copyrights have been duly maintained and are in full force and effect, and none of the patents, trademarks and
copyrights have been adjudged invalid or unenforceable in whole or in part. The Company knows of no infringement, misappropriation or
violation by others of any Intellectual Property owned or licensed by the Company or its Subsidiaries which would reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to or bound by any options, licenses or
agreements with respect to the Intellectual Property of any other person or entity that are required to be set forth in the General Disclosure
Package and the Prospectus and that are not described therein in all material respects. The Company and its Subsidiaries have taken all
reasonable steps necessary to secure their interests in the Intellectual Property of the Company and its Subsidiaries from their employees
and contractors and to protect the confidentiality of all of their confidential information and trade secrets. None of the technology
or intellectual property used by the Company and its Subsidiaries in its business has been obtained or is being used by the Company or
its Subsidiaries in violation of any contractual obligation binding on the Company or its Subsidiaries, or, to the Company&rsquo;s knowledge,
any of its officers, directors or employees or otherwise in violation of the rights of any persons. No third party has been granted by
the Company or its Subsidiaries rights to the Intellectual Property of the Company or its Subsidiaries, including any rights that, if
exercised, could enable such party to develop products competitive to those of the Company as described in the Registration Statement,
the General Disclosure Package and the Prospectus. All Intellectual Property owned or exclusively licensed by the Company or its Subsidiaries
are free and clear of all liens, encumbrances, defects or other restrictions (other than non-exclusive licenses granted in the ordinary
course of business), except those that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect. The Company and its Subsidiaries are not subject to any judgment, order, writ, injunction or decree of any court or any federal,
state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or
any arbitrator, nor has it entered into or is it a party to any agreement made in settlement of any pending or threatened litigation,
which materially restricts or impairs their use of any Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company and each of its Subsidiaries (i) are and have at all times been in material compliance with all laws, statutes, rules,
regulations or guidance applicable to the Company and its Subsidiaries and the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal
of any pharmaceuticals or biohazardous substances, materials or any other products developed, manufactured or distributed by the Company
(including, without limitation, from the United States Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;), European Medicines Agency
(&ldquo;<U>EMA</U>&rdquo;) and any local or other governmental or regulatory authority performing functions similar to those performed
by the FDA or EMA) (collectively, &ldquo;<U>Applicable Laws</U>&rdquo;), except as could not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect, (ii) have not received any notice of adverse finding, warning letter, untitled letter
or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the
Company, any of its Subsidiaries or their activities alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (collectively,
the &ldquo;<U>Governmental Permits</U>&rdquo;), (iii) have made all filings with, the appropriate local, or other governmental or regulatory
agencies or bodies that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement, the General Disclosure Package and the Prospectus, except where any failures to possess or
make the same would not, singularly or in the aggregate, have a Material Adverse Effect, (iv) possess all material Governmental Permits
necessary to conduct their respective businesses as described in the Registration Statement, the General Disclosure Package and the Prospectus,
and such Governmental Permits are valid and in full force and effect and are not in violation of any term of any such Governmental Permits,
(v) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Governmental Permits and that all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects on
the date filed (or were corrected or supplemented by a subsequent submission), and (vi) are not a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders or similar agreements with or imposed by any governmental authority. All Governmental
Permits are valid and in full force and effect, except where the validity or failure to be in full force and effect would not, singularly
or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary has received notification of any revocation,
modification, suspension, termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company
has no reason to believe that any such Governmental Permit will not be renewed. Neither the Company, any of its Subsidiaries nor, to the
Company&rsquo;s knowledge, any of their respective directors, officers, employees or agents has been convicted of any crime under any
Applicable Laws or has been the subject of an FDA debarment proceeding. Neither the Company nor any of its Subsidiaries has been nor is
now subject to the FDA&rsquo;s Application Integrity Policy. To the Company&rsquo;s knowledge, neither the Company, any of its Subsidiaries
nor any of its directors, officers, employees or agents has made, or caused the making of, any false statements on, or material omissions
from, any other records or documentation prepared or maintained to comply with the requirements of the FDA or any other governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>There is no legal or governmental proceeding to which the Company or any of its Subsidiaries is a party or of which any property
or assets of the Company or any of its Subsidiaries is the subject, including any proceeding before the FDA, the EMA or any foreign, local,
national or other governmental agency with jurisdiction over the types of products being developed by the Company that is required to
be described in the Registration Statement, the General Disclosure Package or the Prospectus and is not described therein, or which, singularly
or in the aggregate, if determined adversely to the Company or any of its Subsidiaries, could reasonably be expected to have a Material
Adverse Effect; and no such proceedings are threatened or contemplated by governmental or regulatory authorities or threatened by others.
The Company and its Subsidiaries (i) have not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any governmental authority or third party alleging that any product operation or activity is in violation
of any Applicable Laws or Governmental Permits and have no knowledge that any such governmental authority or third party is considering
any such claim, litigation, arbitration, action, suit, investigation or proceeding and (ii) have not received notice that any governmental
authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Governmental Permits and the Company
has no knowledge that any such governmental authority is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The research, non-clinical pre-clinical studies and clinical studies and tests conducted or being conducted by or on behalf of
the Company or any of its Subsidiaries or in which any of their respective product candidates have participated and, to the Company&rsquo;s
knowledge, the preclinical studies and clinical trials directed or sponsored by the Company&rsquo;s collaborators (collectively, the &ldquo;<U>Studies</U>&rdquo;)
that are described in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package and the
Prospectus were and, if still pending, are being conducted with reasonable care and in all material respects in accordance with the protocols,
procedures and controls pursuant to all Applicable Laws and Governmental Permits and with standard medical and scientific research procedures;
each description of the results of such Studies is accurate and complete in all material respects and fairly presents the data derived
from such Studies, and the Company and its Subsidiaries have no knowledge of any other research, non-clinical studies or tests the results
of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the
General Disclosure Package and the Prospectus; the Company and its Subsidiaries have made all such filings and obtained all such approvals
as may be required by the EMA, the FDA or any committee thereof or from any other United States or foreign government agency with jurisdiction
over the types of products being developed by the Company; neither the Company nor any of its Subsidiaries has received any notice of,
or correspondence from, any governmental authority requiring the termination, suspension or modification of any Study; and the Company
and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations
and policies of all governmental authorities. There have been no material serious adverse events resulting from any Study. To the Company&rsquo;s
knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all Applicable
Laws and Governmental Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company is not required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo; in accordance with the provisions of
the Exchange Act and does not, directly or indirectly through one or more intermediaries, control or have any other association with (within
the meaning of&nbsp;Article I<I>&nbsp;</I>of the By-laws of FINRA) any member firm of FINRA. No relationship, direct or indirect, exists
between or among the Company, on the one hand, and the directors, officers or shareholders of the Company, on the other hand, which is
required by the rules of FINRA to be described in the Registration Statement, the General Disclosure Package and the Prospectus, which
is not so described. All of the information (including, but not limited to, information regarding affiliations, security ownership and
trading activity) provided to the Representative or its counsel by the Company, its officers and directors and the holders of any securities
(debt or equity) or warrants, options or rights to acquire any securities of the Company in connection with the filing to be made and
other supplemental information to be provided to FINRA pursuant to FINRA Rule 5110 in connection with the transactions contemplated by
this Agreement is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>As of the close of trading on Nasdaq on May 28, 2025, the aggregate market value of the outstanding voting and non-voting common
equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144 of the Securities
Act, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control
with, the Company) (the &ldquo;Non-Affiliate Shares&rdquo;), was approximately $86,122,617 million (calculated by multiplying $0.91, the
price at which the common equity of the Company was last sold on Nasdaq on May 28, 2025, by 94,640,238, the number of Non-Affiliate Shares
outstanding on May 28, 2025). The Company is not a shell company (as defined in Rule 405) and has not been a shell company for at least
12 calendar months previously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described
in the Registration Statement, the General Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Each of the independent directors (or independent director nominees, once appointed, if applicable) named in the Registration Statement,
the General Disclosure Package and Prospectus satisfies the independence standards established by Nasdaq and, with respect to members
of the Company&rsquo;s audit committee, the enhanced independence standards contained in Rule 10A-3(b)(1) promulgated by the Commission
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Neither the Company nor, to the Company&rsquo;s knowledge, any of its affiliates (within the meaning of Rule 144 under the Securities
Act) has, prior to the date hereof, made any offer or sale of any securities which could be &ldquo;integrated&rdquo; (within the meaning
of the Securities Act) with the offer and sale of the Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>Neither the Company nor any of its Subsidiaries has (i) failed to pay any dividend or sinking fund installment on preferred stock
or (ii) defaulted on any installment or payment due on indebtedness for borrowed money or on any rental on one or more long-term leases,
which defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(li)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section 27A of the Securities
Act or Section 21E of the Exchange Act) contained in the Registration Statement, the General Disclosure Package or the Prospectus (i)
was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions,
estimates and other applicable facts and circumstances and (ii) as required, is accompanied by meaningful cautionary statements identifying
those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was
made with the knowledge of a director or senior manager of the Company that was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>There are no relationships, direct or indirect, or related party transactions involving the Company or any of its Subsidiaries
or any other person (including any director, officer, stockholder, customer or supplier of the Company or any of its Subsidiaries) required
to be described in the Registration Statement, the General Disclosure Package or the Prospectus that have not been described as required.
There are no material outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or
guarantees of indebtedness by the Company or any of its Subsidiaries to or for the benefit of any of the officers or directors of the
Company or any of its Subsidiaries, or any of the family members of any of such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(liii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company is not in or subject to a bankruptcy or insolvency proceeding in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(liv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>The Company and its Subsidiaries (i) are in compliance, in all material respects, with any and all applicable foreign, federal,
state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all governmental authorities (including
pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety the workplace (&ldquo;<U>Occupational
Laws</U>&rdquo;); (ii) have received all material permits, licenses or other approvals required of it under applicable Occupational Laws
to conduct their respective businesses as currently conducted; and (iii) are in compliance, in all material respects, with all terms and
conditions of such permit, license or approval. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or,
to the Company&rsquo;s knowledge, threatened against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company
does not have knowledge of any facts, circumstances or developments relating to its operations or cost accounting practices that could
reasonably be expected to form the basis for or give rise to such actions, suits, investigations or proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>No director or officer of the Company or any of its Subsidiaries is subject to any non-competition agreement or non-solicitation
agreement with any employer or prior employer which could materially affect each director&rsquo;s or officer&rsquo;s ability to be and
act in the capacity of a director or officer of the Company or a Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company has duly and properly filed or caused to be filed with the U.S. Patent and Trademark Office (the &ldquo;<U>PTO</U>&rdquo;)
and applicable foreign and international patent and trademark authorities all patents, trademarks, copyrights and applications relating
to the same owned by the Company and its Subsidiaries (the &ldquo;<U>Company Patent and Trademark Applications</U>&rdquo;). To the knowledge
of the Company, the Company has complied with the PTO&rsquo;s duty of candor and disclosure for the Company Patent and Trademark Applications
and has made no material misrepresentation in the Company Patent and Trademark Applications. To the Company&rsquo;s knowledge, the Company
Patent and Trademark Applications disclose patentable subject matter. The Company has not been notified of any inventorship challenges
nor has any interference been declared or provoked nor is any material fact known by the Company that would preclude the issuance of patents
with respect to the Company Patent and Trademark Applications or would render such patents, if issued, invalid or unenforceable. Except
as would not have a Material Adverse Effect, neither the Company nor any of its Subsidiaries has breached and is currently in breach of
any provision of any license, contract or other agreement governing the use by the Company or its Subsidiaries of Intellectual Property
owned by third parties (collectively, the &ldquo;<U>Licenses</U>&rdquo;) and no third party has alleged any such breach and the Company
is unaware of any facts that would form a reasonable basis for such a claim. To the Company&rsquo;s knowledge, no other party to the Licenses
has breached or is currently in breach of any provision of the Licenses. Each of the Licenses is in full force and effect and constitutes
a valid and binding agreement between the parties thereto, enforceable in accordance with its terms, and there has not occurred any breach
or default under any such Licenses or any event that, with the giving of notice or lapse of time, would constitute a breach or default
thereunder. Except as would not have a Material Adverse Effect, neither the Company nor any of its Subsidiaries has been and is currently
involved in any disputes regarding the Licenses. To the Company&rsquo;s knowledge, all patents licensed to the Company pursuant to the
Licenses are valid, enforceable and being duly maintained. To the Company&rsquo;s knowledge, all patent applications licensed to the Company
pursuant to the Licenses are being duly prosecuted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under
the Registration Statement, except for such rights as have been duly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company and its Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted,
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its Subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including &ldquo;Personal Data,&rdquo; used in connection with their businesses. &ldquo;<U>Personal Data</U>&rdquo;
means (i) a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification
number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any
information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended;
(iii) &ldquo;personal data&rdquo; as defined by the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU
2016/679); (iv) any &ldquo;personal information&rdquo; as defined in the California Consumer Privacy Act (&ldquo;<U>CCPA</U>&rdquo;);
(v) any information which would qualify as &ldquo;protected health information&rdquo; under the Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &ldquo;<U>HIPAA</U>&rdquo;);
and (vi) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any data related to an identified person&rsquo;s health or sexual orientation. There have been no breaches, violations,
outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the
duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries
are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court
or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation
or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal
data privacy and security laws and regulations, including without limitation HIPAA, the CCPA and the GDPR (collectively, the &ldquo;<U>Privacy
Laws</U>&rdquo;). To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate
steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &ldquo;<U>Policies</U>&rdquo;). The
Company and its Subsidiaries have, to the knowledge of the Company, at all times made all disclosures to users or customers required by
applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge
of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The
Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating
to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably
be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation
or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Officer&rsquo;s Certificates</I>. Any certificate signed by any officer of the Company delivered to the Representative or to
counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Sale to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly,
agrees to purchase from the Company, at the price per Pre-Funded Warrant and accompanying Common Warrants set forth in <U>Schedule&nbsp;A</U>,
that number of Securities set forth in <U>Schedule&nbsp;A</U> opposite the name of such Underwriter, plus any additional number of Securities
which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such
adjustments among the Underwriters as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Payment</I>. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Securities shall
be made at the offices of Covington &amp; Burling LLP, or at such other place as shall be agreed upon by the Representative and the Company,
at 10:00&nbsp;A.M. (New York City time) on June 3, 2025 (unless postponed in accordance with the provisions of Section 10), or such other
time not later than ten business days after such date as shall be agreed upon by the Representative (such time and date of payment and
delivery being herein called &ldquo;<U>Closing Time</U>&rdquo;). The Company shall physically deliver, or cause to be delivered, the Securities
as set forth below according to instructions of the Representative at or prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing, the Company and the Representative shall instruct purchasers of the Pre-Funded Warrants and accompanying Common
Warrants to make payment for the Pre-Funded Warrants and accompanying Common Warrants on the Closing Date to the Company by wire
transfer in immediately available funds to the account specified by the Company at a purchase price of $0.7499 per Pre-Funded
Warrant and accompanying Common Warrants, in lieu of payment by the Underwriters for such Pre-Funded Warrants and accompanying
Common Warrants, and the Company shall deliver the Pre-Funded Warrants and accompanying Common Warrants to such purchasers on the
Closing Date in definitive paper form against such payment, in lieu of the Company&rsquo;s obligation to deliver the Pre-Funded
Warrants and accompanying Common Warrants to the Representative. On the Closing Date, payment shall be made to the Representative by
wire transfer of immediately available funds to a bank account designated by the Representative in an amount equal to $0.0450 per
Pre-Funded Warrant and accompanying Common Warrants. In the event that any purchaser of the Pre- Funded Warrants and accompanying
Common Warrants fails to make payment to the Company for all or part of the Pre-Funded Warrants and accompanying Common Warrants on
the Closing Date, the Representative shall make payment to the Company on the Closing Date for such Pre-Funded Warrants and
accompanying Common Warrants at the Purchase Price. In the event that any purchaser of the Pre-Funded Warrants and accompanying
Common Warrants fails to make payment to the Company for all or part of the Pre-Funded Warrants at the Closing Time, the
Representative may elect, by written notice to the Company, to receive shares of Common Stock at the share purchase price specified
in <U>Schedule A</U> in lieu of all or a portion of such Pre-Funded Warrants to be delivered to the Underwriters under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the foregoing,
the Company shall pay the Representative a fee, payable quarterly on each January 1, April 1, July 1 and October 1 (or the following business
day if such day is not a business day) while any Common Warrants remain outstanding, for any cash exercises during such quarter of any
Common Warrants sold in connection with the offering, equal to 6.0% of the aggregate cash consideration received by the Company in connection
with such Common Warrant exercise and deliver a report on each such date detailing the warrant exercises and cash proceeds during such
quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section 3(b), will comply with the
requirements of Rule 430B, and will notify the Representative as soon as practicable, and confirm the notice in writing, (i) when any
post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have
been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment
to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein)
or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus,
or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the
Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection
with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time
period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly
whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that
it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order,
prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Continued Compliance with Securities Laws</I>. The Company will comply with the Securities Act, the Securities Act Regulations,
the Exchange Act and the Exchange Act Regulation so as to permit the completion of the distribution of the Securities as contemplated
in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus
relating to the Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<U>Rule 172</U>&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Securities or at any time prior to the date on
which the Warrants are no longer outstanding, any event shall occur or condition shall exist as a result of which it is necessary, in
the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration
Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that
the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at
the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package
or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations,
the Company will promptly (A) give the Representative notice of such event, (B) prepare any amendment or supplement as may be necessary
to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with
such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any
such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file
or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object. The Company
will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The
Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange Act Regulations within 48
hours prior to the Applicable Time; the Company will give the Representative notice of its intention to make any such filing from the
Applicable Time to the Closing Time and will furnish the Representative with copies of any such documents a reasonable amount of time
prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for
the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representative and counsel for the
Underwriters if requested, without charge, conformed copies of the Registration Statement as originally filed and each amendment thereto
(including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference
therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representative, without charge, a
conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters.
The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary
prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted
by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the
Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such number
of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments
or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the
Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Blue Sky Qualifications</I>. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities
for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative
may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided,
however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation
or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing
business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Rule 158</I>. The Company will timely file such reports pursuant to the Exchange Act as are necessary in order to make generally
available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the
benefits contemplated by, the last paragraph of Section 11(a) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in all material respects
in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &ldquo;Use
of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Listing</I>. The Company will use its best efforts to effect and maintain the listing of the Common Stock (including the Warrant
Shares) on the Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Restriction on Sale of Securities</I>. During a period of 90 days from the date of the Prospectus, the Company will not, without
the prior written consent of the Representative, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or
dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially
submit any registration statement under the Securities Act with respect to any of the foregoing, (ii)&nbsp;enter into any swap or any
other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership
of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common
Stock or such other securities, in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other
transaction described in clauses (i) and (ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B)
any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a convertible security
outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (C) any
securities issued pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure
Package, and the Prospectus or any documents incorporated by reference therein, as such plan may have been amended after the date hereof;
(D) any shares of Common Stock issued pursuant to any existing non-employee director stock plan or dividend reinvestment plan referred
to in the Registration Statement, the General Disclosure Package and the Prospectus; (E) the adoption by the Company of an amendment to
an existing equity incentive plan or the filing by the Company of any registration statement on Form S-8 or a successor form thereto;
(F) the issuance of shares of Common Stock pursuant to, that sales agreement with Leerink Partners LLC, dated May 2, 2022, as amended
from time to time, or (G) the issuance of equity securities (including securities convertible into or exchangeable for equity securities),
provided that such issuance is made in connection with a bona fide commercial or business development agreement, strategic partnership,
joint venture, license, collaboration, or similar arrangement<FONT STYLE="background-color: white">; <I>provided that&nbsp;</I>the aggregate
number of </FONT>equity securities (including securities convertible into or exchangeable for equity securities) <FONT STYLE="background-color: white">that
the Company may issue or agree to issue pursuant to this clause (G) shall not exceed 5% of the total number of shares of Common Stock
of the Company immediately following the completion of the transactions contemplated by this Agreement and that each recipient thereof
provides to the Representative a signed&nbsp;Lock-up&nbsp;Agreement substantially in the form of&nbsp;<U>Exhibit A</U>&nbsp;hereto</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally,
the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp; </FONT><I>Issuer
Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of the Representative, it will
not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or
retained by the Company under Rule 433; provided that the Representative will be deemed to have consented to the Issuer Free Writing
Prospectuses listed on <U>Schedule&nbsp;B-2</U> hereto and any &ldquo;road show that is a written communication&rdquo; within the
meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that
it will treat each such free writing prospectus consented to, or deemed consented to, by the Representative as an &ldquo;issuer free
writing prospectus,&rdquo; as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule
433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time
following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such
Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement which has
not been superseded or modified, any preliminary prospectus or the Prospectus, or included or would include an untrue statement of a
material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will
promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue
statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Testing-the-Waters Materials</I>. If at any time following the distribution of any Written Testing-the-Waters Communication
there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would
include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative
and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Tax Indemnity</I>. The Company will indemnify and hold harmless the Underwriters against any documentary, stamp or similar issue
tax, including any interest and penalties, on the issue and sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Transfer Agent.</I> The Company has engaged and will maintain, at its sole expense, a transfer agent and registrar for the Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>SEC Correspondence. </I>The Company agrees to supply the Underwriters with copies of all correspondence to and from, and all
documents issued to and by, the Commission in connection with the registration of the Securities under the Securities Act or any of the
Registration Statement, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document incorporated
by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Warrant Matters</I>. The Company shall, at all times while any Warrants are outstanding: (i) use reasonable best efforts to
maintain a registration statement covering the issue and sale of the Warrant Shares upon exercise of the Warrants such that the Warrant
Shares, when issued, will not be subject to resale restrictions under the Securities Act except to the extent that the Warrant Shares
are owned by affiliates, and (ii) reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved
shares of Common Stock, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding
Warrants, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this
Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits)
as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies of each
preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs
associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery
of the certificates or security entitlements for the Securities to the Underwriters or purchasers, as applicable, including any stock
or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters,
(iv)&nbsp;the fees and disbursements of the Company&rsquo;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the
Securities under securities laws in accordance with the provisions of Section&nbsp;3(e) hereof, including filing fees and the reasonable
fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a &ldquo;Blue
Sky Survey&rdquo; and any supplement thereto, (vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii)
the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken in connection with
the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics,
fees and expenses of any consultants engaged by the Company in connection with the road show presentations, travel and lodging expenses
of the representatives and officers of the Company and any such consultants, (viii) the filing fees incident to, and the reasonable fees
and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (ix)
the fees and expenses incurred in connection with the listing of the Securities on Nasdaq, and (x) the fees and disbursements of counsel
for the Underwriters in connection with the offering contemplated by this Agreement; <I>provided, however</I>, that the Company&rsquo;s
obligations to pay the fees and disbursements of counsel for the Underwriters pursuant to clauses (v), (viii) and (x) of this Section
4(a) shall not exceed an aggregate amount equal to $120,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Termination of Agreement</I>. If this Agreement is terminated by the Representative in accordance with the provisions of Section&nbsp;5,
Section&nbsp;9(a)(i), Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their reasonably
documented out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters, subject to the limitation
in the proviso to Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any
of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations
hereunder, and to the following further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Effectiveness of Registration Statement; Rule 430B Information</I>. The Registration Statement, including any Rule 462(b) Registration
Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or
any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the
Company&rsquo;s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information
to the reasonable satisfaction of counsel to the Underwriters. A prospectus containing the Rule 430B Information shall have been filed
with the Commission in the manner and within the time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective
amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements
of Rule 430B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion of Counsel for Company</I>. At the Closing Time, the Representative shall have received the opinion and the negative
assurance letter, each dated the Closing Time, of Dentons US LLP, and Dentons Europe LLP, each counsel for the Company, together with
the opinion of Boehmert &amp; Boehmert, counsel for the Company with respect to intellectual property matters, each in form and substance
satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representative shall have received the opinion, and negative
assurance letter, each dated the Closing Time, of Covington &amp; Burling LLP, counsel for the Underwriters, in form and substance satisfactory
to the Representative. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent
they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public
officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Officers&rsquo; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a
certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing
Time, to the effect that (i) there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the Company
in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the
Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing
Time, (iv) the Company has delivered executed copies of the Warrants to the purchasers thereof, and (v)&nbsp;no stop order suspending
the effectiveness of the Registration Statement under the Securities Act has been issued, no order preventing or suspending the use of
any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are
pending or, to their knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Accountant&rsquo;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representative shall have received
from Baker Tilly a letter, dated such date, in form and substance satisfactory to the Representative, containing statements and information
of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements
and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Bring-down Comfort Letter</I>. At the Closing Time, the Representative shall have received from Baker Tilly a letter, dated
as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this
Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Approval of Listing</I>. At the Closing Time, the Warrant Shares shall have been approved for listing on the Nasdaq Global Select
Market, subject only to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>[Reserved].</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Lock-up Agreements</I>. At the date of this Agreement, the Representative shall have received an agreement substantially in
the form of <U>Exhibit&nbsp;A</U> hereto signed by all of the Company&rsquo;s directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Chief Financial Officer&rsquo;s Certificate.</I> On the date of this Agreement and at the Closing Time, the Representatives
shall have received from the Company a certificate of its principal financial officer with respect to certain financial data contained
in the General Disclosure Package and the Prospectus, which certificate shall be substantially in the form attached hereto as <U>Exhibit
B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Additional Documents</I>. At the Closing Time, counsel for the Underwriters shall have been furnished with such other documents
and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein
contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated
shall be reasonably satisfactory in form and substance to the Representative and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Termination of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required
to be fulfilled, this Agreement may be terminated by the Representative by notice to the Company at any time at or prior to the Closing
Time, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except that
Sections 1, 4, 6, 7, 8, 14, 15, 16 and 17 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as
such term is defined in Rule 501(b) under the Securities Act (each, an &ldquo;<U>Affiliate</U>&rdquo;)), its selling agents and each person,
if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section 20 of the Exchange Act as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be
a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or
necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material
fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the
General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&ldquo;<U>Marketing
Materials</U>&rdquo;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically),
or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters
Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section
6(d) below) any such settlement is effected with the written consent of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representative), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">provided, however, that this
indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement
or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information
deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto)
in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Indemnification of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the
Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all loss, liability, claim,
damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including
the Rule 430B Information, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon
and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Actions against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to
each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify
an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced
as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by
the Representative, and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties shall be
selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however,
that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified
party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition
to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar
or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall,
without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect
to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified
parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release
of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include
a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying
party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into
more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received
notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such
indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on
the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand,
in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any
other relevant equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities
pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received
by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public
offering price of the Securities as set forth on the cover of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative fault of the
Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses
incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement
or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the provisions
of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received
by such Underwriter in connection with the Securities underwritten by it and distributed to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Section
7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act and each Underwriter&rsquo;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same rights to contribution
as the Company. The Underwriters&rsquo; respective obligations to contribute pursuant to this Section 7 are several in proportion to the
number of Securities set forth opposite their respective names in <U>Schedule&nbsp;A</U> hereto and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and
in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents,
any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment
for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Termination of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Termination</I>. The Representative may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i) if there has been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, or (ii)&nbsp;if there has occurred any material
adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial
or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representative, impracticable or
inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading
in any securities of the Company has been suspended or materially limited by the Commission or Nasdaq, or (iv) if trading generally on
the NYSE MKT or the New York Stock Exchange or in the Nasdaq Global Select Market has been suspended or materially limited, or minimum
or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of
the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or securities
settlement or clearance services in the United States or in Europe, or (vi) if a banking moratorium has been declared by either U.S. Federal
or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any
party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall
survive such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time to purchase
the Securities which it or they are obligated to purchase under this Agreement (the &ldquo;<U>Defaulted Securities</U>&rdquo;), the Representative
shall have the right, within 24&nbsp;hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any
other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon
the terms herein set forth; if, however, the Representative shall not have completed such arrangements within such 24-hour period, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the
non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that
their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement shall
terminate without liability on the part of any non-defaulting Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action taken pursuant to
this Section shall relieve any defaulting Underwriter from liability in respect of its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any such default
which does not result in a termination of this Agreement either the (i) Representative or (ii) the Company shall have the right to postpone
Closing Time for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General
Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term &ldquo;Underwriter&rdquo; includes
any person substituted for an Underwriter under this Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given
if mailed or transmitted by any standard form of telecommunication, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>if to the Underwriters, shall be directed to Leerink Partners LLC at 1301 Avenue of the Americas, 5<SUP>th</SUP> Floor, New York,
New York 10019, attention: Stuart R. Nayman;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>if to the Company, shall be directed to Immunic, Inc. at 1200 Avenue of the Americas, Suite 200, New York, New York 10036, attention:
Dr. Daniel Vitt; with a copy (which shall not constitute notice) to Dentons US LLP, 1221 Avenue of the Americas, New York, NY 10020, attention:
Ilan Katz, email: ilan.katz@Dentons.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a) the purchase and sale of the Securities
pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on
the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been
acting solely as a principal and is not the agent or fiduciary of the Company or its stockholders, creditors, employees or any other party,
(c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering
of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company
or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the
Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided
any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Recognition of the U.S. Special Resolution Regimes</U>. In the event that any Underwriter that is a Covered Entity becomes subject
to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation
in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
(A) &ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance
with, 12 U.S.C. &sect; 1841(k); (B) &ldquo;Covered Entity&rdquo; means any of the following: (i) a &ldquo;covered entity&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered bank&rdquo; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C) &ldquo;Default Right&rdquo; has the meaning assigned to that term
in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable; and (D) &ldquo;U.S. Special
Resolution Regime&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Parties</U>. This Agreement shall inure to the benefit of and be binding upon the Underwriters and the Company and their respective
successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation,
other than the Underwriters and the Company and their respective successors and their respective controlling persons, officers, directors,
Affiliates and selling agents referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right,
remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions
hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors and their
respective controlling persons, officers, directors, Affiliates and selling agents and their heirs and legal representatives, and for
the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor
by reason merely of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Waiver of Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or based upon this Agreement
or the transactions contemplated hereby shall&nbsp;be instituted in (i) the federal courts of the United States of America located in
the City and County of New York, Borough of Manhattan or&nbsp;(ii) the courts of the State of New York located in the City and County
of New York, Borough of Manhattan (collectively, the &ldquo;<U>Specified Courts</U>&rdquo;), and each party irrevocably submits to the
exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such
jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document
by mail to such party&rsquo;s address set forth above shall be effective service of process for any suit, action or other proceeding brought
in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other
proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any
such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER
TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Partial Unenforceability</U>. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Counterparts</U>. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by
any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute
one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable
law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SECTION
22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Entire Agreement</U>.
This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters,
or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES FOLLOW]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along
with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">IMMUNIC, INC.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Glenn Whaley</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Glenn Whaley</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Principal Financial Officer</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIRMED AND ACCEPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEERINK PARTNERS LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%">/s/ Gabriel Cavazos</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Gabriel Cavazos</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Senior Managing Director</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representative of the other Underwriters named
in <U>Schedule&nbsp;A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">[S<FONT STYLE="font-variant: small-caps">I</FONT>GN<FONT STYLE="font-variant: small-caps">ATURE</FONT>
P<FONT STYLE="font-variant: small-caps">A</FONT>G<FONT STYLE="font-variant: small-caps">E TO</FONT> UND<FONT STYLE="font-variant: small-caps">ER</FONT>W<FONT STYLE="font-variant: small-caps">RITIN</FONT>G
AG<FONT STYLE="font-variant: small-caps">REEMENT</FONT>]</FONT></P>

</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The combined initial public offering price shall be $0.7499 per Pre-Funded
Warrant and accompanying Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The combined purchase price per Pre-Funded Warrant and accompanying
Common Warrants to be paid by the several Underwriters shall be $0.7049, an amount equal to the initial public offering price set forth
above less $0.0450 per Pre-Funded Warrant and accompanying Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name of Underwriter</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Number of<BR> <U>Pre-Funded
Warrants</U></P></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center">Number of Series A Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center">Number of Series B Warrants</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Leerink Partners LLC&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: center">77,038,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: center">77,038,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: center">77,038,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">B. Riley Securities, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5,876,000</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5,876,000</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5,876,000</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Brookline Capital Markets, a division of Arcadia Securities, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3,752,667</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3,752,667</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3,752,667</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0.5in">Total&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">86,666,667</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">86,666,667</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">86,666,667</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Pricing Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities to be Sold:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Pre-Funded&nbsp;Warrants to Purchase
86,666,667 shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Series A Warrants to Purchase 86,666,667
shares of Common Stock (which equates to 100% warrant coverage); Exercise price of $0.75 per underlying share of Common Stock; The Series
A warrants will expire on December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Series B Warrants to Purchase 86,666,667
shares of Common Stock (which equates to 100% warrant coverage); Exercise price of $0.75 per underlying share of Common Stock; The Series
B warrants will expire five years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Offering Price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">$0.7499 per&nbsp;Pre-Funded&nbsp;Warrant
and accompanying Common Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriting Discounts and Commissions: 6.00%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimated Net Proceeds to the Company (after underwriting
discounts and commissions, but before transaction expenses, and assuming no exercise of Common Warrants): $61.1 million</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Free Writing Prospectuses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>List of Written Testing-the-Waters Communications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Pre-Funded Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Series A Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Series B Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&#9679;], 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o&#9;Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1301 Avenue of the Americas, 5<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Re:&#9;<U>Proposed Public
Offering by Immunic, Inc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, a stockholder,
officer and/or director of Immunic, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), understands that Leerink Partners
LLC (&ldquo;<U>Leerink Partners</U>&rdquo;) proposes to enter into an Underwriting Agreement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;)
with the Company providing for the public offering (the &ldquo;<U>Public Offering</U>&rdquo;) of pre-funded warrants to purchase shares
of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo; and such warrants, the &ldquo;<U>Pre-Funded
Warrants</U>&rdquo;), accompanied by Series A warrants to purchase shares of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrants)
and Series B warrants to purchase shares of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrants). In recognition of the benefit
that the Public Offering will confer upon the undersigned as a stockholder, an officer and/or a director of the Company, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter
to be named in the Underwriting Agreement (collectively, the &ldquo;<U>Underwriters</U>&rdquo;) that, during the period beginning on the
date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the &ldquo;<U>Lock-Up Period</U>&rdquo;),
the undersigned will not, without the prior written consent of Leerink Partners, on behalf of the Underwriters, directly or indirectly,
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible
into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;<U>Lock-Up Securities</U>&rdquo;), or exercise
any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in
connection therewith, under the Securities Act of 1933, as amended, or (ii) enter into any swap or any other agreement or any transaction
that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether
any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of Leerink Partners,
provided, in each case, that (1)&nbsp;Leerink Partners receives a signed lock-up agreement for the balance of the Lock-Up Period from
each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value,
(3) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16
of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and (4) the undersigned does not otherwise
voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of
the Lock-Up Period):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">as a <I>bona fide</I> gift or gifts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned
(for purposes of this lock-up agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not
more remote than first cousin);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">as a distribution or other transfer by a partnership to its partners or former partners or by a limited
liability company to its members or former members or by a corporation to its stockholders or former stockholders or to any wholly-owned
subsidiary of such corporation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability company
or other business entity, to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case
may be;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">to the undersigned&rsquo;s affiliates or to any investment fund or other entity controlled or managed
by the undersigned;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">pursuant to a qualified domestic relations order or in connection with a divorce settlement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">by will or intestate succession upon the death of the undersigned;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">to the Company to satisfy tax withholding obligations associated with the exercise or vesting of equity
awards under any equity compensation plan of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, no provision
in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned&rsquo;s Lock-Up Securities to the Company in
connection with the termination of the undersigned&rsquo;s services to the Company, provided that any filing under Section 16 of the Exchange
Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances
described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common
Stock or options to purchase shares of Common Stock, in each case for cash or on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo;
basis, pursuant to any stock option, stock bonus or other stock plan or arrangement in existence as of the date of the Underwriting Agreement;
provided, however, that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in
this letter and that any filing under Section 16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate
in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2) and (b) no shares of Common Stock
were sold by the reporting person; (3) the acquisition of shares of Common Stock in open market transactions or otherwise, provided such
shares of Common Stock will be subject to the restrictions set forth in this letter; (4) the transfer of Lock-Up Securities upon the completion
of a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company&rsquo;s
securities involving a change of control of the Company; provided, however, that in the event that such tender offer, merger, consolidation
or other such transaction is not completed, such Lock-up Securities held by the undersigned shall remain subject to the restrictions on
transfer set forth in this letter; and (5) the conversion of outstanding preferred stock of the Company into shares of Common Stock, provided
that any such shares received upon such conversion shall be subject to the restrictions on transfer set forth in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under
the Exchange Act (&ldquo;<U>10b5-1 Trading Plan</U>&rdquo;) or from amending an existing 10b5-1 Trading Plan so long as there are no sales
of Lock-Up Securities under any such 10b5-1 Trading Plan during the Lock-Up Period; and provided that, the establishment of a 10b5-1 Trading
Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment or amendment of such plan is not required
to be reported in any public report or filing with the Securities and Exchange Commission, or otherwise and (ii) the undersigned does
not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of
the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and
the undersigned shall be released from the undersigned&rsquo;s obligations hereunder, upon the earliest to occur, if any, of (i) prior
to the execution of the Underwriting Agreement, the Company advises Leerink Partners in writing that it has determined not to proceed
with the Public Offering; (ii) the Underwriting Agreement is executed but is terminated prior to the closing of the Public Offering (other
than the provisions thereof which survive termination), or (iii) June 6, 2025, in the event that the Underwriting Agreement has not been
executed by such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action
from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting, financial, regulatory
and tax advisors to the extent deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement shall be governed
by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement may be delivered
via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com
or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="background-color: white">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 4%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT>Name of Security Holder <I>(Print exact name</I>) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT>By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signature </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT>If not signing in an individual capacity:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT>Name of Authorized Signatory <I>(Print</I>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT>Title of Authorized Signatory <I>(Print</I>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Chief Financial Officer&rsquo;s Certificate</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>to be Issued Pursuant to Section 5(J)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>e664551_ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNIC, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-Funded Warrant No. [ <FONT STYLE="font-size: 12pt">]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Issue Date: May [&#9679;], 2025 (such date, the
&ldquo;<B><I>Issue Date</I></B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS PRE-FUNDED WARRANT TO
PURCHASE COMMON STOCK (the &ldquo;<B><I>Warrant</I></B>&rdquo;) certifies that, for value received, [&#9679;] or its assigns (the &ldquo;<B><I>Holder</I></B>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<B><I>Initial Exercise Date</I></B>&rdquo;) until this Warrant is exercised in full (the &ldquo;<B><I>Termination
Date</I></B>&rdquo;), to subscribe for and purchase from <B>IMMUNIC, INC.</B>, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
up to [&#9679;] shares of common stock, par value $0.0001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) (as subject to adjustment
hereunder, the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in <U>Section 2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.&#9;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement, dated
May 28, 2025, among the Company and Leerink Partners LLC, as Representative of the Underwriters named therein, as amended, modified or
supplemented from time to time in accordance with its terms (the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;). For purposes of
this Warrant, the following terms shall have the meanings set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><I><U>Person</U></I></B>&rdquo;
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the shares of Common Stock are traded on Nasdaq or, if not traded on Nasdaq, a day on which the
principal Trading Market on which the shares of Common Stock are traded is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><I>Trading
Market</I></B>&rdquo; means any of the following markets or exchanges on which the Warrant Shares are listed or quoted for trading on
the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange,
the NYSE American, the OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<B><I>Notice of
Exercise</I></B>&rdquo;). Within the earlier of (i)&nbsp;one (1) Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period (as defined in <U>Section 2(d)(i)</U> herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type
of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject
to adjustment hereunder (the &ldquo;<B><I>Exercise Price</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;<B><I>cashless exercise</I></B>&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(A) = as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to <U>Section 2(a)</U> hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered
pursuant to <U>Section 2(a)</U> hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule
600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either
(y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of
the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<B><I>Bloomberg</I></B>&rdquo;) as of the time
of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)&nbsp;hours after the close of
&ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii)&nbsp;the VWAP on the date of the
applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and
delivered pursuant to <U>Section 2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(B) = the Exercise Price of
this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(X) = the number of Warrant
Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise when there is no effective registration statement registering, or the prospectus contained therein is not
available for, the issuance of the Warrant Shares to the Holder, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of
this Warrant may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this
<U>Section 2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Bid Price</I></B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>VWAP</I></B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the transfer
agent for the Common Stock (the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;) to the Holder by crediting the account of the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<B><I>DWAC</I></B>&rdquo;)
if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are eligible for resale by the Holder
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the later of (i)&nbsp;the
earlier of (a)&nbsp;two (2) Trading Days after the delivery to the Company of the Notice of Exercise and (b)&nbsp;the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, and (ii)&nbsp;one (1) Trading
Day after delivery of the aggregate Exercise Price to the Company (providing the foregoing clause (ii)&nbsp;shall not apply in the event
of a cashless exercise) (such date, the &ldquo;<B><I>Warrant Share Delivery Date</I></B>&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;one (1) Trading Day and (ii)&nbsp;the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<B><I>Standard Settlement Period</I></B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section 2(d)(i)</U>
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<B><I>Buy-In</I></B>&rdquo;), then the Company shall pay in cash to the Holder the amount, if any, by which (x)&nbsp;the
Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the
product of (1)&nbsp;the lesser of the (a)&nbsp;the number of shares of Common Stock so purchased and (b)&nbsp;the aggregate number of
Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue multiplied by (2)&nbsp;the
actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions).
For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice after the occurrence of a Buy-In, indicating
the amounts payable to the Holder in respect of the Buy-In together with applicable confirmations and other evidence reasonably requested
by the Company. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver the Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in
the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. Notwithstanding anything to the contrary herein, the Company shall not effect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s affiliates (as such term is defined in Rule 501(b) under the Securities Act (each, an &ldquo;<B><I><U>Affiliate</U></I></B>&rdquo;)),
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d)
of the Exchange Act (such Persons, together with its Affiliates, its &ldquo;<B><I>Attribution Parties</I></B>&rdquo;)), would beneficially
own a number of shares of Common Stock in excess of <B>[&bull;] </B>([&bull;]%) of the total number of issued and outstanding shares of
Common Stock following such exercise (the &ldquo;<B><I>Beneficial Ownership Limitation</I></B>&rdquo;). For purposes of the foregoing
sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of
shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes
of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the
rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that
such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any schedules required
to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with its Attribution Parties) and
of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by
the Holder together with its Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s
most recent periodic or annual report filed with the SEC, as the case may be, (B)&nbsp;a more recent public announcement by the Company
or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Any portion of an exercise that would result in the issuance of shares in excess of the Beneficial Ownership Limitation shall be treated
as null and void ab initio. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this <U>Section 2(e)</U>,
provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this
<U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this <U>Section 2(e)</U> to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt, Section 2(e) shall not restrict the number of shares of Common Stock which a Holder or the Attribution Parties
may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution
Parties may receive in the event of a Fundamental Transaction as contemplated in Section 3(d) of this Warrant. For purposes of clarity,
the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Beneficial Ownership Limitation shall not be
deemed to be beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section 13(d) of the
Exchange Act and the rules promulgated thereunder or Section 16 of the Exchange Act and the rules promulgated thereunder, including Rule
16a-1(a)(1). No prior inability to exercise this Warrant pursuant to Section 2(e) shall have any effect on the applicability of the provisions
of this paragraph with respect to any subsequent determination of exercisability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.&#9;<U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of
reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock
(the &ldquo;<B><I>Purchase Rights</I></B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase
Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase
Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any
such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding and except as covered by <U>Section 3(d)</U> below, if the Company
shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<B><I>Distribution</I></B>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the participation in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any
such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to
such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as
its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
shares of Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires securities representing more than 50% of the aggregate voting power, including the power to vote on the election of directors
of the Company, of the issued and outstanding equity securities of the Company (not including any shares of Common Stock held by the other
Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<B><I>Fundamental Transaction</I></B>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
<U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<B><I>Alternate Consideration</I></B>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B><I>Successor Entity</I></B>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the
Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to
be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K.The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth herein, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)&nbsp;Trading
Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 4(a)</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date set forth above and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B><I>Warrant
Register</I></B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;<B><I>cashless exercise</I></B>&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken, or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>. The Company covenants that it will, during the period the Warrant is outstanding, reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who
are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company
covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not
increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all
such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant. Before taking any action that would result in an adjustment in the number of
Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED
AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF
THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY
OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN
ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF
DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a)&nbsp;upon personal delivery
to the party to be notified, (b)&nbsp;when sent by email or facsimile if sent during normal business hours of the recipient, and if sent
at a time other than during normal business hours of the recipient, then on the next Trading Day (provided, with respect to notices sent
by email so long as such sent email is kept on file by the sending party and the sending party does not receive an automatically generated
message from the recipient&rsquo;s email server that such email could not be delivered to such recipient), (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one Trading Day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. The addresses for such communications
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Immunic, Inc.<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, NY 10036<BR>
Attention: Glenn Whaley<BR>
Email: glenn.whaley@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">With a copy (which will not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Dentons US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Ilan Katz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1221 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Email: Ilan.Katz@Dentons.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to the Holder: To the address, email address or facsimile number set forth in the Warrant Register, or as otherwise provided by the Holder
to the Company in accordance with this <U>Section 5(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended, or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">IMMUNIC, INC.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Daniel A. Vitt</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TO: IMMUNIC, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 15%; border: Black 1pt solid; font-size: 10pt">________</TD>
    <TD STYLE="width: 85%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt">in lawful money of the United States; or </TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt">________</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt">the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">__________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">(4) By its delivery of this
Notice of Exercise, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the
Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d)
of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;2(e) of the Warrant to which this notice
relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The Warrant Shares shall
be delivered to the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">Name of Investing Entity:____________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><I>Signature of Authorized Signatory of Investing Entity</I>: ______________________________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">Name of Authorized Signatory:________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">Title of Authorized Signatory:_________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: justify; text-indent: -10pt">Date:____________________________________________________</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Phone Number:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Email Address:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Dated: _________________ </TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Holder&rsquo;s Signature:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>e664551_ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF SERIES A WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNIC, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES A WARRANT TO PURCHASE COMMON STOCK OR
PRE-FUNDED WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issue Date: May [&#9679;], 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IMMUNIC, INC., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, [&#9679;], or its permitted registered assigns (the &ldquo;<B><I>Holder</I></B>&rdquo;), is entitled,
subject to the terms set forth below, to purchase from the Company up to a total of [&#9679;] shares of common stock, par value $0.0001
per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of the Company (each such share, a &ldquo;<B><I>Warrant Share</I></B>&rdquo;
and all such shares, the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;) at an exercise price per share equal to $0.75 per share (as adjusted
from time to time as provided in <U>Section 8</U> herein, the &ldquo;<B><I>Exercise Price</I></B>&rdquo;), or Pre-Funded Warrants (as
defined below) to purchase the same number of Warrant Shares (as subject to adjustment hereunder), upon surrender of this Warrant to Purchase
Common Stock or Pre-Funded Warrants (including any Warrants to Purchase Common Stock or Pre-Funded Warrants issued in exchange, transfer
or replacement hereof, the &ldquo;<B><I>Warrant</I></B>&rdquo;) at any time and from time to time on or after the Issue Date (as defined
herein) and through and including 5:30 P.M., New York City time, on the Expiration Date (as defined herein), and subject to the following
terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 1.</TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"><U>Definitions</U>. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement, dated May 28, 2025,
among the Company and Leerink Partners LLC, as Representative of the Underwriters named therein, as amended, modified or supplemented
from time to time in accordance with its terms. For purposes of this Warrant, the following terms shall have the following meanings:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Closing Sale Price</I></B>&rdquo; means, for any security as of any date, the last trade
price for such security on the Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Trading Market
begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior
to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of
such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets,
or, if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the bid and ask prices, of any
market makers for such security as reported in the &ldquo;pink sheets&rdquo; by Pink Sheets LLC. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value.
The Board of Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such determinations shall
be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Initial Warrant</I></B>&rdquo; means the pre-funded warrant (No. [ ]) to purchase [&#9679;]
shares of Common Stock issued to the Holder on the Issue Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Issue Date</I></B>&rdquo; means May [&#9679;], 2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Person</I></B>&rdquo; means an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental
authority or any other form of entity not specifically listed herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Pre-Funded Warrant Exercise Price</I></B>&rdquo; equals $0.0001 per share of Common Stock,
subject to adjustment for reverse and forward share splits, share dividends, share combinations, ratio changes and other similar transactions
of the shares of Common Stock that occur after the Issue Date; <I>provided</I>, that in no event shall the Pre-Funded Warrant Exercise
Price be adjusted to an amount below the par value of the shares of Common Stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo; means, the pre-funded warrants to purchase a number of
shares of Common Stock equal to the number of Warrant Shares as to which this Warrant is being exercised in the form of a Pre-Funded Warrant
attached as <U>Exhibit A</U> hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Registration Statement</I></B>&rdquo; means the Company&rsquo;s Registration Statement on
Form S-3 (File No. 333-275717), originally filed with the Securities and Exchange Commission on November 22, 2023, and declared effective
on May 31, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Trading Day</I></B>&rdquo; means a day on which the shares of Common Stock are traded on
Nasdaq or, if not traded on Nasdaq, a day on which the principal Trading Market on which the shares of Common Stock are traded is open
for trading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Trading Market</I></B>&rdquo; means any of the following markets or exchanges on which the
Warrant Shares are listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq
Global Select Market, the New York Stock Exchange, the NYSE American, the OTCQB or the OTCQX (or any successors to any of the foregoing).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 2.</TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"><U>Registration of Transfers</U>.
Subject to compliance with all applicable securities laws and the rules of the Trading Market, the Company shall, or will cause its Transfer
Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment
for all applicable transfer taxes (if any) and (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory
to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the
registration requirements of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and all applicable
state securities or blue sky laws (other than in connection with any transfer (i) pursuant to an effective registration statement, (ii)
to the Company or (iii) pursuant to Rule 144), and (y) delivery by the transferee of a written statement to the Company certifying that
the transferee is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act (other than in connection with
any transfer (i) pursuant to an effective registration statement, (ii) to the Company or (iii) pursuant to Rule 144). Upon any such registration
or transfer, a new warrant to purchase Common Stock or Pre-Funded Warrants in substantially the form of this Warrant (any such new warrant,
a &ldquo;<B><I>New Warrant</I></B>&rdquo;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and
a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder.
The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and
obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer
Agent to, prepare, issue and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section 2</U>. Until due presentment
for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company
shall not be affected by any notice to the contrary.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 3.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Exercise and Duration of Warrants</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Except as set forth in Section 3(c) below, this Warrant shall expire on December 31, 2025 (the &ldquo;<B><I>Expiration
Date</I></B>&rdquo;). All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by <U>Section
9</U> of this Warrant at any time and from time to time on or after the Issue Date and through and including 5:30 P.M. New York City time,
on the Expiration Date. At 5:30 P.M., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto
shall be and become void and of no value and this Warrant shall be terminated and no longer outstanding.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form
attached as <U>Schedule 1</U> hereto (the &ldquo;<B><I>Exercise Notice</I></B>&rdquo;), completed and duly signed, and (ii) payment of
(x) the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised if this Warrant is being exercised
for Warrant Shares, or (y) the aggregate Exercise Price minus the aggregate Pre-Funded Warrant Exercise Price, if this Warrant is being
exercised for Pre-Funded Warrants, and the date on which the last of such items is delivered to the Company (as determined in accordance
with the notice provisions hereof) is an &ldquo;<B><I>Exercise Date</I></B>.&rdquo; The Holder shall not be required to deliver the original
Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation
of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares or Pre-Funded
Warrants. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">If the Holder exercises the Initial Warrant in full on or prior to September 30, 2025, this Warrant shall
automatically terminate and be of no further force or effect, without any required further action by the Holder; provided that if such
Initial Warrant is not exercised in full, this Warrant shall terminate proportionally to the extent the Pre-Funded Warrant is exercised.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 4.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares
or Pre-Funded Warrants</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">If this Warrant is being exercised for Warrant Shares, upon exercise of this Warrant, the Company shall
promptly (but in no event later than one Trading Day after the Exercise Date), upon the request of the Holder, credit such aggregate number
of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance
account with The Depository Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;) through its Deposit Withdrawal Agent SEC system, provided
that the Registration Statement is effective or the Warrant Shares are freely transferable without restriction under Rule 144, or if the
Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend
regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice,
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of shares of
Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any Person permissibly so designated by the Holder
to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective
of the date such Warrant Shares are credited to the Holder&rsquo;s DTC account or the date of delivery of the certificates evidencing
such Warrant Shares, as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">If this Warrant is being exercised for Pre-Funded Warrants, the Company shall issue and dispatch by overnight
courier to the address as specified in the Exercise Notice, Pre-Funded Warrants to purchase a number of shares of Common Stock with respect
to which this Warrant is being exercised by the date that is the latest of (i) five (5) Trading Days after the delivery to the Company
of the Exercise Notice, (ii) five (5) Trading Days after delivery of the aggregate Exercise Price less the aggregate Pre-Funded Warrant
Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the
Company of the Exercise Notice. As used herein, <B>&ldquo;<I>Standard Settlement Period</I></B>&rdquo; means the standard settlement period,
expressed in a number of Trading Days, on the Company&rsquo;s Trading Market with respect to the shares of Common Stock as in effect on
the date of delivery of the Exercise Notice.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">If by the time frames set forth for delivery above, the Company fails to deliver to the Holder a certificate
representing the required number of Warrant Shares in the manner required pursuant to <U>Section 4(a)</U>, or fails to credit the Holder&rsquo;s
balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such time frame set forth for
delivery above and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise; provided
such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B><I>Buy-In</I></B>&rdquo;),
then the Company shall, within two Trading Days after the Holder&rsquo;s written request and in the Holder&rsquo;s sole discretion, either
(1) pay in cash to the Holder an amount equal to the Holder&rsquo;s total purchase price (including commercially reasonable brokerage
commissions, if any) for the shares of Common Stock so purchased, at which point the Company&rsquo;s obligation to deliver such certificate
(and to issue such Warrant Shares) or to cause the Holder&rsquo;s DTC account to be credited for such Warrant Shares shall terminate or
(2) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash
to the Holder in an amount equal to the excess (if any) of Holder&rsquo;s total purchase price (including commercially reasonable brokerage
commissions, if any) for the shares of Common Stock so purchased in the Buy-In (assuming such sale was executed on commercially reasonable
terms at prevailing market prices) over the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the
Closing Sale Price of a share of Common Stock on the Exercise Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">To the extent permitted by law and subject to <U>Section 4(c)</U>, the Company&rsquo;s obligations to
issue and deliver Warrant Shares and Pre-Funded Warrants in accordance with and subject to the terms hereof (including the limitations
set forth in <U>Section 10</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce
the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to
enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or
any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the
issuance of Warrant Shares and Pre-Funded Warrants. Subject to <U>Section 4(c)</U>, nothing herein shall limit the Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 5.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Charges, Taxes and Expenses</U>. Issuance and delivery of
certificates for shares of Common Stock or Pre-Funded Warrants upon exercise of this Warrant shall be made without charge to the Holder
for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided, however</I>, that the
Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates
for Warrant Shares, Pre-Funded Warrants or the Warrants in a name other than that of the Holder or its affiliate (as such term is defined
in Rule 501(b) under the Securities Act, each, an &ldquo;<B><I>Affiliate</I></B>&rdquo;). The Holder shall be responsible for all other
tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares or Pre-Funded Warrants upon
exercise hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 6.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Replacement of Warrant</U>. If this Warrant is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof,
or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested
by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s
obligation to issue the New Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 7.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Reservation of Warrant Shares</U>. The Company covenants
that it will at all times while this Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares or Pre-Funded Warrants upon exercise
of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this
entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account
the adjustments and restrictions of <U>Section 8</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall,
upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued
and fully paid and nonassessable. The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities
exchange or automated quotation system upon which the shares of Common Stock may be listed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 8.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Certain Adjustments</U>. The number of Warrant Shares or
Pre-Funded Warrants issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this <U>Section
8</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)
pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the
Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this <U>Section 8(a)</U> shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 8(a) above, if
at any time the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of Common Stock (the &ldquo;<B><I>Purchase Rights</I></B>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding and except as covered by
<U>Section 8(d)</U> below, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Warrant, then, in
each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)
the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding shares of Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires securities representing more than 50% of the aggregate voting power, including the power to vote on the election of directors
of the Company, of the issued and outstanding equity securities of the Company (not including any shares of Common Stock held by the other
Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<B><I>Fundamental Transaction</I></B>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
<U>Section 10</U> on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in <U>Section 10</U> on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B><I>Successor Entity</I></B>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Calculations</U>. All calculations under this <U>Section 8</U> shall be made to the nearest cent or
the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this <U>Section 8</U>, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Notice to Holder</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 3%">(i)</TD><TD STYLE="text-align: justify"><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision
of this <U>Section 8</U>, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price
after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 3%">(ii)</TD><TD STYLE="text-align: justify"><U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption
of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its
Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a
record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K.The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 9.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Payment of Exercise Price</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">From and after the Issue Date and through and including 5:30 P.M., New York City time, on the Expiration
Date, the Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company a duly
executed Exercise Notice and a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment
acceptable to the Company for the aggregate Exercise Price for the Warrant Shares or Pre-Funded Warrants being purchased.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Cashless Exercise</U>. If at any time after the Issue Date, there is no effective registration statement
registering, or the prospectus contained therein is not available for, the issuance of the Warrant Shares to the Holder, this Warrant
may also be exercised for Warrant Shares, in whole or in part, at such time by means of a &ldquo;<B><I>cashless exercise</I></B>&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(A) = as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Exercise Notice if such Exercise Notice is (1)&nbsp;both executed
and delivered pursuant to <U>Section 3(b)</U> on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to <U>Section
3(b)</U> on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP on the Trading
Day immediately preceding the date of the applicable Exercise Notice or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<B><I>Bloomberg</I></B>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Exercise Notice if such Exercise Notice is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within
two (2) hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to <U>Section 3(b)</U> or (iii)&nbsp;the VWAP on the date of the applicable Exercise Notice if the date of such Exercise Notice
is a Trading Day and such Exercise Notice is both executed and delivered pursuant <U>Section 3(b)</U> after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(X) = the number of Warrant
Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise when there is no effective registration statement registering, or the prospectus contained therein is not
available for, the issuance of the Warrant Shares to the Holder, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of
this Warrant may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this
Section 9(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&ldquo;<B><I>Bid Price</I></B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&ldquo;<B><I>VWAP</I></B>&rdquo; means,
for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 10.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Limitations on Exercise</U>.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary herein, the Company shall not effect any exercise of this Warrant
(other than for Pre-Funded Warrants), and a Holder shall not have the right to exercise any portion of this Warrant (other than for Pre-Funded
Warrants), to the extent that after giving effect to such issuance after exercise as set forth on the applicable Exercise Notice, the
Holder together with the Holder&rsquo;s Affiliates, and any other Persons whose beneficial ownership of Common Stock would be aggregated
with the Holder&rsquo;s for purposes of Section 13(d) of the Exchange Act (such Persons, together with its Affiliates, its &ldquo;<B><I>Attribution
Parties</I></B>&rdquo;)), would beneficially own a number of shares of Common Stock in excess of <B>[&bull;] </B>([&bull;]%) of the total
number of issued and outstanding shares of Common Stock following such exercise (the &ldquo;<B><I>Beneficial Ownership Limitation</I></B>&rdquo;).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii)&nbsp;exercise or conversion of the
unexercised or nonconverted portion of any other securities of the Company subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding
sentence, for purposes of this <U>Section 10(a)</U>, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 10(a)</U>
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with its
Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of an Exercise Notice shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with its Attribution Parties) and of which portion of this Warrant is exercisable, in each case
subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of
the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section 10(a)</U>, in determining the number
of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the SEC, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding. Any portion of an exercise that would result in the issuance of shares in excess of the Beneficial Ownership Limitation
shall be treated as null and void ab initio. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this <U>Section 10(a)</U>
provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this
<U>Section 10(a)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this <U>Section 10(a)</U> to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">This <U>Section 10</U> shall not restrict the number of shares of Common Stock which a Holder may receive
or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of
a Fundamental Transaction as contemplated in <U>Section 8</U> of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 11.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Transfer Restrictions</U>. This Warrant may not be transferred
prior to September 30, 2025. From and after October 1, 2025, and subject to compliance with any applicable securities laws and the conditions
set forth herein, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares or Pre-Funded Warrants without having a new Warrant issued.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 12.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>No Fractional Shares</U>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 13.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Warrant Agent</U>. The Company shall initially serve as warrant
agent under this Warrant. Upon ten (10) days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any corporation
into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company
or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act.
Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 14.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>No Rights as a Stockholder</U>. The Holder, solely in such Person&rsquo;s capacity as a holder of this
Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor
shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder
of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant
Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or
as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Authorized Shares</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(i)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Except and to the extent as waived or consented to by the Holder, the Company shall not by
any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth
in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value
of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take
all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations
under this Warrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(ii)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Before taking any action which would result in an adjustment in the number of Warrant Shares
or Pre-Funded Warrants for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations
or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. Subject to the restrictions on transfer set forth in this Warrant and compliance
with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the
written consent of the Holder except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure
to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in
this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause
of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and
assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant will contain a legend to the effect that the Warrant Shares are not registered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and
the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time
to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Warrant may be modified or amended, or the provisions hereof waived only with the
written consent of the Company and the Holder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement
to all of the terms and conditions contained herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify"><U>Notices</U>. All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by email or facsimile if
sent during normal business hours of the recipient, and if sent at a time other than during normal business hours of the recipient, then
on the next Trading Day (provided, with respect to notices sent by email so long as such sent email is kept on file by the sending party
and the sending party does not receive an automatically generated message from the recipient&rsquo;s email server that such email could
not be delivered to such recipient), (c) five days after having been sent by registered or certified mail, return receipt requested,
postage prepaid, or (d)&nbsp;one Trading Day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. The addresses for such communications are:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 3%">(i)</TD><TD STYLE="text-align: justify">If to the Company, to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Immunic, Inc.<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Attention: Glenn Whaley<BR>
Email: glenn.whaley@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">With a copy (which will not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Dentons US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Ilan Katz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1221 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Email: Ilan.Katz@Dentons.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 99pt">&nbsp;</TD>
<TD STYLE="width: 3%; text-align: left">(ii)</TD><TD STYLE="text-align: justify">If to the Holder: To the address, email address or facsimile number set forth in the Warrant
Register, or as otherwise provided by the Holder to the Company in accordance with this <U>Section 14(h)</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><U>Jurisdiction</U>. THIS WARRANT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
WARRANT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW
PROVISIONS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><U>Pre-Funded Warrants in lieu of Common Stock</U>. Notwithstanding anything to the contrary in this Warrant,
to the extent the limitations set forth in <U>Section 10 </U>restrict the exercise of this Warrant into Warrant Shares, the Holder may
choose, in lieu of receiving Warrant Shares upon exercise of this Warrant, to receive a Pre-Funded Warrant in the form attached hereto
as <U>Exhibit A</U> to purchase an identical number of shares of Common Stock it would have received upon the exercise of this Warrant
for shares of Common Stock; <I>provided</I>, <I>however</I> that the Exercise Price shall instead be the Exercise Price less $0.0001 per
share, and the resulting issued Pre-Funded Warrant shall have an exercise price of $0.0001 per share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">IMMUNIC, INC.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Daniel A. Vitt</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF EXERCISE NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock or Pre-Funded Warrants under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To Whom It May Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(1)</TD>
    <TD>The undersigned is the Holder of Warrant No. ___ (the &ldquo;<I>Warrant</I>&rdquo;) issued by IMMUNIC, INC., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>The undersigned hereby exercises its right to purchase Warrant Shares or Pre-Funded Warrants pursuant to the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Holder intends that payment of the Exercise Price shall be made:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________ in cash; or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________ wire transfer of same-day funds</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>The Holder shall pay the sum of $_____ in immediately available funds to the Company in accordance with the terms of the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>Except as set forth in paragraph (6), pursuant to this Exercise Notice, the Company shall deliver Warrant Shares or Pre-Funded Warrants, determined in accordance with the terms of the Warrant, to the Holder. Provided that the Warrant Shares are registered for resale on an effective Registration Statement or the Warrant Shares are eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Warrant Shares shall be delivered to the following DWAC Account Number: _______________________________________ </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>The Holder hereby elects to receive a Pre-Funded Warrant (in the form attached hereto as <B><U>EXHIBIT A</U></B>) to purchase an identical number of shares of Common Stock that it would receive if it had exercised this Warrant for shares of Common Stock, in lieu of receiving the Warrant Shares in accordance with this Warrant. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under <U>Section 10(a)</U>, of the Warrant to which this notice relates. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name of Holder:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of the Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; text-align: center; margin-top: 0; margin-bottom: 0">20</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>e664551_ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF SERIES B WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNIC, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES B WARRANT TO PURCHASE COMMON STOCK OR
PRE-FUNDED WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issue Date: May [&#9679;], 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IMMUNIC, INC., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, [&#9679;], or its permitted registered assigns (the &ldquo;<B><I>Holder</I></B>&rdquo;), is entitled,
subject to the terms set forth below, to purchase from the Company up to a total of [&#9679;] shares of common stock, par value $0.0001
per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of the Company (each such share, a &ldquo;<B><I>Warrant Share</I></B>&rdquo;
and all such shares, the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;) at an exercise price per share equal to $0.75 per share (as adjusted
from time to time as provided in <U>Section 8</U> herein, the &ldquo;<B><I>Exercise Price</I></B>&rdquo;), or Pre-Funded Warrants (as
defined below) to purchase the same number of Warrant Shares (as subject to adjustment hereunder), upon surrender of this Warrant to Purchase
Common Stock or Pre-Funded Warrants (including any Warrants to Purchase Common Stock or Pre-Funded Warrants issued in exchange, transfer
or replacement hereof, the &ldquo;<B><I>Warrant</I></B>&rdquo;) at any time and from time to time on or after the Exercisability Date
(as defined herein) and through and including 5:30 P.M., New York City time, on the Expiration Date (as defined herein), and subject to
the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 1.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Definitions</U>. Capitalized terms used and not otherwise
defined herein shall have the meanings set forth in that certain Underwriting Agreement, dated May 28, 2025, among the Company and Leerink
Partners LLC, as Representative of the Underwriters named therein, as amended, modified or supplemented from time to time in accordance
with its terms (the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;). For purposes of this Warrant, the following terms shall have
the following meanings:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Closing Sale Price</I></B>&rdquo; means, for any security as of any date, the last trade
price for such security on the Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Trading Market
begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior
to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of
such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets,
or, if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the bid and ask prices, of any
market makers for such security as reported in the &ldquo;pink sheets&rdquo; by Pink Sheets LLC. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value.
The Board of Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such determinations shall
be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Excluded Stock</I></B>&rdquo; means the issuance of (a) shares of Common Stock or options
to consultants, employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by
a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, (b) the Warrant Shares and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the original date of issuance of this Warrant, provided that
such securities have not been amended since the original date of issuance of this Warrant to increase the number of such securities (or
the shares of Common Stock underlying such securities) or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant
to mergers, acquisitions, joint ventures or strategic transactions approved by a majority of the disinterested directors of the Company
provided that any such issuance pursuant to this clause (c) shall only be to a Person or Persons (or to the equityholders of a Person
or Persons) which is, itself or through its subsidiaries, an operating company or an owner of an asset providing to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) any securities issued pursuant
to the Underwriting Agreement or exercise of any such securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Exercisability Date</I></B>&rdquo; means the earlier of (1) October 1, 2025, (2) the first
day following any five Trading Days during which the VWAP for the Common Stock during such five Trading Day period is $1.25 or greater
(the &ldquo;<B><I>VWAP Target</I></B>&rdquo;), or (3) immediately prior to the consummation of a Fundamental Transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Initial Warrant</I>&rdquo;</B> means the pre-funded warrant (No. [&#9679;]) to purchase [&#9679;]
shares of Common Stock issued to the Holder on the Issue Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Issue Date</I></B>&rdquo; means May [&#9679;], 2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Person</I></B>&rdquo; means an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental
authority or any other form of entity not specifically listed herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Pre-Funded Warrant Exercise Price</I></B>&rdquo; equals $0.0001 per share of Common Stock,
subject to adjustment for reverse and forward share splits, share dividends, share combinations, ratio changes and other similar transactions
of the shares of Common Stock that occur after the Issue Date; <I>provided</I>, that in no event shall the Pre-Funded Warrant Exercise
Price be adjusted to an amount below the par value of the shares of Common Stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo; means, the pre-funded warrants to purchase a number of
shares of Common Stock equal to the number of Warrant Shares as to which this Warrant is being exercised in the form of a Pre-Funded Warrant
attached as <U>Exhibit A</U> hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Registration Statement</I></B>&rdquo; means the Company&rsquo;s Registration Statement on
Form S-3 (File No. 333-275717), originally filed with the Securities and Exchange Commission on November 22, 2023, and declared effective
on May 31, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Trading Day</I></B>&rdquo; means a day on which the shares of Common Stock are traded on
Nasdaq or, if not traded on Nasdaq, a day on which the principal Trading Market on which the shares of Common Stock are traded is open
for trading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Trading Market</I></B>&rdquo; means any of the following markets or exchanges on which the
Warrant Shares are listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq
Global Select Market, the New York Stock Exchange, the NYSE American, the OTCQB or the OTCQX (or any successors to any of the foregoing).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 2.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Registration of Transfers</U>. Subject to compliance with
all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of
this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any) and (x)
delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company to the effect that the transfer
of such portion of this Warrant may be made pursuant to an available exemption from the registration requirements of the Securities Act
of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and all applicable state securities or blue sky laws (other than
in connection with any transfer (i) pursuant to an effective registration statement, (ii) to the Company or (iii) pursuant to Rule 144),
and (y) delivery by the transferee of a written statement to the Company certifying that the transferee is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act (other than in connection with any transfer (i) pursuant to an effective registration
statement, (ii) to the Company or (iii) pursuant to Rule 144). Upon any such registration or transfer, a new warrant to purchase Common
Stock or Pre-Funded Warrants in substantially the form of this Warrant (any such new warrant, a &ldquo;<B><I>New Warrant</I></B>&rdquo;)
evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion
of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the
Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&rsquo;s
own expense any New Warrant under this <U>Section 2</U>. Until due presentment for registration of transfer, the Company may treat the
registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 3.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Exercise and Duration of Warrants</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Except as set forth in Section 3(c) below, this Warrant shall expire on May [&#9679;], 2030 (the &ldquo;<B><I>Expiration
Date</I></B>&rdquo;). All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by <U>Section
9</U> of this Warrant at any time and from time to time on or after the Exercisability Date and through and including 5:30 P.M. New York
City time, on the Expiration Date. At 5:30 P.M., New York City time, on the Expiration Date, the portion of this Warrant not exercised
prior thereto shall be and become void and of no value and this Warrant shall be terminated and no longer outstanding.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Holder may exercise this Warrant by delivering to the Company (i) an Notice of Exercise, in the form
attached as <U>Schedule 1</U> hereto (the &ldquo;<B><I>Notice of Exercise</I></B>&rdquo;), completed and duly signed, and (ii) payment
of (x) the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised if this Warrant is being exercised
for Warrant Shares, or (y) the aggregate Exercise Price minus the aggregate Pre-Funded Warrant Exercise Price, if this Warrant is being
exercised for Pre-Funded Warrants, and the date on which the last of such items is delivered to the Company (as determined in accordance
with the notice provisions hereof) is an &ldquo;<B><I>Exercise Date</I></B>.&rdquo; The Holder shall not be required to deliver the original
Warrant in order to effect an exercise hereunder. Execution and delivery of the Notice of Exercise shall have the same effect as cancellation
of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares or Pre-Funded
Warrants. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">If the Holder exercises the Initial Warrant in full on or prior to September 30, 2025, this Warrant shall
automatically terminate and be of no further force or effect, without any required further action by the Holder; provided that if such
Initial Warrant is not exercised in full, this Warrant shall terminate proportionally to the extent the Pre-Funded Warrant is exercised;
and provided further that this Section 3(c) shall cease to apply immediately as of the date of achievement of the VWAP Target.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 4.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares or Pre-Funded Warrants</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">If this Warrant is being exercised for Warrant Shares, upon exercise of this Warrant, the Company shall
promptly (but in no event later than one Trading Day after the Exercise Date), upon the request of the Holder, credit such aggregate number
of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance
account with The Depository Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;) through its Deposit Withdrawal Agent SEC system, provided
that the Registration Statement is effective or the Warrant Shares are freely transferable without restriction under Rule 144, or if the
Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend
regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Notice of Exercise,
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of shares of
Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any Person permissibly so designated by the Holder
to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective
of the date such Warrant Shares are credited to the Holder&rsquo;s DTC account or the date of delivery of the certificates evidencing
such Warrant Shares, as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">If this Warrant is being exercised for Pre-Funded Warrants, the Company shall issue and dispatch by overnight
courier to the address as specified in the Notice of Exercise, Pre-Funded Warrants to purchase a number of shares of Common Stock with
respect to which this Warrant is being exercised by the date that is the latest of (i) five (5) Trading Days after the delivery to the
Company of the Notice of Exercise, (ii) five (5) Trading Days after delivery of the aggregate Exercise Price less the aggregate Pre-Funded
Warrant Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise. As used herein, <B>&ldquo;<I>Standard Settlement Period</I></B>&rdquo; means the standard settlement
period, expressed in a number of Trading Days, on the Company&rsquo;s Trading Market with respect to the shares of Common Stock as in
effect on the date of delivery of the Notice of Exercise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">If by the time frames set forth for delivery above, the Company fails to deliver to the Holder a certificate
representing the required number of Warrant Shares in the manner required pursuant to <U>Section 4(a)</U>, or fails to credit the Holder&rsquo;s
balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such time frame set forth for
delivery above and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise; provided
such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B><I>Buy-In</I></B>&rdquo;),
then the Company shall, within two Trading Days after the Holder&rsquo;s written request and in the Holder&rsquo;s sole discretion, either
(1) pay in cash to the Holder an amount equal to the Holder&rsquo;s total purchase price (including commercially reasonable brokerage
commissions, if any) for the shares of Common Stock so purchased, at which point the Company&rsquo;s obligation to deliver such certificate
(and to issue such Warrant Shares) or to cause the Holder&rsquo;s DTC account to be credited for such Warrant Shares shall terminate or
(2) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash
to the Holder in an amount equal to the excess (if any) of Holder&rsquo;s total purchase price (including commercially reasonable brokerage
commissions, if any) for the shares of Common Stock so purchased in the Buy-In (assuming such sale was executed on commercially reasonable
terms at prevailing market prices) over the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the
Closing Sale Price of a share of Common Stock on the Exercise Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">To the extent permitted by law and subject to <U>Section 4(c)</U>, the Company&rsquo;s obligations to
issue and deliver Warrant Shares and Pre-Funded Warrants in accordance with and subject to the terms hereof (including the limitations
set forth in <U>Section 10</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce
the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to
enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or
any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the
issuance of Warrant Shares and Pre-Funded Warrants. Subject to <U>Section 4(c)</U>, nothing herein shall limit the Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 5.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Charges, Taxes and Expenses</U>. Issuance and delivery of
certificates for shares of Common Stock or Pre-Funded Warrants upon exercise of this Warrant shall be made without charge to the Holder
for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided, however</I>, that the
Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates
for Warrant Shares, Pre-Funded Warrants or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall
be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares
or Pre-Funded Warrants upon exercise hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 6.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Replacement of Warrant</U>. If this Warrant is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof,
or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested
by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s
obligation to issue the New Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 7.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Reservation of Warrant Shares</U>. The Company covenants
that it will at all times while this Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares or Pre-Funded Warrants upon exercise
of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this
entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account
the adjustments and restrictions of <U>Section 8</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall,
upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued
and fully paid and nonassessable. The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities
exchange or automated quotation system upon which the shares of Common Stock may be listed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 8.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Certain Adjustments</U>. The number of Warrant Shares or
Pre-Funded Warrants issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this <U>Section
8</U>.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)
pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the
Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this <U>Section 8(a)</U> shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 8(a) above, if
at any time the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of Common Stock (the &ldquo;<B><I>Purchase Rights</I></B>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding and except as covered by
<U>Section 8(d)</U> below, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Warrant, then, in
each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)
the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding shares of Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires securities representing more than 50% of the aggregate voting power, including the power to vote on the election of directors
of the Company, of the issued and outstanding equity securities of the Company (not including any shares of Common Stock held by the other
Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<B><I>Fundamental Transaction</I></B>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
<U>Section 10</U> on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in <U>Section 10</U> on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B><I>Successor Entity</I></B>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Subsequent Equity Sales</U>. If the Company, at any time while this Warrant is outstanding, shall sell,
enter into an agreement to sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue
any Common Stock or securities convertible into Common Stock (other than Excluded Stock), at an effective price per share less than the
Exercise Price then in effect (such issuances collectively, a &ldquo;<B><I>Dilutive Issuance</I></B>&rdquo; and such price, the &ldquo;<B><I>Base
Price</I></B>&rdquo;), then simultaneously with the consummation of each Dilutive Issuance the Exercise Price shall be reduced to equal
the Base Price. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this <U>Section 8(d)</U> in respect
of Excluded Stock or any adjustment pursuant to <U>Section 8(a)</U>. The Company shall notify the Holder, in writing, no later than the
Trading Day following the issuance or deemed issuance of any Common Stock subject to this <U>Section 8(e)</U>, indicating therein the
applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the &ldquo;<B><I>Dilutive
Issuance Notice</I></B>&rdquo;). If any shares of Common Stock or Common Stock Equivalents are issued or sold for a consideration other
than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where such consideration
consists of publicly traded securities or Common Stock (including Common Stock transferred from existing third-party stockholder), in
which case the amount of consideration received by the Company will be the volume weighted average price of such publicly traded securities
on the date of receipt of such publicly traded securities. The fair value of any consideration other than cash or publicly traded securities
will be reasonably and in good faith determined by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Calculations</U>. All calculations under this <U>Section 8</U> shall be made to the nearest cent or
the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this <U>Section 8</U>, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Notice to Holder</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(i)</TD><TD STYLE="text-align: justify"><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to
any provision of this <U>Section 8</U>, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth
the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(ii)</TD><TD STYLE="text-align: justify"><U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend
(or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend
on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or
warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders
of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the
Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be
delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K.The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 9.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Payment of Exercise Price</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">From and after the Exercisability Date and through and including 5:30 P.M., New York City time, on the
Expiration Date, the Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company
a duly executed Notice of Exercise and a check, wire transfer of same-day funds (to an account designated by the Company), or other form
of payment acceptable to the Company for the aggregate Exercise Price for the Warrant Shares or Pre-Funded Warrants being purchased.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Cashless Exercise</U>. This Warrant may also be exercised for Warrant Shares, in whole
or in part, at such time by means of a &ldquo;<B><I>cashless exercise</I></B>&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(A) = as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to <U>Section 3(b)</U> on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant
to <U>Section 3(b)</U> on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of the Common Stock on
the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<B><I>Bloomberg</I></B>&rdquo;) as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to <U>Section 3(b)</U> or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant <U>Section
3(b)</U> after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(B) = the Exercise Price of
this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(X) = the number of Warrant
Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise when there is no effective registration statement registering, or the prospectus contained therein is not
available for, the issuance of the Warrant Shares to the Holder, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of
this Warrant may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this
<U>Section 9(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Bid Price</I></B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>VWAP</I></B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so
reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: right">Section 10.</TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"><U>Limitations on
Exercise</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary herein, the Company shall not effect any exercise of this Warrant
(other than for Pre-Funded Warrants), and a Holder shall not have the right to exercise any portion of this Warrant (other than for Pre-Funded
Warrants), pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s affiliates (as such term is defined in Rule 501(b)
under the Securities Act, each, an &ldquo;<B><I>Affiliate</I></B>&rdquo;)), and any other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d) of the Exchange Act (such Persons, together with its Affiliates,
its &ldquo;<B><I>Attribution Parties</I></B>&rdquo;)), would beneficially own a number of shares of Common Stock in excess of <B>[&bull;]
</B>([&bull;]%) of the total number of issued and outstanding shares of Common Stock following such exercise (the &ldquo;<B><I>Beneficial
Ownership Limitation</I></B>&rdquo;). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned
by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties
and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this <U>Section 10(a)</U>, beneficial ownership shall be calculated in
accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amened (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), and
the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder
that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 10(a)</U> applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with its Attribution Parties) and
of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of an Notice of Exercise
shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by
the Holder together with its Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this <U>Section 10(a)</U>, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s
most recent periodic or annual report filed with the SEC, as the case may be, (B)&nbsp;a more recent public announcement by the Company
or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Any portion of an exercise that would result in the issuance of shares in excess of the Beneficial Ownership Limitation shall be treated
as null and void ab initio. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this <U>Section 10(a)</U> provided
that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this <U>Section
10(a)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after
such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than
in strict conformity with the terms of this <U>Section 10(a)</U> to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">This <U>Section 10</U> shall not restrict the number of shares of Common Stock which a Holder may receive
or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of
a Fundamental Transaction as contemplated in <U>Section 8</U> of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 11.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Transfer Restrictions</U>. This Warrant may not be transferred
prior to September 30, 2025. From and after October 1, 2025, and subject to compliance with any applicable securities laws and the conditions
set forth herein, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares or Pre-Funded Warrants without having a new Warrant issued.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 12.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>No Fractional Shares</U>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: right; width: 0.75in">Section 13.</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify"><U>Warrant Agent</U>. The Company shall initially serve as warrant
agent under this Warrant. Upon ten (10) days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any corporation
into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company
or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act.
Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: right">Section 14.</TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>No Rights as a Stockholder</U>. The Holder, solely in such Person&rsquo;s capacity as a holder of this
Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor
shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder
of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant
Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or
as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Authorized Shares</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(i)</TD><TD STYLE="text-align: justify">Except and to the extent as waived or consented to by the Holder, the Company shall not by
any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth
in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value
of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take
all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations
under this Warrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 15%">&nbsp;</TD>
<TD STYLE="width: 15pt; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Before taking any action which would result in an adjustment in the number of Warrant Shares
or Pre-Funded Warrants for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations
or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. Subject to the restrictions on transfer set forth in this Warrant and compliance
with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the
written consent of the Holder except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure
to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in
this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause
of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and
assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant will contain a legend to the effect that the Warrant Shares are not registered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and
the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time
to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Warrant may be modified or amended, or the provisions hereof waived only with the
written consent of the Company and the Holder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement
to all of the terms and conditions contained herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify"><U>Notices</U>. All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by email or facsimile if
sent during normal business hours of the recipient, and if sent at a time other than during normal business hours of the recipient, then
on the next Trading Day (provided, with respect to notices sent by email so long as such sent email is kept on file by the sending party
and the sending party does not receive an automatically generated message from the recipient&rsquo;s email server that such email could
not be delivered to such recipient), (c) five days after having been sent by registered or certified mail, return receipt requested,
postage prepaid, or (d)&nbsp;one Trading Day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. The addresses for such communications are:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 3%">(i)</TD><TD STYLE="text-align: justify">If to the Company, to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Immunic, Inc.<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Attention: Glenn Whaley<BR>
Email: glenn.whaley@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">With a copy (which will not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Dentons US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Ilan Katz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1221 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Email: Ilan.Katz@Dentons.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 99pt">&nbsp;</TD>
<TD STYLE="width: 3%; text-align: left">(ii)</TD><TD STYLE="text-align: justify">If to the Holder: To the address, email address or facsimile number set forth in the Warrant
Register, or as otherwise provided by the Holder to the Company in accordance with this <U>Section 14(h)</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><U>Jurisdiction</U>. THIS WARRANT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
WARRANT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW
PROVISIONS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><U>Pre-Funded Warrants in lieu of Common Stock</U>. Notwithstanding anything to the contrary in this Warrant,
to the extent the limitations set forth in <U>Section 10 </U>restrict the exercise of this Warrant into Warrant Shares, the Holder may
choose, in lieu of receiving Warrant Shares upon exercise of this Warrant, to receive a Pre-Funded Warrant in the form attached hereto
as <U>Exhibit A</U> to purchase an identical number of shares of Common Stock it would have received upon the exercise of this Warrant
for shares of Common Stock; <I>provided</I>, <I>however</I> that the Exercise Price shall instead be the Exercise Price less $0.0001 per
share, and the resulting issued Pre-Funded Warrant shall have an exercise price of $0.0001 per share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">IMMUNIC, INC.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Daniel A. Vitt</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock or Pre-Funded Warrants under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To Whom It May Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(1)</TD>
    <TD>The undersigned is the Holder of Warrant No. ___ (the &ldquo;<I>Warrant</I>&rdquo;) issued by IMMUNIC, INC., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>The undersigned hereby exercises its right to purchase Warrant Shares or Pre-Funded Warrants pursuant to the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Holder intends that payment of the Exercise Price shall be made:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________ in cash;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________ wire transfer of same-day funds; or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________ Cashless Exercise.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>If the Warrant is being exercised for cash, the Holder shall pay the sum of $_____ in immediately available funds to the Company in accordance with the terms of the Warrant. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>Except as set forth in paragraph (6), pursuant to this Notice of Exercise, the Company shall deliver Warrant Shares or Pre-Funded Warrants, determined in accordance with the terms of the Warrant, to the Holder. Provided that the Warrant Shares are registered for resale on an effective Registration Statement or the Warrant Shares are eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Warrant Shares shall be delivered to the following DWAC Account Number: _______________________________________ </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>The Holder hereby elects to receive a Pre-Funded Warrant (in the form attached hereto as <B><U>EXHIBIT A</U></B>) to purchase an identical number of shares of Common Stock that it would receive if it had exercised this Warrant for shares of Common Stock in lieu of receiving the Warrant Shares in accordance with this Warrant. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>By its delivery of this Notice of Exercise, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under <U>Section 10(a)</U>, of the Warrant to which this notice relates. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name of Holder:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">
</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of the Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; text-align: center; margin-top: 0; margin-bottom: 0">21</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>e664551_ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; font-size: 10pt"><IMG SRC="image.jpg" ALT=""><FONT STYLE="font-size: 12pt"></FONT></TD>
    <TD STYLE="width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Dentons US LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">1221 Avenue of the Americas</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">New York, NY 10020-1089 USA</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">T&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1
    212 768 6700</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1
    212 768 6800</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 Avenue of the Americas, Suite 200</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Immunic, Inc.--Registration Statement on Form S-3</U></FONT></TD>
    </TR>
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In our capacity as counsel to Immunic, Inc.,
a corporation organized under the laws of the State of Delaware (the&nbsp;&ldquo;<U>Company</U>&rdquo;), we have been asked to render
this opinion in connection with a registration statement on Form S-3 (File No. 333-275717) (the&nbsp;&ldquo;<U>Registration Statement</U>&rdquo;),
which Registration Statement the Company initially filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
on November 22, 2023, and which the Commission declared effective on May 31, 2024, as supplemented by the prospectus supplement filed
pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), dated May 28, 2025 (the
&ldquo;<U>Prospectus Supplement</U>&rdquo;), under which (i) pre-funded warrants to purchase an aggregate of 86,666,667 shares (the &ldquo;<U>Shares</U>&rdquo;)
of the Company&rsquo;s common stock, par value $0.0001 per share (&ldquo;<U>Common Stock</U>&rdquo;), with an exercise price of $0.0001
per share (&ldquo;<U>Pre-Funded Warrants</U>&rdquo;), (ii) 86,666,667 Series A Warrants of the Company (&ldquo;<U>Series A Warrants</U>&rdquo;),
each exercisable for the purchase of one share of Common Stock, and (iii) 86,666,667 Series B Warrants of the Company (&ldquo;<U>Series
B Warrants</U>&rdquo;), each exercisable for the purchase of one share of Common Stock, are being sold by the Company pursuant to the
Underwriting Agreement, dated May 28, 2025, between the Company and the underwriters named therein. The Pre-Funded Warrants, the Series
A Warrants and the Series B Warrants are collectively referred to herein as the &ldquo;<U>Warrants</U>.&rdquo; The shares of Common Stock
issuable on exercise of the Warrants are referred to as the &ldquo;<U>Warrant Shares</U>,&rdquo; and the Warrant Shares together with
the Warrants are referred to as the &ldquo;<U>Securities</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">We are delivering this opinion to you at your
request in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5) of Regulation S-K under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In connection with rendering this opinion, we
have examined originals, certified copies or copies otherwise identified as being true copies of the following: (i) the Company&rsquo;s
amended and restated certificate of incorporation, (ii) the Company&rsquo;s by-laws, as amended, (iii) the Registration Statement, including
the prospectus contained therein (the&nbsp;&ldquo;<U>Base Prospectus</U>&rdquo;), (iv) the Prospectus Supplement (the Base Prospectus
and the Prospectus Supplement are collectively referred to herein as the&nbsp;&ldquo;<U>Prospectus</U>&rdquo;), (v) corporate proceedings
of the Company relating to the Securities and (vi) such other instruments and documents as we have deemed relevant under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt"><IMG SRC="image.jpg" ALT=""><FONT STYLE="font-size: 12pt"></FONT></TD>
    <TD STYLE="width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">May 30, 2025</FONT></P>
                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Page 2</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">In making the aforesaid examinations, we have
assumed the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity to originals of
all copies of all documents examined by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">Based on the foregoing, and in reliance thereon,
and subject to the qualifications, limitations and exceptions stated herein, we are of the opinion that (i) the Warrants, when duly executed
and delivered by the Company against payment therefor as described in the Registration Statement and the Prospectus, will be binding obligations
of the Company, and (ii) the Warrant Shares, when issued and paid for in accordance with the terms of the Warrants, will be validly issued,
fully paid and nonassessable..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">The foregoing opinion is limited to the laws
of the State of Delaware (excluding local laws) and the federal law of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">We hereby consent to the use of our opinion as
Exhibit 5.1 to the Registration Statement and to the reference to this firm and this opinion under the heading&nbsp;&ldquo;Legal Matters&rdquo;&nbsp;in
the Prospectus comprising a part of the Registration Statement and any amendment thereto. In giving such consent, we do not hereby admit
that we come within the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the
Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&#9;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dentons US LLP&nbsp;</I></FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>e664551_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immunic, Inc. Announces Pricing of Oversubscribed
$65 Million Underwritten Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK, May 29, 2025 /PRNewswire/ &mdash; <FONT STYLE="color: #2683C6">Immunic,
Inc.</FONT> (&ldquo;Immunic&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline
of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten
public offering of (i) pre-funded warrants to purchase shares of common stock (the &ldquo;Pre-Funded Warrants&rdquo;), (ii) series A warrants
to purchase shares of common stock (or pre-funded warrants) (the &ldquo;Series A Warrants&rdquo;), and (iii) series B warrants to purchase
shares of common stock (or pre-funded warrants) (the &ldquo;Series B Warrants&rdquo;). The combined public offering price of one Pre-Funded
Warrant, one Series A Warrant, and one Series B Warrant, which are being sold together but are immediately seperable, is $0.7499. The
Pre-Funded Warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The Series A Warrants
will be immediately exercisable any time before December 31, 2025. The Series B Warrants will be exercisable beginning on October 1, 2025,
or earlier if certain thresholds are met, until five years from the date of issuance. The Series A and B Warrants will immediately expire
in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to September 30, 2025, subject
to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All securities in the offering are being sold
by Immunic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial gross proceeds from the offering are
expected to be approximately $65 million before deducting underwriting discounts and commissions and offering expenses. The Company may
receive up to an aggregate of $130 million of additional gross proceeds if the Series A Warrants and Series B Warrants are exercised in
full for cash. The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds received
from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leerink Partners is acting as the sole bookrunner
for the offering. B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-managers
and William Blair &amp; Company, L.L.C. is acting as financial advisor to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is being made by Immunic pursuant
to a shelf registration statement on Form S-3 (File No. 333-275717) previously filed with the Securities and Exchange Commission (the
&ldquo;SEC&rdquo;) on November 22, 2023, which became effective on May 31, 2024. The offering is being made only by means of a prospectus
supplement and the accompanying base prospectus that form a part of the registration statement. A final prospectus supplement relating
to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at <U>www.sec.gov.</U> Copies of the final
prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained by contacting Leerink
Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by
email at syndicate@leerink.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immunic, Inc. (Nasdaq: IMUX) is a biotechnology
company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
The Company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing
multiple sclerosis, for which top-line data is expected to be available end of 2026. It has already shown therapeutic activity in phase
2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium
combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional
anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets
the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially
be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease
and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically
address the needs of gastrointestinal diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &quot;forward-looking
statements&quot; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development
and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements
include, but are not limited to, statements relating to consummation of the proposed offering, Immunic's development programs and the
targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for
vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple
sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the
Company and further updates with respect thereto; and the development and commercial potential of any product candidates of the Company.
Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current
expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected
in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics
trends, impacts of the Ukraine &ndash; Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks
and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities
and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements,
the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any
changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided
by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive
products and technological changes, the Company&rsquo;s ability to close the proposed public offering, and the risk that warrants issued
in this offering will not be exercised for cash in the future. A further list and descriptions of these risks, uncertainties and other
factors can be found in the section captioned &quot;Risk Factors,&quot; in the Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, filed with the SEC on March 31, 2025, and in the Company's subsequent filings with the SEC. Copies of these filings
are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the
date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances
that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken
based on any or all of the contents of this press release.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jessica Breu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President Investor Relations and Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+49 89 2080 477 09</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #2683C6">jessica.breu@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>US IR Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rx Communications Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paula Schwartz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 917 633 7790</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #2683C6">immunic@rxir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>US Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KCSA Strategic Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Caitlin Kasunich</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 212 896 1241</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #2683C6">ckasunich@kcsa.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>imux-20250528.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /KM5s7xRiXgOn8uFZXIsSaOIWcP9wZJ1SelBsG1+fYkKfyYs9Q7sYyQxsYrGgRsB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:IMUX="http://imux.com/20250528" elementFormDefault="qualified" targetNamespace="http://imux.com/20250528">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://imux.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20250528_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20250528_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>imux-20250528_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>imux-20250528_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imux.com/role/Cover" xlink:href="imux-20250528.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imux.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ? 'H# 2(  A$! Q$!_\0
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M6@>(?#MC,7L8[N,3XF@& %^:WD'RA0RNF5#*2?O/XW_LKZ_X67P<GPE_9/\
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MM_.OLWX!_MK_  %?_@GUH7P1^,'A7XF:PNB^([GQ")_#DT%NAD=YC&-[3*Q
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.A\PS"IBZG//;HNQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 28,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNIC, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">&#160;Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="e664551_8k-immunicpricing.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="e664551_8k-immunicpricing.htm">e664551_8k-immunicpricing.htm</File>
    <File>imux-20250528.xsd</File>
    <File>imux-20250528_lab.xml</File>
    <File>imux-20250528_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e664551_8k-immunicpricing.htm": {
   "nsprefix": "IMUX",
   "nsuri": "http://imux.com/20250528",
   "dts": {
    "inline": {
     "local": [
      "e664551_8k-immunicpricing.htm"
     ]
    },
    "schema": {
     "local": [
      "imux-20250528.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imux-20250528_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imux-20250528_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://imux.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e664551_8k-immunicpricing.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e664551_8k-immunicpricing.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193805-25-000757-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193805-25-000757-xbrl.zip
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MPE'Z;9?T/!]<E;SI.0X=<P@F]6^[!,'-<_L;DS +KW O\/4T]\P/;),Z&K#
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M[(!$31^9Q.PHP\##^'B,J)NODK6KY)AN%(F<>P52K5;SE:WZ5GEK7:31,:$
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MP@\TM![6H<?\\5M?RIME@Y(.//AK2.^9+*59J:V!H0%%U1]M!SKDLF2_D1P
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M(^BO?OSY]'T@XG^L^,>IU_BA7-U<UO"?-P_\7[SU=<; LG$*8E[,65_A(\*
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M>?"B)@CXBAMD)(]/'IV,%)%.)Y:W][2J$(S.B2MMAP0'U]'_&2]>HXKA4,O
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M2G -T3\5Y)J!2=)@!H_ SQKS&J227>1L2;=3H@;Z4<SXZ[,,I-HDS!(<B*J
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M'T;> 4M.YMA!R9&HH.,;E5DN-CE$VRR(7=+^;64.67T1IYCA1F6GT@TITL.
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MTQ_/W*9:$AWZU@<+)-' \):T9&VU(ROV1AWCF VEU[6Z$ DJ^#X=$; LG,_
MWS*]!66T\7O#H#8B&,'TI@:P'GX^0@:/6"V=NX*7!9\#=LZX!(:MEG6F4N\D
MR N2RU$(K#Q:3&X093$^J>D$[MN+,/.RV^9\/O.OK?KZ0GY)W7MUBX!?FY\)
M>P^'ZI!'/?F4YVOXJ%_!C; X]:-"(I!=NYZ&RD7)#2\S_9MFW'7S"AST6($R
M,]_M>!3&\V$B19J<AJ+/_(S8MLQ!T[?QX)0, E:3=27)?KO!%L*YH&BY8RSC
MFZ_!?R25&5AT:P:]J[(948&1,MS@Q;?7.E^[+-=1T&@A+AO<HY6X&L29<7:A
MD^!2OS!ZD#5SM:E;6--D'Y&[S1='"G2IG0SF=^O+BFI+*(3#[8)W2*QM5%*[
MIFT*16=Y2F5EL%UDI(KU#^8 ')1WFL[]F).8'8%P'/TM(T#0+R+>8C;U^"?"
M(% ?\HJ7_4U.Q\BM7]H#4\J<;D2A[?W0H8I -,N7L!_<AHIPE5\#'9'\DU0$
M1OD7O8NOIR+V7IEMRF(Z&:[,'U=%K.XH1/<Q^YR\AF>OJJ*[&L'^%/S]DMN:
MG%.6-6M6Y%$-L(;::L*F[8@D!99UM;9I #(=83MDGZUEQE3"<*N\Y9 6"%I6
M<O):\J8<)'?%!D.6O3^8K%1W)2L*23D%4QBC=J]_&-3-Y=59=F;-=T6%.?5!
M3<^<_L@\T"4[TZR!Y@L#FAP/;_BCK6]]5RT87[V$B6[0;:IQ"-@< Q<Y%E6I
M^62(]-#I4Q:0"V=OFH@'CE%EZ;J-YJG)\7.:72Y3A++QS498S8,T\S!"/0I'
M\JREW3B?*+LJ[XRKT@_6#%R5K92Y$HI ZR=&CDMUF@-PPQ]-\M=W)/G*3?\+
MM]L=GH.4(NFU9?>,_@'QF 'Z<+]PS*88CHX>@A:]4\'-9F- ">K^J_9X_/33
M-V ,+8.8+(#)7"/P&!>0Z^%O4\Z]*>&HXP*9>;Y<:A=#3V\\5'3+!HM6C/:?
M+T,':Q0G\5);-R\Q1H,%@JD#B^%3\T9\6PS!F Y/6)0\Z&(@!"[9ICNO&Q")
M!64*P2QE1>,J#PD,MZGD]@MMJ=G/H+,^\GGVWMQS"Z%&R9,I+XU!("[K<#T/
MZ.\HV(S2?K &1T:4?*.ME$[0\JI?#4*P$Q0QBCIU'DVP2S38A->65'\L#;-7
M+N[9O<[%/7O(Q=T?>=:^'T]OJ>]'O_N':83[BDWZ]J%)^NW9*7Z.HXXZ]D&J
MP_:PZZP@^UH]+D+0$HS?=<'.&PKQ5Y[IS'=^'&FP9AUVSG/E0G0H:+\UF"N=
M)DN4]6\KH8]!Y2W!OJX(EF@BZT3XHS1"U-OV&DQ$MIA@^U@=ICY61QGPA."3
MB,H]DKM(>1P[0N<1O/.0%23T&SPIB%XYK]N.>OVV];R@W"!WUW'D'T&90*S2
M(MH)E1#("$^NL6*"JP,&,^=R6W;F'+YP[X[7@Y1Y;.H;T_V44;DN#]@/'[4"
M<Y12!!]AZ++/N9]C%Y#BJQ8;>KAV"W.6&=JYYE4I7.TG=/?04R0=NS#"M\QE
M$(NBG6V:-J0L[7=A%2ZU5'N5NKZ34OBRN"A:7B/[C%@OD(!PA[=UGY+C.KVX
M^6%/L$^' @KL%F9"1'U5=L_5!YI.QN=@*R=FZ/AWCK%-:+EC00$CL!SIE\0U
MLJ? C'RZ2CYLP-B_<HEJE8Z!KXY3++O #=]I5=E;O6!6W41B61],.0[<L3B4
MY"!NY,%-;3S?HDQT<R8^DD_+4T6!#?IRM.K8T2,60^%AK*C ,MJ]Q"ZP$D"A
M\NM$';AQ]Y61R-!B,]=E\)"+MB0(,+XWE9X7<]PQHQ/\_[?WI4UM:]G:WUWE
M_Z#*O=T%50IA"!E.TJF7P21T$Z" =&ZJJS_(M@SJ(TM<289P?_V[ICUIL W!
M!+ _=)]@6]+6'M9>>ZUG/0\"%$8QKP(5:QPG1&=%A_0CG2[S<<RNPIB>%J?]
M<Z8&Y*=J6Y8Y&1-9@' T[5G:W3I$IF<09T!5>WFTU0RR%HBU(_LUJX5^Q$F:
MQM529S*K_>#+G1&&@KVVMW]XHL5MX)JA?I?ZP#IN!#]ENE9'"%Z#DWP- U J
M";9YWA,I]I4S_L_2*FMZ;:8?FN+%Z3>:IF@\;MTI-O ]H?%!CZM*Y:.L-,P3
MRV7"FDY1I+RCG;/!P;I<[FI9SR#52]25T/A3I4'T&KD:*B4"6-:C@R$5$>NU
M]55_=75UWGSVAQ+3.$-FM$1O0'J>Z=1[J6P"*SWEDK%RY+?;IS=]VO[-!^]A
MIH#K[FN>#_X@XLI33?ZQJC=WV\0IQ'@TI$E=G<!:T9K6>F2S&YI(/V;71\7+
M=/#R$ARVL-"FQ$%J56WA[1>4HU3(MDAM6YKI@CLOM<7(<#7-V;)0 83-!PH@
M["C9#1I#>\S$MGI'QK(:35';W*HM"\TTF#1G'NIJ8 K(NI. U.)'6=#3CKR]
MRRLA3"GVC:KNF('#&=$+W'I*3+V"$D97H7P'7</.Q^[343>/^E&0X<-,%4JY
M4L1:Y7IM5H_RU4I,YOY1&JSF"&'U9;NE.TP3"_%942&"!J.,+M)R*0NQUIF"
MMSIE@<KZ\,D'HZ7J[1O(IHD3-24UW9.SU.JLH^9>@Z*,+WCFD@HJ"T*(<V2Q
MW"-"Z5?T-QUI$:[F;Y9OE="(!EQ+?J>YC"M)O3M+=3J$OE4!C7(C<#4E:9-<
M)ARF<HO7RU2L1PKLSYCO#!>YD ADOC9DY:#!GTEZ+70GMK/[H4HG;$.NC2RS
MDHY=8BW"Y3K)V3$BK5I.UMJX<_@F'P3Z!#CFY++B;96PZFAGU6C43G1+5-<S
MFKKUE7<3)33A;6%2-0IH3M;/5/46]CR%N:LG*I\NM))[-.D]Y/#&438X#V"C
MS *H!TC4^8<V7IYV'=V7<^;ES-CY+QOQ(Z,+MF-YJ5HI'8WT5IWMK'']K0FB
MN=[H="O/4"L\P=,>SSLP0!E-A#@LB+V;UGA?"7:5G@F-W(6GH7OQ[=0[.#CF
MB:<^ZXRR]#+DS^D^9;_;4C0[9_H;$URR!-*VT_!B"*Z2]]=@>/E!_^DWW:]"
M&H0@P1BCW'B.16D3N!K+Z@MV^*EM4<*UX(26X$IQU%[0MBCE0/^XH\.<K8RI
M$N)OGG5"_,TB(?Y\YO.,!7:FM/2V0;E7<\^V^5=L_0ZX(LDYF'9EB$<91:;)
MP(^/J=1:5\\VKMH1+)<ZGHZLG0-Y TB]ADLKN&(7'-]T$&2:S4EM'5%RE<88
M@L='H.G7%A^><Z-Z*HY$+-L SF@'NJ%"1]DN?$[RE0_L.JYOCLCE\']-Q+]R
M@*]3[6%^-72]X$.LOYFSW67&8B^5U2@CJ4)).V8XQJ_"S":>T\ZX[^61@'$=
M[C:J:5!?B(="J['/P@:Y*62R7?U(*>7]&M57#?:8^86D/"GH(SL=%HXS,X@\
M30=P? MO8;,"2K4EKR"FHLY]PQ(5# 9!Q(EY_9DZM$VU0+B2/>I3C O[* D]
MVNXN,WJZ(D^$!Q#]'WQJ*9R"[\"@BUY*$6AXH&J&R:%-84M1 <O,"M5NA(3T
MHLL 83-A;\2*=O4Q/,X$EJZR>K3V*K]JD=LMF7VI%1CAA),@;&#,=5 A$4F_
M\BA[/,AEO,NM INUNM<9<C^-E+P;5VWI<V4>4-5@)D@0Q1&)8)5T='Z!<7UX
M?![?,"U9P%4>@7FPL_XH":';[DI+NK$*'$[-4)8+)AIW'RH@9PDU'5U.: 8B
M=YF"1G&T5'1]S'64MG<4)$M#A'".2A3%Q&MYRE0$[#3Z6@5K-9R%!U=QN6L<
M1U/@C(]2MXF<-0*S2T&JVP7$)!HW9?'VS )B[58U(A9E32&P>=MP9RM&5-YP
MMS1&28<B88U@J8-W0/ZHL^U2K$UFKMA9!5:RC<^T?K'P,VX'?\+\/8L0%QAH
M-YCM+>N7PC^G<5Z;1!2M>&0)G^B$0!6L @Z;:K>*B*).BI,E1B>0+N6B"'*G
M)[W&S<\5?@=:-*K46EDQ$4:65-&3C![!C0[K3,PO[L#N< ?JT7E;<P^K<;*-
MF):7?:S*'K/6[G30G+2>&(9;MX?7>#%T^LI"+.C)1)/"K!Y%5TJY>7J$I7IG
M)T"I )Z3"(@\%&.AL0U&G4XA=8QR!;GL-E\QOW(7B_GI.ZJE3S,Z@6)3$+9K
M6%&1U[[.*Z WGK<I_E!**%N7F"LA/]IS!"H:IW6IVJF<3PGHACBW82 U(JU9
M<*+=8L4)@R!)$Z8A5V=X6R5<0,+S-AL>2J+D7R=2F?=O*CZ?LUY^6!$0X=LU
M;I@;N#3"'G=QU1B1V,3A*P!3)O'U#'^O</_:3&XBG(V%HAIM5H'0*R9V%[8[
M;XMTMJ2_Y>FS<Q&% V]/>YH2BC/' A-T82*)HV3,O.)XP72>3$YEN_6^C!.X
M\4J!'PH/C GAE)WMJCL-C0^,'ZV1A;=REGV)%-J-TXY*,]MU4!0!4AYJBL/<
M6CCMUO8<5N5-E<I\^ZQ3F6\7J<SG,Y]GQK-;<;H-J&M7D;*,\;K'5C)4\$SZ
M5$?FU%(ITOPO'*R0?%\N2L\W=;KJL*^/94& SX=<C9'GIJ#/J5ILT$4,<@'U
ML@:8BAZJG(@F> M)S$52/S:<V"JT+ ??C8(0DUJ)@,HH'L 96S/2F>M-$-MG
M?&YD!6L^* (=)Y#*)5[3U47=JCN<6*K::+NA/3!."*T^RM:@]T"IA042YV%8
M(F]1H")@=YZ$92E04WU4ES)5TSI4B@Z<]U'02L('=$/S*[_L^(FFP,2*F.Z-
M.H>KZ(QR\RQBR\FI'9ZGR(YC=8J>Y:;H$?;;&$N9%2PX0.R94K(C<\8?232*
MQ'V%"!MZ3=>72 &=CECI.%;NK?G>:]][XWMO?>^=[ZW!'VN;\+\W=,W:6VD5
M>)-7O'ANJ@UG+C7D%Z*%.(KC2I9NSA:5*F]Y\T#E+4*MJ"JQY] +?^!ZB5*'
MEXN*FF4"TK$TEX2BLF[D,Z&4)J?REI#M6B] Q':4Z<XW5]<0/=Z8BUW"9Z %
M4CD@F#Y;Z@$D7,1)H.5E7X3$8W)RJ-(\-^07R+.=)N J,'8?SY,I:Y.F<4YV
MPGH/&_IN,=D[E8)KFS4>@?#F*4NVOJI^4Y)*5U3HSZ),B/\?;WV[N%UUP@I+
M*J?0E0<'6U'NF\W%Q]+?:(BYEJ&*%4B%)(QI4.0I5KP1%X8JO?8U3$9XT%B2
MH4JK"X\+SZDTID++765#GI;W?:G">5AP-&*Y2O!J\HY&^*&+ $9!: BTRD[]
MZ&(%[3.G1I%"OY'^C&Y!49^:5RI)7]#K]_F2B 4N#*'S>*KW$@,S@Q+N, 9-
MA-2P@+#!.FV,ZJ=14BY&<KAG\+OQU#/\FVEIFRG*UF[=!H-6,Q=J^2^764%Q
M6[^3>NV<3UIFFBC_2<0QA9J&BE_2S%&'4 DC?YK33X7N0K,$5&W>DC',7]5E
MF!_27.K&1I<G/))/$/<$O54M=0>E0$OOYKS!DD+$H68Q&7G2*-1$/Q@31&7(
M:1;'S&<0P;9*4VA,(-2_Z_R1 SG^5(^)H;=GE-*]JSGPL=QA:N=MG4.W%*ZX
M1KP>CFF9H_TW;T>/8TMT]\29[88NXVB%%U2H,(@C#8:8I;6'A!47NPU/EMIH
MS>C+ZU,^Y?.D"KQ0'@I^<HY\K0DQG\?DG_6HUKN;]O$U4'45YDR?K28)^B02
M6E(D-_BFUENU6]T@QYWB4OA]R-$<1Y>O6TN_;-YIS!5EJ:8EJUA>TXN\6>HO
MPWX)_MRRN;OI-G1[^5AI,_\TZ&N)65LLAT\6X'7BJI@PY6T:/8HJ3J3+Z"'0
M,JF/JBS[#F^'3?!CK0*4G6"6+?%_X.2CI)(L,8![6TJTPTU>2W4+R;O/==0@
M9E.V.DP'K&ZAQ@]6"FX+9'IX[UABYA4B. ZZ\-J+E3%="N_=LT[AO5ND\)[,
M')_JR?C<"KV8IA9#+&.D]%ALC(R.K0<LN\"QY@E.$IX/Q."X1FF*(RH3:-8<
M(L;92P?(>9]A@G;+CA-XTX4))H O[GYJ)6B'YG^0[401WV&;<?"T V3'VRS.
MB@<.!#]KQH6Q 6!==+7K ,%4=2#'A#NE"*_BDXJG#1';M4H<H=6X,ZG"5>S*
MJKX4 [,"8!N'MR]'=KW:P*Y3P#4VJNO=/:#K.Q[=A),:UC]6CFK],.]E4=?$
M$HVQ<\*,-LX[J! =EHYYJ.9 L-PR1*OBJ.6VL1*5E@:S5O[I?5DV1C?6LMC,
MT&)Y98/%*(M';;%^>^IJMMP!=MF4E&7*XCJ&O0W6)'B#:6'E#K694F8(D_"<
M9V;W ,N)51J<4\ZBYI?; (W+#%F86$$7]6="^Y8WI-]+]Q2_0"B;S%%+M3(J
M>%+Q:K-*G-6"EMQ]CC6@A6<QR^%Z'011C%,;0;RIB!/BG*QKB7%^J+(?,<6C
M^C93O)]/FRI%;R@ 71<H*M0A3(4'J6_"_\ J[4EMBU:B5(Z&K!E\ JM75IL&
M]ZUIA?0- QH('F$49ZC<)-7E8-K8Z9Z$MBA'< 76(X<? P8[7?)<<>>$Y0XI
M@_X&S2B=*PUB2SJD/)TB73>!HT<!9L)=B.4JE<,1\UMTUT9U[](H,.BF5?;.
MM^)MU4X@['2Z"6)[B[!&R5*] <4N#-\;'_NIL29 9KQV[)&@:&IZ[0Q>$KB'
MMK6EL%AE;2\S-T8W'--#[1;]E"9'DCI3L[9!V)G=D*9G;"!T=32K-O^VJ8W"
M6GW5FB5<#X(8I.0,GTMZ0:Q^L@R3B#C80XW"CC+J?!ONA8VM&_2:Q VA;))0
MF2;2%I 'H&D1@4DZP!!G.AHM,;&1(O4?AF#\X1349_6J\HE(_^A<=F-R$PR"
MSXG^KX"A;AQUG]TQO&_!) &8KZJ/B=:\OR_Q599+':)-)]VF3%^KS!KX+]IH
M@Q$[9RUNRR,RH_.P4>WZD/:8O<,X[QD[N$I^N$=*O&9/,>(DQJ387NQ;1=&Q
M5&*3J%T_A'3,:%J-F SC,L6M C-'ZGOCT(T2<OM+(7"_89 PNB<Y7-(^'B4:
M41<@DW(,:R^DM$-8O\/SGH+>MMY32E.66F(/K3.FOCVBV# :$"VIUD]#W@RE
MD9@V,R?\@$X_-)2PUG5,8 "[..R.\,ZC^%)#XI#[T-K=,>76I8_ADFX(2V*@
M9FGE+>?-P9PM'8ZE[&E2-,H6[<C$A,/DGAFL$T7I72L,;GEG9==3BFV(-I3K
MNVQ[*/L3"P?:I.$U\QPF2NWNHX50FGP_=4R_H-W=>#!FE^-4BI6O$K.;! 6^
M?UD7P':=:)$XN2WL1'0BRJ8<.A07>UUJC&2-T8$DV4>]F[[>Y.KB8% 0UU0O
MC"YIS32]J4ID8EPWQPR"=#S3OC1>5LN98*I7\99:!*+<_ "Y" +P^C=62Z70
MY5]V0U+0L-Y569GFIBDDN<8.ZUG2=R\Q\Z2&XI1^J:AK'92OJBHKM77.S,U4
MV93WSSJ;\GZ137D^\UF!N=\^G%:!=D59BF"_Y+;W7*P:;68&[\_W>Z-\TL@0
M'O')"YQ"(V3+_E:4Y"/B&:"$#'*;.S'GV@W9=:Q5EBBT0K1TK" ',%>IHMS*
M%>4.2X8&0158P,&J=XV;B_;6=<*I@K;1GNHTC:H7&)*MT;1#OWPI,,Q>-S\/
M.1_3C,]ZJ#'.4$'8)@)N++QSS&0EH2AM40U+$@YPE]=UQ&[  <XW4JZ.Y]$+
M9L&7FEZ7+%.*S[@XA'^H2Y+'8 Y=\0>G-$:!!2+Q!F(\=/,I7$_ [HWH!W%7
M".@ 2T0*<7*,C!Y*P/FW[BZ\(5-BU/5;NV5/)3S*F]90W(<.[!3@<*ZG<T6%
M-$_UH=/5\J-)O4T'SCH$:$/ 7TZD'/]3.8EIIZVUEFA&7H?(5$?H>SCC%4PI
M&H=7 0LQ107UO^)#Y"C#G#DG9V.77;M577<U<V&J93=)'FSL(L3%[JQ"?<QP
M\M-VF,DP@EJ+2M6UPN\QG)*$A3J?Y]/8!5CBS89AB7T4:!$I[EEZ=LOC[%A#
M?W(#->T8WJX?Y1RIK@S/-)W/K/$8*49N7WAQY*RZ4#\FK7OUPC;>N!L&6753
M$8UUFUF7NPPL5:^AE'7:9\[S"K0-L)76OONJL]8)ERCR'*3M@2NH4?QPF.)L
MI\LP@WV>&QY8LITV8&_J$@J&?3>@64R]B.*?KM:*Q%3B11N8!4BA+&M4U9_$
MF&B-HJ[J*8DD*L(_W>.H9X#Q0XNX$@ZXA"QP'LR;WB7:D1$GATC!@"E94\W<
M*6?=.I#.',YKFZVW/#*27=.!HVL*,J-?TPWISNR%ZFTZ&KA!Z8HE-M%G*@)P
M)SQ8>2]#GACCKWE+.&)4L%>9-72'@L+I-DMR))$R=M68^F!99IZI01["RDG)
M0[(>QGZ-CO<B58";>83UWN23. <#]M_*1>!ON;RRSNV_M<=O08[IO6H..USB
M/+%1==NT1+KYA 1M-?37]D&H!OY<CLPY1Z]9 Z-IJ[WW=,PX8/08.]N($9Q3
M4W.8%NA/8EI00_"-7)]PPMKSDAB7'=298=0P%8K6J9JQ/K2BT)7ZV;/8GVM]
M-!$BT-I0)9^:!MIN0(-W7)8.5U%ON$54J H#::26#62G;.[F@*K..Q]%,4?K
M!UDPZH]B6C$P#BXCC+<T :ZWMC18KD?L+9OY0IM"7)HO>+D&HTBK$#5XC879
M:/U-$VDBF'9ZE6;.V3#NH=55]..E==MNO?6G@&3"AC5UJ?T=09GM%I79*X2H
M]3C-M+=E2 J(W<2E#;!R0N; BF6.>64B*246AP9!/;K=4FC72M1&L*^UZ@GW
M#8$U:@&S@L#>HL<(0N:@D\Y*[ITY!.@004E(W#+]8_Q,$K<5_=LHL6-W2B$R
M&0V[W/W6"UL'83A/Y!&)[[!:LVY/$@P9A//QVZ=39!@$\U!#Q,EL_H7WGS1:
MY-5J\FH;J\\YK[:QNLBK/9_YK/)J[V:45S,9M1.7&L]7[-U*/\N0#Q-JE+FN
M./6V%<=E9CW?UK2AX@1S>8G#!,NLG$Q*C7"WKM,H[5E&I*2B^96/NI)9T<::
M[:.*?PD;%ZJ/!8KTCC(3M>1<'AZALWXL/CXE32JG0ZI+: !8V>X'OF3AN .$
MF[2] 5\D7=A1E'TU5M58%?HCTT&9Q;$LW5-SDZ(4B&'@&>OF"'(1#](W?+)4
MJ%2S7\W9MJ*6X?L'2F\W\P N2,L>@'O1UFIWJ T1O*[Y#[TRX7H3\:%_*^9#
M3@\/.-FOI9HTKE_#B;7.E%L#8.3OZ&F(8FW6\UGHY3TVO3Q!$O#D=&9!VI.8
MI]U%L$LX:G/J&:9?F%5)H^V_)1'NB31&6AH,\QT93WV';EVNY5%)1P6YA]C>
MBQ16+(>-*<&>]X)84C&%46+D "Y^-10T<@][0N]+TF2*QEZ%<7K)Z$Q2%:6=
M3H\*KCWS@M]63E=XA.UF7Z;8('B:-2LH*!K"8*7#J&>S][K)3YHGO,V;Z2Y'
M;,9;$R515$R]"J.A7=J5$L8>1BK*%:!(HLAV[<GP,@[-,K53SLQOG+!/0MMX
M@#-5;<OU3,%J+MF3*0LX;BUU4[DY?Y9FO5:($[DYCEY;U5G(5>46_5BA9U9O
MD09<L37C1ZL:COA&HW4.?YQVO*__.%.3$:WYCS3[$^9H"B<J?> W2[I.'$8H
MIZ9N.#4.['@T' UIE@R#G_AO3E9+WTJ;+0K=Z*>Z5'Z>8=OXYW*E^;6*&_LZ
M%33P"",<RCOEDB9BYBLDR'+[TO?V]@]/MK2;2^O)33:,BHLTHTI?[&RE5VCE
M3?M1GHTN:5XY5B22.L*,5GHW2/Y4 H,6LL'&9V.= AA3UF8+P?WOA<U6!3YG
M=7II%V]I@7[.,(7- AH./:A'K!_VXD"2.F%$[THK?2_$I!>O93TYU(O/GR_Z
M8.7[!R8WJ$L02NX#_&'103=%Q?P[\#A;90JW)7*V%3P-_'.4"90!_*]&9N<J
MJS-B"YC6>4'I//4Q:6UUYN&*W9!A,6 KCA+:'+XBSJH&@:CAP2G_;MCP.YF3
M6"Y5IV]#F[;HQ+*=MJ*WNJ28][ ;B@)+^)CS0.I2NT[.@HGA_0REI;P<6E3]
M#)?2LNIS.%([Y,UC(-Q7P??UU]R#%^ASLE=)-2Z^]FXH7G,N,9H!A3 J_96D
MR<L^-P[[I80TRFQ0Y<CYSNX!+,0DK"GZQL+7@<5L^+$\IZX#-.R3<ZYT.)&R
M=@HN]0WY"Y,J%+J(1NAA=8S] VQ&#M]/@U"6KH$1YTR5P#A=)1U,7ZR_?HD=
MC!&7*.TS3GN>V98?8*,2I(Y)JM3.'8VQP<T#OEI;_8N>TW7I&)&EEBG;QW">
M)5BK*&0XG=.\)LPVIVV!;Y/9V(F:^,9=)72*PSU%( ;J7"4>EPU?9;F"2KK(
MP2#8N2Q#PV #.1M_SIBE26M_P9"'Y_9',^%YGN>_.-'K -8PTW0$K,9[2S2R
M4D6^FR?._;E'3W;23)6P7'O6"<NU1<+RR<SQVX&OA!2$);"JE1NN6)$B[4&3
M46\N&#]E;(U;74<T;WS=G!V[A(:(L>8V6XYT1[M5 AH+DQ)& 9T3;34_('$8
MO#VF)4I>LBI[LR.'=:<0<FS2O "W'&%!]JF*RB[%7[8<-/P>':6$*]P=G3<.
MU'*MI@ S53AM^G1$NS45IUNJ*>U+RGATVK&. 2O>5NZ-<E']E!I-%J"1<YT#
M"*-/- N)D^LE;;:H(/ F%Z4Z:Z"&9P6/VW,UX76<86WF<89#2NCE!NC &3[1
M+^8$AZVN8'O7VON'*:0<:\+]50'P)FC<'\')@))K5(4P#*)8H.,PV7*K6!37
M&H*;@ZRO!9H+C(6[8@_PB^=P GUT&6-TP].:>BLSN 3#X.$]"#&3\R>Q"29X
M,#PXV,$@T]K&ZIJW!6,]TB&6K2'\M!? G38_GGX[_E1<?'R%__7VXC3-?!T!
M]]LM'0Q?6UU=>X]99J)(2J&#3HL1>N G*^!NW<![_I:!>.XQ<C,%=**_=O3W
M>4'ZWG[26Z%A7U]=;1SVTQ&"/^$7UEA[]E!OO+&'&C:R;,7;#1)P.;U_@GGX
M(,1L8)<N2:D&MWX3S\+,-6\O8LJ6L8F[<#<T7M].86H>^]#"]>:):37K!S9H
M?=5MT'X,>]8_@N+_? _#X_$?7@2?K/P)G_P_>= *6*EYW;36'V#3\K8PV8RR
MK[!S[$7]42]"Q,%)R&GZ_"*ZY"W-J<CKZ8)'"[0G-$[(6<F%)"J,VZA1.ZXB
MVN85QZM415Y@9[[=2F)O<B%QTA=_D FC=,$-,^M:%3<^T2<@Q>!0H?)?QF%R
M#@O&RH;25BN'EVY87..^["SSQMI;A?PNU^ *,45ABG"1;O/VY>^Z<A7A WGN
M*:FS0F$;R[4'_+Y]G66%'N$Z=#CTA\Q'BS +&)3H$O/)B';)-2\?81%Q"@WT
M%*HB,$D!$7/U2(A"[]L#GSP2MNWA99S>A&'N)K&9(:3=6NHME\NNL*5!GH^&
M[/9<1\37@'\SY9V9UZ91> Q$1(XY& Z"JTK]0X63VNYLJ0AS>EO. PV=#6>?
MS*X6&&C<3Z62B]X)6\[O!#U,6?B$&('Q\Q(FDW+=3<A67"?TF"$:W2Q?ED!R
M]8EX QW(+:OQCNL,'=PN110O>5K8T>'P)QX)\_C&*F%0-9_6JD>UHDK&36:S
M&[:VE#PEO0/K$R8B@W,#KXL";HR[H&::M:H(YPA )*BF,"_DXWZ$+Z<8'42?
MO(*##6N:2<XYL;5HX3M=J.JK@ETJ,<W"\U$<%#(_B^ GC:XB11O?V77+W(;C
MX,8M_"?"EVOC]<8WANXGK<D1&5SA7Y:CB,4L,Z_;\\8#0.U[Z7D2V3L> 5U.
M4<X;C/!)",:9$9L8R1BJXZ<3Y]%:1O:JY_F/)GT'44(PH!TN4._BL9!1\?_1
M]+,V#2F?6(,)#9&H!BXYO98JQJX21?+U!JV6))^>M16AE9UFM;EQGW> KD+H
MH8F0V4OU7DI%)7>;=JWH:<U51NZWX27;+7Y+1M_6OX%4F]>^AL\4 0S0,MBX
M.+C6^+H*4$JH7=WOP>[2#^9L"4Z<W\+Q73?!J2NWO^Q07: NK-#5M/;\+*T%
M[XY+ 0Y>@D$YX9+#6F0'-5CM8S_1O\PMWOY*VQ W8CC!.#EG+BN0G=\[)PJ!
M3&8^]8DD[4H-TA3-Y@X3UX#7M 0FSNUV:[K)[<WEW)XJS[?^K/-\ZXL\W_.9
MS[4U^6:_A)/=UK+*?%3,LLI_7,BNK:K"X9@G!>AI)7T2E"^..+AM1]FI B,4
MBD!#2<RL_QC4(JNWL^+]%06-/GAK[UZO+?VY_(%4K^4Y[KZB'H8MS-6)C* Y
M:1RGU]#H/[@64%W>D\M#Y_) @W3PC2)*5$H%I"]")@UM]W33=U;V5DYTT]<W
MUU?>K2]UL?%170,0:5UZO"=/1P&W7WS\Z[<K&_1P56-0;<#>Z7[#\]7;H]MW
MQ^=OO%M?D;??T4/G;'_3S3%IE&G)Y-G4T"1[7!!6_'9E'3L'&[I&Q).&W?,#
M'S5W=</MO1B=T-)F[$Y"!3Y;DL2KP.-A\R?> #@EY"-&Z2L^"LK#\F&03LFH
MB3"*!9IJTE6Z#O0,V4O:K?U]#<=,^_V7>W#3/[WOV#VG!:QSZ.>0\DYX'5+8
MCX9PD^,L+22>=;O'SYD_H(^;KV=^W!0)*Q7OK:',C!+1',"A$L)/500,2Z$;
M,842X6N;@CAE7C<GJ$-L@1A#2S-2:"%"014ZDA(=3A^8JG"WS( H^:2:1Z]1
MRF5D(U[,YY& 1Q0QR2#"I"CF9V&;8C" K]#)Y#/?Z54\\R;UW]MEUMP4C !+
M?;9O*1&V6^/Y8$ITO:IH05%7XQ5OK2;@__%]F$$M<[ :4L2GR=4,K1SCQ)$=
M>!CV;XP>"1L%!D!8,)MJ 2GUN6+64EAK7>1?F7)*JM!4XYE*#>'F4@I?66C&
MG<]"NN0MC96882\>Y191;2VT_\X#B]UR^Y&=0/1SJS'KLUI&:67",5 "Z<V3
MG:205+JFC/O45%2UC&<E@5?=,\13)@SI8.TQ@:!.V.I!\VK'-V=NQ[\'D7#C
MGE%E'PS%WT?9336/MX05VD6N""@HW>0&?,?2CCO4%>7D#F?43(Q^V1!"U2T\
M7,G(2P=V["KMD>;A=<!36UJ$&'<,I4W3,DOI%!:F0I85JC?^ [VAX%J\GJRH
M3DFA*14],DJ\U/&YZVBBRBTXDC3\7O,ZU]_,?*Y_/OIGY^1P__"S=[#U76;X
ME_U3;^OS2:?SM0//WCK<A?_]\'8.MO:_^MX.7'B"%YW^\(Y.O-W]T^-O9QUO
MZV3_%._R[7"W<X)?G'0.MLXZN][94?F&IU^V#@Z\[4Z[Q0^''VW_\.DY<//3
MLY-O\,G^H;>ULW-TLKMUN-/QON^??8';=+"1I][1GD]_G)[!$^ O[[#SW?MQ
M=/(/^MW1MS-X^.>M$WKV_MFIM_/E:'^'?@B7>\?0>F@K/&E>9]6LM$,<U1 E
MT_=W2W#P@V=,*V-U"K&J6]J2Y".L_C<JAV,MB\7@ZAH6RNM.8UEX*^;VTV%4
M0T+!OJF3WT!.?L@C432E& 8*N$-"D'P'J3./A+1W!U.&M),;9,]VFJ&N'W[X
M-4C@G%R@UF3&+=*@7_?)IRK8J]%*YI%>S1,IY3[AD4L]<+C8_Z(**:=.DH[,
MQ/F[0PUQ:R0-4R$3 EM[$)-#J31HNV6\2$>(4@F$#IP!STO#P<Q01ON1BH -
M];E-%:$S2-1QOI!+"$2+9%2<YQ,2(WFI6[>LO2WI^,BB"&Z>H2NX3*X$.B/>
M>H_81N#,/B0O5DF/&80SN7J(WM+"8M2-FLLRZ/<S$EW467_F>S8LJ#KQEING
M*RB%4MLI-UJ<6DOPDN9$82@K]-NSSZ.E2:W1I1)06]11>1V"B/B/!"ADQ.+@
M1K+P&N_6V#32<U%MDUE=GH4<T9JR/0*R8L0-N.N(,3%GL,I+Z[28\.]/VW\U
M=]*\"\Y/$)Z5)M 1*'.$PS2:6YS>[#GWSO:_=L2Y@7]I#P1= G0D.J>GG<,=
M^=/V55:\SO_L=([!"0*O WYY\GW_%"[OG'E[1R?@DL GG?U#:,UQ9V=_;Q_=
M';@_>BC>[M8/<$/V.B?M%K@AVD/9V3_[03^:L\&>*BVW\:S3<AN+M-SSF<_:
M>,V*J; 45B:HJ[@\4I9GXA%1<@5M[@L\8U3ZG=IG-4D,RH:?9\'EA7@O$E"L
MQARE#)FHU;@8#+=A^UGU3^+-<=+S./C(@KN3FV>$!)QP=4E-T-(=4:)4U-Q2
MO\0,L,K"AD@<\8O2%@[W0B=!RMZ6B+J4I-^JWRY3\@GNF83H>B%<UA":<:^Q
MJVQ:,6>;@%HTZ[.GK:&#3YBAUUJ?D#%0H9XZ7U -O:[=[UEW4-4=>)&24'&^
M%T97BJ:)XO+$DK%EPV]AUXY4HL+H;T;0WX&PN>"/E'MI6L 7%^EY*+5RZNB$
M\S4TN'F$\FF.X!7/[B?5)^9EKB*4->_E$0P-TG'@ 3%+X07XP+)D2@SPE:VO
M,?6K!*9-OV@XE#I0=T[W/Q\R!_T *W%6?3Q54X]US,W.[#,\_)A/I]8/3M73
M^$B L,^LK[GMV1J9$&>[13'.<.5\Q?>NKZ]7\"2&#<9:F65SA=0!,MF>R HI
M=*+5]>!66#TVN>00;T'& /5US(62 K3,A#[6#5AD1L- YM5JS+X(M:.Y*;]P
M"4)N-EE5!'PAWZ@$'%K\ 26$Y#2'!_!$!MJ4@UD;J&13U>UH%YRG(047'5SR
M<S@-)_V7O31.LS_0 A:A'NMV:WWVQ5L(/(*Q<SF?X;16\H%&F/D#>Y7S&B0Z
M88MDG6,.F+$1 23:+-@(*\$@-"E@[I;K:IRT978JF>RZ%/ARZ-<6-BA@+=>G
M_+ZI-&9 9SK'^!CSXM._<!O9.OMVTO&.MS[#^7OOZ.#@Z/N_9_S8!WFWJ0[.
MKY_UP?GUXN#\6&?I^#(#A>#,PO.4XKAY'5[4NT$F/\>&4GIG9-E9GP*V>4B.
MI1""@L-7J;4+',],$91>$_A-9XDBVGZEW"1.L221*[D)+&/\85T1@V4,6! 7
M*2%##;$A[=:)*)@JK)'2_<29>'_FNC+49UO;!QUOIW-P<'J\M;-_^/EO+U9?
MT-_'6[N[ZF]YZ'74+R[PJ:M_T98 4T+!90X+1_VK9G/%6?WQ[$3=YPH517I!
MK&8(+)$7:N:?[>HFPC_UA][.$;;P\&\OUE]\^B?J8L#P@ .%\R+W[=^^.CNY
MW?-*;[>Y^I<7]4UP?_=ZNI]M;-;^[M:MG-PK^U^_?CO<W_&]_<.=E?M_UK0?
MWM/3MF_^J._723O0J_R5]SD.D\3[#HYU>/-0/<%;TN]X,D&$83?4A>-[6C3@
MB %QM2UY16O_TRRLRJ_?<.?H<&__Y&MGE[$E.YAAZ>S>]PYE-J-UVHVV=/H<
M*1<1QX=UA91*%3_]_NA[9M!I!YW.R?[A/\#!/3D[[)P@?<C.O;?W\6\@-8;Z
MCM8$Z5N,%2?+$G0S)'?9":Z"_TOSL:;_36DGN2\C()9F7$MF\5@Q,Z=A@L?;
MKT$2G*.GLRM(VVD:H$W.[.;CK]]VCV%!PSR,KQ2?25YAVQ-9$#K#.XX="D,R
M/<)89<@9^G2_?L.I#I2;O^T8>=OWFG3@K 21KH(L"O 9^1 <_I<]L$H809CR
MA_L2/_I\..4%%):0B]JMXVFO4H^9\O<=[^Q(+D$(YK17G<@UWZ>\X&3_;/]0
M-:W=VIJV>0*GD"O_K6)P:B8NSN[WO]#K@P&G.U\ZN]]@4]]Z6K&Q%Y_.*' ^
M[$HYY3C>*IV#^>_5E;>OW[]'K#MXT.'+/0PR@/T6Q4TV_[T>G]+Q>E0$2A.E
MR#G+L_D]=X@F"^,><%_8:WI?4HZV7UBQE*-VDA /U!%MN3V\^AHI$1/%GP^;
M2!"KN,R$@5*0QG:+'7$2J8![KK[>7)WV)1YPT(P_;/N_9?_8]3[K7&#+59[H
M_K)5JO& *WXTNH[HNU@CQ2[:F&O&!QXV7C1<V!"J/J[S$U:K!A;:JM+L'[=/
M/J$S5;,\*??&%O@AW^+08N\G&K MSS3HMS9DN]20*7S_Z6>/[=/?PQLVN79S
M_\RI!ZTNJ9:==Y?65U_[ZQOO_/7-S>7) ^M.K3@<0'/J2'+_^E_O*YTB9FK]
M+^-?J>F(O%:];KRO4/OTM;?3WN;M6W\5^F5U=;7I5O?2H$5W++KC?E;S=TZ1
MWV4);Z]X)U$<WEB5QLQZ?#?#=IMM:2H#6G_IIO_N[9NZ(;B_!R]>\(F\X"/8
M![>S-/TSAO.3MQ-<1JCR^E7K,'O]R,"BM[)>T(\"9[%1^/T1C]2&_W9SW7_S
MYNUSG8J+%WQDN]1ET$=XA#[FK4WM;D^^]M:YG5\8G*=YZT67+KKTL=[Z@??Z
M)V'=9WWIXNT>_=O]GFUY?673_AA=88W8/$O!"ZX+!4T?0:]]W!VL)%WG]=,1
M\3A.__Q?-'/W^=AW;\![>U/GP?VF-UZ,XF(4%Z/X.T=QIFBIJ9 ];QYW@<BB
MHN-WHD*V7ZX]+5Q(0R(:\\E1C[1OL<9")9*?ZGM)E0T,5%E/_C2-9ZTZ>N_O
M-D%>^X6%!> GV^B48P&ZM%O&HB,<)6,*-L&"G"*1YL,U^*$[J ),L'O&,QW3
M;M7WC*(S0*A.P7,)L2C>M4!LJ&8?[-CR!Z\CBB9&$A A/YL$SJ&2K9@P./2<
M\F,^2-UT1E*%6^KV.9=5A3\OL?P6?KP;]D*".FRL^=[ZZOKF_4%X'NO0;3^I
MH=NN'[H!@J5OPB#+E=B;U%8@G6V.NI2]>V0X>>BA;'C*D8*PX0X3/CO;:T$F
M^=$-QECHB<?@\)[;P&M8'1=&B/"IL&QJW5/P-5=@/3ZQ:='PE [\=TB\HH=A
M@8H32':8EVMNEX)!H4R*]$^[U7<ZR!&&10X;=M\=_5<P*F&2*RYV$B+%GDY2
MK:IE&2DUR9;_\/[[S=K*FC<$NP1W>1[]/M5![NWB(/=T#G*_8SK5G.[6G_(I
MR#K=[2&3ZW>QQ6"7B!5EE(=/\*3WXM-AFH2/N=!@*FOT;F&-GHXU>GC#L_&T
M%F6CX3F(<J('^R[,3F=ACC;H)?A#+[\'5!NS8W/\/5F#]*A+GZ:R2.\7%FEA
MD4I+9>OPL/,_3ZWVL=D+$F;1:I'<T[,Z=R<_>[VZ6.A/9Z'_QLG$BW_[6:P+
ML_C+N8"Y6OIKBZ6_6/I3+_W[XTMZ5$M_>RZ7_B,G.ETL_=\\F4BU\L6GSL^+
MJ!L5,_/YY3$/LB[VCDZ^DHKAT<X_7GX[-C)%3_C='K+__O77_WK_YNW[#_]F
ME,'3,I7U9?OW>/M&'K0Z!IC''!WJO4H1PC[C[EK;6%WSMK20'7:4Z#_")9L?
M3[\=?RHN/K["_WI[<8H<>O<7H--2CH<_$/ZQ]O[QCL<M^*)/PC^H]@#1>RDJ
M7?2]8^(-:K<TZJ)[(\JA/57O/C.?YR&U$V!U!_U(& D_PX-B))A^Q(2DM^@J
M1!(QNS?\-NQC<;4E=(U2!TQDB^_^"H4QA732J,3*6..5NV$<7 >D*Z/UU[TE
M5ZU4@ FN2*GA%\]9V[%L']HM,!#>DKE-^0?V_5"7BK18$ Q!!M^+$OAGD'@.
M3L3H2)3:6/\K^Q%"2FXC+4@,BRC(!R)O6^;5*CV%EX^G5H_S!B02&KX<<.#P
MVH*C:3(QAJ")\I9NAE8F[3$6@P:39+M0O69$I&"K8)0(:,;HLNH 62A-W296
M3$%E(]6:L@YM$TN4I44KB*2(A<UU=&3,^U4A=FGF(V=['(6C\I=^3;0U7V8T
ME#Z/S?9A*[ 8/%@BZ7D2%5JX#26&DG 0%2BS%+#03&GX&;S72Y,!PG68#M]9
MFB1@YBQ.4I]REV?@+%!K7C!P9V 47,]344S":4'B\JA\$Z'T$RN]X<5PJS"Z
M+&3L\5$HH7-C5+%P_HA6,QS3DO0Z#OOG:$8JC<=5E#.]/@EKC8S# IU">&DB
M<%5ZLDTK=9P2LNL$6<L).]WW^B/J:%J:T.<I:CJ!T4Q(TR!A#62"2+(T@>C!
M]<W7#*"D$8QR[_TJ_'U3 Z\<UWRWP0<PF"^_77K'U!QGL; @E]V%-$&2M&"Y
M&=39IC<AS1LE9M,3;6]H1=E"^O@2W? BB >51M+7/'-BD@Y$,07^"QJ"2MMD
MQ$CH <;7![<SCGV2[,X"EKSA3_#_61KG4HGQVC]2Z\TW*Z_YQWS'<^$51)WL
M2YZ9="S!7RM<K3*X>1#C /A:)NP:@6G]*,?=0%3)"=4V"$5XN7[9*UEF ^@G
M_:BLB$BAC#83U%?\R>*"M'KH;X+"T9_8)-=:*-TA6"1>>HT#FK(J$"/T@M[_
MCB+68JLL'GS5DL(0+;_J'$$YX[K;YCQ7TFOFK.,N80,U=D6I"6IJ&UR+;MXZ
M9&4]'ILZ/:0,UEI>B%.@M"AY'E:?0G<>1-ROO6 $P\<V C_KBZBD=;\<1==9
M=C)IMV"T$J5NC5V!S1$G@[6JS<"*O-W:^XT-$B('$X0&G9Y/ N^._P!SXCJX
M5/-#M.OTXI:/+=RD,O<RYW+:3*[!?(>\R$BXNW'EL9(ZO$PZA(V"EK:HZ^!4
MOL9%?1%=CNM$F7,B>DA2V=)^&]P9J8*5/"R*F*>@:-_=U*T-?N_<>@Z\"1RM
M+IQU-U>J:8C+*'"::9$<1US'9Q]$28+)BM!:Z"A!'J?7U5T3-1^UP:H.\!TW
M I)O!U\5ISF,'&W'/;+*-%N7UI:Y&RN'='('B)K=DP;&V*;1I;4(E"WN!G$@
M4]6>G;S3T9[9;M&3^VD2XJ,SZ%W\1Q]7==0=T1^6P<8_ [9CV%B/]3!];VE]
MV8BZZ\XRVGY1<I7&J#+O6#UL)CG$N+]M++M7BU(L7)R%8I5Y@60A'&L*VHO%
M^[<& T>X(UN"A3K';9>2 J_KI(:4<.':&^W)6[?4MS-FZK5MILK^A/W[DNL-
MC5MZO5R98?T4'H-OJM=MNP7]-4J*((O (K'0)76P'&?  I-'E$EOH"$.,IKS
MI4Y<$JG."^0?UM?AOZD_-CU2\N5]BDP=5JZH_8'W-G?:+,^XHN.QV92I<BT;
MBUS+4\VUW&;:34=O_7U_]^S+WUX0>?5=FSI)M&&BF$F5OE//YUIR3_D6CAGE
M']3B\ND<_''_4S=-T*KTPX^O]C]YY]& /##\;VX5]-<7\T_QIM,S"\SE6$TY
M6.(VT^ZN?0/V<&UO5\5'E+M0.OT06_UP&/8C4H<BI=F:G\)6CH]04LR>$J6O
M>"F^VC/+-U7!+G8?AF&0R%DC9L0P^MO@'7?C- 7G";H\B] \H.??5\=3V$W;
MK2%64&7A,.6 02*25KUTE$?)\F)^SGY^WL:::)]3PA"6QC@ZDQC=HJ.:.G+!
MK$:-2/41'5;!I8&?VA_197$TC J<FG$4=,$%*E"?G"/&<I<AU5?;-[$^Z;)L
MI@FGRT56'-"^LORQ+#\\<L8W+RGLT&[!,22/8-;SZ4[4ZO43%G-SYG/S:KJI
M&54,7'.H@ )G:9R[L\6W9ZVOYJ)7F8JD:,V3OHL&"I4^P$S"+WPUA2A4I@+/
M<E=L!,]5'76[3CC"E,.CXB##4GA\3H0^69@7J.]:.>8ZYSHPG72P6TS#64_#
M*6>A!"NL\=(YIF" ASJB.C"V!L[;,- <"X"+C#GE":5F:LP[^Q#5[- H5<.>
MBQDP\QDPY1X)#A421E#@*O!00B@:1!0\&&*)5<_X1QX=*"6X:85A6<(9>;O3
MK*<"C3A'%H,\^T&><I1A!5**B08/UC2&U-$[Z(4<Q]))R7X8P&A6W>_%6#[
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M5:'9VAN#XU88Y,I0-H55[+ <FB+ZC6\.$GCB@_<BIR[MP6OZN)(I\)+RBB9
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MCC^),.)4<8Z%(/J3C4G\OFFG2'X[__-E?WO_[-FI2NQ<1.$ AE"R0IAG0@Y
MG3K>03,Y(#OV *SST#"&?^SG^8A880TV7.&=-Y?^OOQ<"/";'J(OG=%/7FT?
M[?[ VJ%77\Z^'GSZ_U!+ P04    " "0A;Y:X"O^.<E&  ""=P$ $0   &4V
M-C0U-3%?97@T+3$N:'1M[7U[<]O6M>__G.%WP/5M.^0,K4AVG#:VZ[F41,=L
M94E'C[B>3N<,2((48A!@ % R^^GO>NTG (IT8LN1W+GWQ"()[-?:Z[U^Z^6;
MB[='K]JMEV\&_4/X;X#_>WDQO#@:O'KY'?\7OOU.OGZY?W+X/CB_>'\T^/NC
M:9:6SX.]W4497,3SJ B.HYO@+)N':8\_Z 7G41Y/'\&#\.BI>FX>YK,X?1[L
M/GKUEW14+%Z\_.[4^\FFKWX1Z)?!3W=?!&7TL7P<)O$,/AI':1GECUZ]W'_U
M^N3L;7#R.C@]&SQ^?7E\.#@,WO7/SOK'%R^_VW_UF<?_4HNL+BZX. E.+\\.
MWO3/!\'!R=NW)\<P^,G!/^_1JH=OWUX>#P]ZP?#X8.>/OJY?ED493U>/7IWF
MT>/7RW0238)W89Z':1D<9SO!OX.7KT_@7*TQ'Q?Q?R,8^,FB?/3J/R^_P^\_
MUQ[HZ7V935 K/[\*\ZAX'OS[+__WQQ_^^N.+_]R/Y0V+8AD%AV$)Q_<V7)GE
M]8(GNT^>!9UB.;X*)O!]+RBOHG;K+\GDUV7V HC^Y=!Z^N5WPU=(^'_)Z>ON
M?=@=^3"&&X OW=UY%J>/7EV\&9[7\'!@<^U6+9\+.K!Q@;-O0E3^IL']SF'@
M&*9=7H5E+YAF>7 =)K#'>32.XNMHTC,G%,"7<5D$85' K(N:8=YDR23*_5':
MK;@(8$5QF>#[EHLLQ:.%Q>9S>%LZ"8KEZ)=H7 9E1E\D\3PNPS+.8!#X;?0Q
MRL=Q$=%/\?MQEDYB_OHJRJ,X#:?PKJ"(2EQ >=4+PA)^O I*. !\ TR<?M)N
MX>-(7/1@-JU9PS"%5X=),%"CUE%;L(3E)# 96)FZL+A(>682Q&DP729)S?LO
M8-4P8YQ^NU7W[AYN ^Q(,<[C441'@@M?+//Q50CSF>;9/*B3 ;#LX#!*PAM@
M'+!'^2++:9B:21QD\P5L4&7H=FNYP.'-F1?$A@+8JG$VG\/+BC(;?^@%BU!1
MRI]V=W9W=_>"!1X!_KI^/'SV')^M[&4G+&P*""=X'>9 ,.T6GA(*A)R802U-
M"Z/TW[H37, #>M,6>3R.<!59&LDLX0][6@&-XQXI_!#.< 1<*/IU"30A]*E)
MXQ3?"MM>!)-H&J=\[B\O7YW#4G#CGW1&P)@N7^W<!=^X.XZEEK^W V3T O;C
M$'>';RQM1[MU$"[@BB<@Q2?"!Y9X;9#0TZP,,MCF_ :W6&TL7W0YD:OP.J*3
MF$=A&J>SPMQ]/ 'D9<3:0OCC$H_U)H?1TUG0G^51A*35(RXP:;=0!CWY&PL?
M.$D@AQF]66X(S>@H@OU(/P2G85ZF45X$1T<'=.IGT0)(#UX']^R:* H?U2/B
M3]-P'A'7PNG30_ !JCB]8)Y-D/=.@#VU6\5RL4AH:O !77%B7DAQ^%]82#B&
M.ST)4Z#CFQ@7"JR8MZYZW^H77;TCKX&YP!U99 7=<>2/AOSYSDVS),EN\#T\
MV.TG,(K@@8="\GLX;B?L\M ;_5_[H.!RG *99"G>"^]\VBW<7)20</R3^#J>
M  _JV9R=V#"1Y%6\Z+'<!/))XG 4)W&Y0IZ-5 PGF</L>\%H6<!M*@KU-XCR
M;!S+NW[)8N1YQ SU@_1ANW4-BUWFP.N*+$%NF@%#C<I,!EX"":AI$3W/@"C^
M*Z^=9==1GB+] 0<-E^55EN/42*RM^*8CX<SQ^I"6L"(64"RB,5R/,5#;"E94
MT&WE:_1E:6OO3BEK]*F4=9&'$[B8J&/X<CX0N@(>N$+UZ.8J!IT;;[.1]HYH
M1'%9POOP;-/@."PFX:]P@+T@GM)9^=_U:M[=;@')I.-X 50@<P,#(/\ ;&/+
M*0"'RA912II1R6]Z2!0Q_LT4P=O>0!1X)Z<>YY_3 P7>V>@C*%3I+"K<4W.5
M,3HMOK/X#+R>I)HYKP"57ZV+@W#[=1D5R"Z>T]N$PD1)$#+IV5_]E&2CM=^<
M1PGJD\X/X"#>9_D'H:B!K*3',SE^#V94?PY',\:CPH].+@[^9Q\7H/[X5] 1
MM@56ZACX*#! 4EGM3<NC&?#,6?<!T:0>\?\\?AR\CJ-D\AR4I5GT EX+)PLJ
M"_PP>/Q8?*TO#X<_NW[1QV6V>![\L"C5#!Z/LK+,YO+9"!2?*->?[2<AG-\>
M3!&D43R!\?5*J\XK_48:8K=FB%UT(IFM>_D=3*]FIJ,\"C\\'D5XPL]!\.+R
M-IC]YYR=M=W?X7[S%M]SBO.,C"?*R%!6V4,RN+;7/JV-:K> 9VG/$&R:,6R%
MF6GS.8]G5\#_<V7O #<?K5Q;>0[R?@3V (CH'G+TFRO4%-%EE)*6ZCEE<OIO
M08) N6=HS%K_"YEA[,CA"T@_M5PI_"N8TR1*P!3+5\I65W8<K ATDB7HDM''
M:+PD>12."]"8$W26+%8TC=/#U_0'^B- EY9U1H_G89P0[Y=_AF49CJ]0I^VJ
MO3K.2G$QZ)G'J1()<UA "@.S'0M3JYIL^OEVRU"R;Z^] \-/WAJ%>1+#GJ$3
M*Q8"0.=&9Z^K]2M0_6CG.K'Z!3Z9+N<C?M#Z74$J?QX7L1C YR4\&>:@=)]'
M9<FF:0"V2IQ-R&/3Y/&8=&$Z2$YBLG=M"U))?%3UM5</U 4\TB*,)RQWV8TH
MEJ8<* OI< :V[ S?X/I@6+>HZB%B1/ TZ05@98. 'R6U!P9G?1.SHID64]RC
M/!B'8.-$^5_R L^@:+?&5Q%(GTD>WJ1(DB'8^V1UP8:5,.0H3-&7E)"5A<Y*
M>)[^T L&ZVD<3<":<J?G[.*8MY!,:51X_86T6VM7L@.?P2\_/ 9;"S@*7*>:
MU2KO%ESK7Y>P;-C]-%/;CG=F'DW@GSBAV3+$;8TBN@1LLY6K!;,0\R5\!^9
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M* -H14=:4>BZT2A9)@H(?"3Z").%U9-0Y.NK_<]V!$AE!#Q@J8 ^E3^X0)B
M(K;:AI$%G\#'8":NZ_/.Y$.[5<?][T0^:*7ST_?U=Y$/Q&]J=OH+RX=VJTY
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MRDA3M& S<?HYU3'@IUCX(S[$T"K?0^@[2I]4E:)^]HZCA<N[N);]=NE;+RV
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MO(5R?61WRVP6D7#C_3*.,B!:Y*B"BZ]C1\INC.Q\%[%QA=E;RR*L)1M:B3>
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MKP!9.'%+RX16')AVOT_91>V*3$LHRRR![\M<^2WBN>DQ3^%*"6MHIQQYX8@
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MP*\WZ"G-4[WJA[7NPG6OL6T#[I2T]T/X> _1S_>ZE#W*K9CB%!AL0JB7F6U
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M&+@H:-%A&F7+ H0:8B8[&VW#)[MF0W! WF7DH@2W##.BSGI_>_S/G0L_&BF
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M_8>U /\T>8B#-^T6G: FGV [ZN'EZ'$#6,'/PP,B:YKP^;F^)K@O.!OU^?X
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MT66(J,\Z^I=9XB9ZW+-[K<<]^Z;'?:U46L\ GGR_\PPW8'B,Y0G'F*#]CC/
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M_9>+'%\MJZMP/MW..)UD.7Q*M-!W: ''J1*86+Z8#6$5<!3NSM"*+!KCQ<V
M &FN.%P)PR_F2!N+LDSQ SY1H%/U+OCA6QFRV[&)H77>63Z:+L99?AXA2>C/
MK1=%F[PG0ZY)6YU^A%_EYT!--7Q53=(2+G$)-W$^34:I7E Q:2>6,)4LY62!
M[)KG#?.#09()7$MZK>'BM+%R,MT.GWN?WE)?E,7B_(+^;;;A\=.'V]';K3?
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MO<!,AV6:O+\_3)&A/ 42Q>5M,/N;G)VUW3_B?O,6W^!!?X]*Y/ 3E,A#-,9
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M'!X^QNB"4!HP)9AEN;P5SH;;JZD^Y/T5NZ!57U6[LIG6JL-P2 #["T-W)I@
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M\7 D2*"[V6A4$3:K^C#D,7'](KK)CS9()0N!4YYHADY*(9NTEN^#6+";^.$
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M(>/J,2AP45HY$:MA$JS*1 -*))5FO7UK 12_^I!,M5O*+F'W'";2HMK&1@[
MUX=284)KCB7'Q4D3*U76A9_8XN2!<;85F PJ'XR1I3'B2:'\6"=_.>C6&R=P
MQ>LS<%1.1RUP'T[BC9]KLV%JS<&&A/6AF"[R&E&O"L&7YC_I E''"G+A33,X
M)+.QEQE;3YR;0F<_F219XYA-\84-?-F<DPT6*FH4QRRTZD1Q--:=O%Y!-6WV
M%/M2&T5+J3Y:WS)]5[/:1"6Q];3&@U-*THGJX>RO!=L0@%E7=SL[VV@\I]A"
M$VS&9>7ZB*T"6M7KN/3A%=B;)[J=Z@0;6WHAAAA@AWL?K8/T*D8IY4@5/=#>
MF8()S_OM@$7$3J%0;+&I., \5*=PNS"#XG%FQ-AJU>E76ZSB5(5N!LTOLPL+
M5LRX6C=E4)I#E1MX+Y:MVZFJ2!JU319348E<L62#&G90^I>:HF(84I?$Q@8,
M!^:U3@O*(94026/_LMI^#7OA-]O/4#F3!17G)%.&LC%"#,:K:6]@*EYI \&0
M6+.#IBU?I.MCK+8;#G2K7!KAM..4?.VU%%B9BA/3=U=:^X@40G).)NI'#$%H
MA55->9O$M-SV]6XG9VL^6]%9L\P')RC3U>L3'+1N1[$@W#..P?#U0WQ);+\#
MVP?3*#-L&@3ZQ_WY8@B<!GY/;4UD;ABL5&$NK[V-CA,;61=@QQ0&!JLRR=-B
M42'X)[)4>Z-U;./T8,^UHZ,]BDTA%\6<#[Q>+S&T]<O]OVZ=^;D,@L!C7WL=
MKG$W9+PH=08B=U,>85LSZL*N=#DG&)5K-9,.P&6^L@T,C@1LY?P\-96H\DM3
M:#I+,)>]5H68>*FX0?)T:6'9?17AF=MI9FP.F?CD)B 3WQHLTX [Z38<Z"UW
MS&Z(1/BR&7\^)(2)_:16R+1EL3CGCFXF4?CQTX?;T=NM-ULQ[<%O1?D^VJ/6
M'U2RI[/2YIG*D\(7.EFPU!_$+CM&(-H&MJ7#NTPV+1F?!=L/"&D,5@75?8LT
MLN+>.@A-<+B4V\!M'+UFY[P+T>@B)0P:Q"RV#1,,.-\'M32:+!"NL4?^39WK
M,4ZQ8B6Q*B%DV'YLI#RE(V#6!-\-S"E'=JA 8>S)*FVS#7Y-/[ 9-#0G<.C>
MD7?W[VL":-H#57"*=I0Z8NVK"1?EF_L9L\[%QH,ECYT61MK[3#E79(11 8:R
M9\J"DE07E5*(2#>4,GJV2@PH^J0H^0Z[R  -.G3,R=BYN]T.77SLBS TUYO3
M8ORN2L%;KM"C:5N&6-*6Y!)P=)(71VI?4[VO3O8B=4]JH"H%,0L4/&#2[OYW
MVMXB4'1&XF\H.SH4+ R\A__H#>[O]J/>W_O_)*"-W@"X!/DKGGZ_CO^=[6_9
M\[^S?>?ZOT[7_R</(T,$>+%\B%UB\)7;6\S'!_WHSP3_I/U/!*ZL'1[=SM]^
M';Q5"H_5I=U+=\2V)LK:LNVE$,J_*"0JJ:WQ.:@?.S(#V*0+W9F:2P6,K\\V
M(JVHZT,23ER2D:"KC8UHQ>R=1:![YT%HK&B3H;H==RS[S6XYTCS-R>J<*![.
MN/WD'*:?7!0P@LI:Q(9XT@,O4BWP?MK>QA9X\(83#?D?';TYI5CR8GK.U8VF
M0]XDQ1S^J5T;-TTN*XIBT+9;D^6:9]Z%52GG49J1IN=XQ +T@=KP-1 ('LY_
MK)%VL['I]=UT9.4B\+%'Y)SS27DR;[A!.;5%10<#RZO=:5&@L#N/7F^]W8IZ
MCG#57S9* A+M1B,![6R0AI=C*K(VT*RRV[G"/=#4*+Z,38BG08EDV506,:,G
M!FLJZLL"J9]_SDH1JV$69C>CE<B3?!3\N%'8R".Y*6G[L^N[:>'!:UQRD7J8
MY#9G-@U_C_<,-CT.;%W;V6S$+D+K6;MS5*0<W#K_XEZ7Q(BV-Y$9.UN.I^2S
MRZI=E%5VN@LVH-#LP&GB9J7LZ%*'9WA(U[9A_+\XLRLLX5JW;K-#4YOW=[5Y
M#16_V[$[(G']K20_;M+'8U6SGL;#$[?@,;I$^TX9.5Q_Q[$#_028>;H#$G_G
M&#U;7V(SO]PQ'C;SLDJ5ITH&'Z=:-?<)#;#\2O9T](GF-&AI?]R>%J@T7-_H
M?5Y<@J$J#2"I!EXTNB;I&6:;]'M/^CJ%PN\7')@#6\;4^TE$"W:O3D:X W B
MH\J;NW([:1/?!.54!V ).S \B'4-I&-2#6N3VMLB_+O /-W:2=H-'5NM%2ZE
M HVA0RH3U8T2HR/:+0[BZ%NX//2_#T$TM<@2&-!1[)0.V?"6$ N2=BP8$-3^
M7"X2LV+"X@*=9&5E<AYUX>MHBHD)JH$:U^"!396(_I(%5%<NT<^EA1:E+:"+
MA6G#:"2LQ_*DAME8)A;2A97[E%14N";4_Y**V^4+E7-O]')<;[^AQXOJ7.0K
M8%ZLJ4=FYJW:=D]7G+NZ%OG&GZ#?/=F:@3[N^-WA L%2J"#WT=/M!]&\^0@M
MMH]-;<!,@ET^/MO[OUV<$/[C[TWSS]Y-3&%!Z*H4(TDX>0Q2GZ>A'5:% AIA
MDE3*#?;5FX]C<\.D1ZOI0ZJ9K8WN=F2G)X71M0/CY 2;3BNI-&$$SU"?%WR#
M3.9MEK^/CL%TE;WB_"<-P&I#V1#-PH[EHZ6J#Y08!2;:3!:YZ4#(HQ";HSD)
M%L:LJ+C2'#B=(>YY6H9+0; /H9HO9R^-U0;F4J%->@-F#TF\&I.-D'?@2G0%
M9TNE2406N'WCDYPZ[,Y3XF:4MY8 UR?(?TZU@'MV7@#;AG% $J'GT\@T<>#.
MDM^+DDO:,34K)5KQQ0J=A8]A;)6!MH959)FI9&MC#DA>"1"[Y*OH]CC8"]%K
M!/PY6?+GE@$;N6AWOFD7[<Z=B_:V4J^CP:#SPU->V'R*.4OWRRHOMF!J55[&
M8!\LKR)THT^0N<#V7*?U%]-ENIV0IO)%=)E@3OD7T&6D#49CIS^S+F/ 2WR<
MQ,^LRV#P.JS,1%]"ER%7@J/,1%]"EP&&YBLST6?69:Z=VUNZR+>>>;>S?1.I
M=Z]=+!TGJR247W"=)W9=U/0]9@QMF+%W5-3HR;,8QA*C53K?37NTV.D8J@Q!
MV:BP4U: E8%8+HQO>1+.+1-4F*39K:F);ZD'8A=<:0* -D14ZY@Z<YG$2" +
MG.)&YPSB*.M310_:O\H/F9G8K;,5R%]KE$R8KBRU+LX9RED[];THYT!!G%8&
M1]*%.+V\**KVI@V.D-)Q!YT3"!O2-O+$@WS0'.<A2$X#F2B5"P/8J![WJN)Y
MQ=[:4*[;B\&_'9U[4%L]<MZR9]J/#&.2DZQ!+1=1B2]S)ZVJM;$Q)8]S)S\8
M\Q\_#!?3Z;-_1CA"3_WU)[VVNB#<*//>%JB*UG(-!Z9/DTL3(F]-1PE_$P(H
MEVQ@P)$6-!Z:?KF0VOI]\??2&#"JE M50CP^<T*1')#J0*+:9V\TX(91+R(;
MA7^I:P59AW;@.]'ESG$"Q$&)(T13XVDQ\,>&T^+WM\3F=+Z..]U4:B4H?I,7
MN0Y4((Q5F#FMW6ZG #*TZ70@)IO$S*B4JL3*9$5@NHI)D(0G8)*F=-&:HV$L
M[4C/U6+XNQQ&8H.U<A!$#VSSQCR9%N?%HJ):*WR7]3,3W9+@UA_?FBWD2%(?
M8IARIM)6Q,C"+O+JBOALSL>7V-F69M)QF,=J%5FA]@A^:#AHQB>F6"A[+QT>
MJL);Y6(J!UWJ5*3*SD/BB" %W9&92J#,BN3Y>Z>+M3S\3AN!7)^2_1MIS*4Q
MB?"'F?2TRM:LL"DDU (5DF:%/CM,7V)8RBJC_!WE9$%4]C%MA5?;A:5/_D;3
MCN!<@@5>K<0G55[!0^]VQ$'3 ANL.C&LP$?&3!\!<>0H9/.6!2B](3R[G0"Y
M]]T6\FTLQYN0)EFY%W@ 6,@Y*M-00IHZ,;C],V"*ND]&WLC8T2]V$)X"NL7U
M[2->Y:MM9(AM?-(^NN73B,"BN2..O[:95QB3F53>O+! #0G5'PV,I7#X25;.
M6,M$Q,EDM#25Q/:^@IY@]67&&F9WVQF8F'LL8S<#S$I85-S"$;@CW&[B,]2C
MV3Y:[>7XS&QN/0J9Q:MA;FJF*B.2%0"BW4V:B"1VD5&)'$IT>Z-(;* %DEMS
M8J)7-G8&@0HPDJ;<"]NIQ0D*V8B%7HZE >R_$MYGUWJ&0-LLV(Q$]>?@%W-Q
M*KRS6,#!<5U'LY6,QL!P?ZVPBJ4<L_D[<0=SU=/@G,",&V!*ZT'B;!"V:. :
M>S8:KY50Y39OL]-A9!#' MC@CBKM%IE8F2;BILX7"%( )/NAR/!ZP&OQAEE(
ML&J/",^#SHV2 ]BG9R?@N%>?<T8)Y]UV=,N-Q_ O0UE0%9V"RHY\B;V!INM[
M#+F!.V)A:!R(543>[#H=X@XMIK3X%T+*(DZX3?=T^YU8>8B:=(V*V*8V5YEH
M"<V*?@_>>(.+?6D%+"A?2-GTTM7#+736J\"["=- ]RPI[.-4_KT!.5I@O2NY
M']@>C0K]=:_.<LI7H\IK[G=813M/MIX\T7UHUC?2L#;-RDM72&E!2@A<4O^U
MJXU$NZ6,9:ZRNN_OEM=%1+9+89T4J (O4MW7@=F./BQA*^LV\C*S&G+J]#])
M\8;?_[2#0"58,6$!R.4ZX]GD-[N4PREI 0*8)V5R7B9SRUE/* 6E<E5DV/X+
MF;QJ;"!M&G3E/(KGA#NEPIT9$<H!UIEBW*$EUS2XC3!A0I<GM 9G9@K31[%P
M1GGHR]V33#U&AX#%2X,Z:I%2D?ZN9X$Q$'(=KCL%,2B-DL]U(M14FM60BC&"
MYK(YP-93E R"N(/%N"67$F S5<+6 -:+:*2^6]#8%'Q&-@Y]T\CPCTMW$$FL
MG@QVFQ9#Z]\QI-_.@V\Z;>3!7=K('<CTS12'GS78M27RI.,Q<_TK^$@]TX@*
MFXEK-]SR!/,C+3"T;LBVJVZ#9.M\"N? [8]EW%#-<95<9M4%C<WV-C:^:>LV
MF6),[:^+Z7[SX>N=FPA?:_/S1(C;X*N?^34"HJHIG(Z27/>JKO04.Y/2E7BX
M'4</MA\\WHH\N)/C45W@ SO\?:R:A2A7D.\FI8H"$QWT2D>U\CK"#CTU]^7P
MP8Q<, 2>"Z(V,=Z::3NSME<FH3A:=2G\AC[5NZ@-49ZN;J<)HR#P8@@L%=!7
M5&<E4RU:3"9NVIGR&:#%9N&?8&)0[0<0=9LD['NGFOLVQG11'X4W<!.7ND[0
MFQQ)TW>$<C&UA4$CDN9!_A>X"66>LNW-Z"W5 A>3D?,$542J9%P:O)<Z^9BB
MNK<T,21*6Y*&E.*P4X^+\X![\.@-31!A+YMHW[>TX1'PER!"F"S(KI7$V"C<
M?;5#!B.C4ON#?4UT?2?M;9I*MTWZ=Q7[Z6?B@V"?.#;L4:[<TOD;B;<!PF9U
MN4*'B-6HV31YH5"KQFVD1PI_(=)$RW1 #3MM*1.N*M1B= F1330N8#@%<^#"
M3J=HVK<F2XB-X>5,!+IT"HM1I\CT<K&LD(DB5ID^;V=2'IS/(J=:,^OEV$%9
M+<KS4^= I-C;3*.3&,>./3/T66\RMCBFZ@LL"^L][-ON*>VH<5$;K:&$#"L"
M.S(WERXE#Z0=H?*][^11"V(#RP X38QEIC?"=4JKB%"LK$P3"Z7.:TA/8FU-
M5*\,JQWWAMA(BKE>).3B<,F4LP;N](B;U2,>W(0> >;9RY)U1Y!>3 .L1L W
M$_.-1R7H B((94D8:0%0;O-ID3=VFJ4+%9:W1JH:5<0. *+*6;!]N.2M;=:"
MFNEIOU%9,%V/47/7W60^U@*@),9!.&PU3QP!BDO&$N/:S:/M=CB1MN=T1-V;
M%A7>FU,$<Z;"P;XN$22)T=B N]MTL[?IX4W<)D6#%!-2VKA/1Q1+8;&8EA_(
M27^I4@E9'6NV=%.1ES2/>CO;?4)^EI":YX8/Q5X(2FP^+S)JW8F<^U+IKS@>
M>X&M?LZ8MQU$+A>*;;Q!B1Y"V!T;V''36-HT"Y%>?CYF>F@\+@<,#F@Z%TO;
M\\"85UN"TE.K)JPZ\1?4E@T<+ZAW5:V1@Q4R,AXH%17H?NK6/(WSTQVXI8$?
M2EMBC8N2+ 3@#UO=SD QC+:W>8H>PYLKD&)>A?Q4W 7>+A3<;(OBKSV$0:<*
M'P;AQX]CK JOX6&T(5-,FN\W8=$#^1"$DFYAH5<7R(*+,/[Y'?.[6>;WZ":8
MWYNL0H."H9OO &R_JG1XUO1.V'V"1A4[.R^LKB=GEO"0?#5ESG*^L[[*HV2>
MC#!T1B]R(SDZ^SQV+4,;)_)#49/MK=R;"FJ?C \KM>HBM5[.-4FJ0XCG7U&J
ME&3.8)YJJ3(;M#';C%29?%4KH$@.K1S]&]JC<?5M,;]J])R-;3ATU4" JJ[,
MB03\1[KUB=K!F$-U!?N.\'>TB-1T%?/!X[N=GDI"8[^87:T6BT,"MYJS@T+=
M3^2KELX$R2R9GB>S1*/O?TB7'/JV8K']F)I'T,D;N31+4]0.J+]"@"JDA<S<
M\N'%SEMC%RE/!]U=T>36E6G$(BM!@L]4U_^%X$TU68P7[?VW.=]$)Z;!0E?3
MH)6'8\6V*PQML^7 _;^383:5.()-FC@]MZ>.\;GV5F<7.$=#9;=TJ]N),=:9
MC!(;-G.B+D55E9:6N]$B8?AD5*:P)46C6\OW'/A]^$T'?A_>!7[O K\WA@H^
M4!VEQK;OZC;HG3=Q*EKAIX-?<T0M(!%M-L'.XS\Y!D'H?'<:V!/3=%('>ZS*
M+QZ'VOL%YZ6*7G*=-B:5#V3"@EP>2^IXQ7E@:,@N6STBEFZ*V7OHEA^)%K0F
MH#A+)?T/W0&XJZ0><2P)]WC**068W&4\$90SK!I$-#4OY7K@H@/IW=:B8SF]
MT41E*Z5)G)]H8 J>3*\UM<Z$4GNIWU+ZGC1&^H!"%<40'1E*<YNG)?7XD1Q&
M2WL-HC-R<1KE"&*U*8+A$6&[4 "H6%8ZD7D$/UU2T'#!$3,.W*#KAH:P8G&U
MCB[BJQFG4) 4N&$.JE!.HAOU!@3MD-PVE.E6JW9+1OVV_1=6714A&+@1WW/L
MAE2C8I9D)?6AC7ZU"44%Z\[3')&3K69.NGS1I47:*C#DB!QU+B:%:9*281FD
M&F790&VDP@4KUT0%8ZFD *TBTQY+:X NH+(HS1*V-(F@>FQ&#T%,0 ;$LK9\
MDQTWZ3%^<1;^DOI=2<+W-#WGB#81-0;#E@S*@%_F18X7HZHX8]';!ZV2MZFY
M'!'MC?H1NL.H@5,I.3P:1H+2'N'0*7; +0DL&A-!DT@7.!B(F\!5Y*04OE,9
M[Z:4($C-![9>'!;CI8J?_0ZWM!ISV@8?%MW\YFYB/7BNCE1O'9(QWTKB0Z:0
MIC+8W7Z"#S#L=HGX1S"'=C9%K[W_Y(^VI_U.I.4UB,M=4IH5MS0"SBD!-M4D
M&+<V3;PSOPK(O6Y$\:$@,3(<Y7%O+W(S3?'<;CTA";WZ&G)G3GT3U46*(_M&
MUIP,$P>OU[KKBE9K,49QNN+B?@/WZY8;#*.-#893%39AI6) .142\3YUJQM+
M*[..W"TJ[\FKNO;RU$PVG !/M*?">5EN0ITZS\/17]OS^OSG[906U$I(I5/U
M6LI%Z*H\TG'0R]'WTDZCUJQ3;V[:DS647KVH*9 &MRA377_-B;2U[^KTBJ?E
MSZQ4, GH@:O<0^0-J!H':!#'3"V\<L11XX+@I!U/,+E8Q9TJKD$+>&7EO)>L
MT%#YU[\7&:-3D<*)/DY0P;C6%>-SK-XQ3PG%?ALGCZ<^XS*1(F>/M*J5"]."
M.SN%PYV5WE:JO,,OG7WP1?UQC[YI?]RC.W_<G3_NBN)UO+%X#66C&YYHD#LJ
M8P[Z)NU(0#!:;3IC_9'E+"$5A&M)P>8V[B'55;EEG#*5XA!..;@E^8NWG)+2
MZU;4-E:N-!R#Q,!1V%EVLTJUEN3YH4G6DJ;?GLJ"K[,T'$VLGFHRQW*@FJOJ
M:0$!=8=3<C?YH=$$@W6R>JFE548J6#*"6N"L8*DNINXGR\J9;DCE;9_5]!'>
M-TIIUQM5!29HZ'6<N+M>-WZ])IL'3E!]G%E9BDT-<P:&+U4UH$>/M4V[@8NB
M/G%>*1\\JJ.JF+G5[ BKI;>"0KZVK*\K4LCYYA3"F+JY-"./3C#]8=XL1W(9
M@ 8:@!?55*6C7Z/8)C6;F:FJ(O+RV.$$MJ%5:5@#0>TV$<FM<5<JZEGCL60J
M"OHL+ZZ0AX8Y/R+)!QR%HYQ9#7_&,2<1?Z;6S\;T4M:N%DM4C"")8QJ30N ,
M<@MZG@3UG"QYL,VE;F>I/0:42LPB$Z>%[(_B'_QC:GY%? R('D$1R;J?)"."
M_\;N@ R[I_HLYA@VFYID8&YYJ%$51]D\TT5AV-,LY8K"1$2P<31<\7V8NJ1Q
MZZF\P0;;Z2GHE+B!/ZF.PEUC5433 C>[DM1C0E"AKX /O$?/$8R%D$V*&502
M)*7]Y'ZKC8^C<9$J>#[I&YVC?[? _#$N&^,0&E+!#/VU8-VQIF*OUC3+Y+EB
M2KV-ZL<?C]#?W>V(Q\Q!(*&G].OZA#L/B\$,-"S]XA)8\?X.4XL C.5 CAR.
M!>-<*4NZ3.M%F?/:YK7"1X)-1]A,2J".)'_:A6KWH9%X_'%*O;A4F2B7'DKX
M:E2<YY0!4<":<DH1A.66&64L4FDBA5:)#A"411%]+/Y)):,)@,W*]9.IL[HI
MF=N"E\]XB<5LMLCE!V10/;UA1_B&;G _??E;D.]/GH1"/_+EPS\%<RR"'/AP
MTH3(+VYK1_6V,(GN%4?-#IE,X^@P'VT]WSV!,7<>;&]' Y ,"UT4# IQ"2>!
M(RPRT%O@"7Y6==2(HZ/?D!X>_O29YCW 6XEWZVGTEVF:Y]&O(.C2)<_J +G,
MT^@<O]BZI"_^-YLM/F[!K?Q,\_L"[2NE=>ROS 5'Q1RDF00T!9.JV[%T3Q9G
M?2;P6][A]DHC[\,?R)/?G4; [;[$# ZG(,W_FM3_^1*#[SQXL--RO;_$='P.
M\F#[2\Q". 8>S!8>S/\*D5PKQ_CTV_%M&E9/G)!\BUGU\$^;IH&LD>AL@S]5
MT-"BL\6B ZOB.\=DD1R/!I"X+DM0)7DQHV58Q=@:@=%'(W9</,'&SAY@TR,R
M'U7B[E>:2/$EIK!1O/+Q-QVO?'P7K[Q+%;I&!^B&3!78T_^S4KW$2_[J\#3Z
M=7!R,C@ZBP9'^_#_OT5[KP>';^)H[_CH[.3X;P<GI[]%QR?1_N'IVW=G!]'@
MY/ 4=BYZ=[1_<()?G!R\'IP=[$=GQ_2Z;D>][_35X/7K:/<@^@N^Y0@>V?TM
MIE'@U:=G)^_@D\.C:+"W=WRR/SC:.X"3.'L%+SF(7@]^/8V.7\;TQ^D9O!_^
MBHX.?HU^.S[Y*SUW_.X,AO[+X(1&/CP[C?9>'1_NT8/P\V[G+4P>I@I#W0H/
MZRVGPM\WCX.FV'B12NR63(6_HDL4G5SSHJ)>$C%#].N83!,QS'A.@8'-R[2V
ML*H8*Y?*_MCQ:2!]"0$<,[0E*\D*MDZ32T[TSSB2N,'@\,A%-LRD-I#RR\(O
M[W;H[0P$IM]K+<+,T"T%49!C:B0IO9!Q8 --38=\ENAT?6YRHXJ-G:$YS]0\
MQ(T:V\*O=]?GYJ_/^XVO3RA-.3/80S;RIX(]VK!QG)?[&>O$1MV1Q05*=E1L
M!ZXTPI$=D-+6:EW"97'CZ@[FV2Q9=CNCBX**X*UULHL=EQ&JG&BOFK#*GI-
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MH^\KK/_+[7Q 6-O"V1?>H9"X,(-1,9TF\PKNCOH72X3[%9P!+X*=X^NEL>=
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M=G8V'O[T^*?MG\B_PP&/'/U1.9(]>O]QD#/C $6%Y%"%&9#6P70G?T\!+_Q
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M(;  FF3D<2"[F7U;9,@-/@[M:ZQJME6&^.<)-D^O>X0C*.X0G"F^Y.DE%Q?
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M:5B:'RPJ75.E/(^KPFN<FJ>PR"DQ7>QOQR:;#$VR?:S$C)NJ(\TQD3?-*/H
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M_O[6TY<WR.[!3 J1Y+L<H:/L6HV5QO$H$7^F*M & %,VA!9+5+8@Z3@:O4*
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M?M@[.?B5E(I?SE^_>O'_ 5!+ P04    " "0A;Y:+MN;2I()  "N*0  $0
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MQ=/P>@[6)O%^Y@&F"=02=8%&4ZXU9#-@+0T\IE2^(!#+%?#6K%[+, P%6!(
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MQZK?_<K7/'_TU?-+?C'F3T[%JY99_3W%M0WIT?<MS1<PZ7N:_P-02P,$%
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M_SD99/.8-1ALD7)(KTKF5*)0;GYR 0&PRQJK[#;9P<43P,?D%X7&V=5\SED
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MA^+@$.[UH"]>[^^+_N'CKG@DEO\UP%=_ KT!3N"7Z&>?C>%^N167-R*8[U,
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ME:"\%MOOE]<W7<M/<K/>)/]:X93(+?\%4$L#!!0    ( )"%OEJG$E]V4P<
M ,Q7   5    :6UU>"TR,#(U,#4R.%]P<F4N>&ULS9Q=4]LX%(;O=V;_@S=[
M'4)"OZ"P'4A))U-:6$+;W;WI*+:2:)"EC"23Y-^O9,=I/BSY<.,#%Q"<5Q_O
M<VS9QY9\_F&9\NB)*LVDN&AUCXY;$16Q3)B87K2^C=J7H_YPV(JT(2(A7 IZ
MT1*R]>&OWW^+[,_Y'^UV-&"4)V?11QFWAV(BWT=?24K/HD]44$6,5.^C[X1G
M;HL<,$Y5U)?IG%-#[1=%PV?1FZ/C<=1N ZK]3D4BU;?[X:;:F3%S?=;I+!:+
M(R&?R$*J1WT4RQ16X<@0D^E-;<?+X_5/4?R<,_%XYGZ-B::1Q27TV5*SBY9K
M=]WLXN1(JFFG=WS<[?SSY684SVA*VDPX;#%ME:5<+57ENJ>GIYW\VU)ZH%R.
M%2_;..F4W=G4;+]E ?U63S0[TWGW;F1,3![UVF8BK\+]URYE;;>IW>VU3[I'
M2YVT2O@Y024YO:>3R/VUT=NTRM)LZ8+5<5]T^M+NB[:7>9&9HI.+EA/8FGNO
MCU_WWKEZ_]P1F=7<[I.:N5VJ%75VVIPKJJDPN<T;NV&G"%T:NRO1I*S(M0_I
ME6'&"=<[23=JNSTJ2VT[]F.A7'>B[ :7\4[+W)&7>S;+O3CGJVE\-)5/G80R
MR[GWRGUP#%[E_NT_/_.&+L?:*!*;LB9.QI3G]?^TFCU)IX%>E20>;(W5G=I5
M[/=I.V"7*HZD2JBRK,NZB(IWPG2X0ZX5G3E1MJ)V/&-\$^&)DJF/SIJ$]'1T
M&Y1MHAF:E[;]Q/5AP,FT&N>>!,BSBP&TT@T6T8]4QXK-'9<:L#M*(-\>*M\*
M;PUC+H^=>SIEKK^N*^XT2]W&\+C@*0($?X(Y4@3=(D7@4HB,\'LZEZH&_*X2
MR/L5)N\J;TB8_\Z(,E3Q%83T@1@(^S4F;(]#)-X/B@C-'!\(\$,UD/@;U L/
MCT<DY*,9Y=QE;D2 ]O(J/1#[6TSL?I\O /SUDSN_VU,+G/U6$2#^=R\%_X%;
MI C<4<5D8D_I"L#^0 RD?HI)W>,0E?>U2*"T-U)P_H,/>\\>$NH!TS'A18\&
M=IL.XZZ00Y&CY)RU-E&Q_TN) D/?$D.1HZ2A-18;!M[/E-KI3'!4\:NAR%$2
MT#J3#3._%H:9E;O5_S5+Q[]NG.ZR/E1!&:,DG3Y3*&S+.PW"N$<8(;[[2BAC
ME%PS9 Z%<]_Z480/14*7G^DJ!/I "B6-DF,&[:&@OE,L)6HU8G']H'&HA<)&
MR2S#!E%H/Y#E,+&NV(05#P'KH7N+0-FCI)4@NR@A&(I8JKG<NEW<EYD]'E=]
MF02'])J"T'"@Y)O/L(X2E,LDL;CT^L\-$[0;"D6E'/R,""\  9LO!'OO>=A[
M<.PH>6BMS1>"_>1YV$_@V%%RT5J;F-C[]N.M>I +SQ-HKQB*'"47K;&("3P_
MT]RJ.R6?6#$7JH[Z00DH>L04-6P6=8<O3O*0O;U40GDCIJO5YC YWTEM"/^/
MS>NN)*OU4.:(B6O(:-,W&(NXNYL6OJE$>Q(H7Y1<M=).TTA=A!4E_MUW5P$%
MBI* 5IEIF.>-=,\^9E($[\<>JJ!<43))GZFF!UXWB5A[#_VMK\$SV%"&U7T;
M#6/\H9BQ/>C+-,W$^AZ-YZF81PK%BY+^!>TUC'HD.8N986+ZQ5XA*D9X-><J
M'10R2K+G-]8PX3M%7:2IO>S.YW&Y50;J=C+QC;PA/90X2JY7;Q27_%#KC*KG
M\J\H!8T"2MH'-=WT.$/CS Y[JVYO_.!6S'A&F0,5E#5*RN<SU3#;K_)!$;=$
M;[1*QY+[EX=4"J&$41*\@+6&(>_THQKOG@0*%B6SJ[2#-"9<+^,9$5/JG[U0
MK80"1LGT0N;0QMXI:.R=/G/L1<GX?*:0V!9SP^T1=3OF;$K\*\F"!<#K;#")
M!ZPVO7XO7_+C5F^K-._'P'ZHQNZ10H'C+)$,V6L:=98P0Y.B2P,FB(AM2K59
MU^;)SNM+00. LX82:!KE]OX/ROEG(1=B1(F6@B;%I7[H#K^W"#0*B,\0:^RB
MA."[Y)FEI/*)H,IS#'BD4.2(SPX]]G#F7A:3FC?GGN(U'2'BOA)0\(@/$<-F
MD>:G&>KZS)[H1V+(NH<A_KX24/Z(#Q3#9M'FSZN^/?%,9?B9^9X02AMQ*FRE
M-13(HY1P?I5I)J@.CBU[0BADQ#FOE=90(%^G5$WMH/9)R869K==VAF!["D"A
M(\YL#5K%@;_\M8Z\6/\6)%^A!K^= !&[UR36:S?BV$VD*,[D(B'*0SVDAW)'
M75CI-]HP^5LSHVK[^BGOS-#F;:%)#_6EH%% 25>AIG'.K5LK^8.GUAT=E#=B
M8EIE#&?-5#;F+!YP28+7Y3LR*%_$++3"%@K>*R(>538W\>I.R9A2]_A$;XXV
M0$($K  :$L3\]%DH<&X7R#1UBXED_#B:6=/Z-C/Y2TMM_X(W#8+EH*'!7,0)
M,(YT%:1_+?2BR=7JGDZH<M,4'NC27-F&'L,718#BT/B@OE$(C*$B3.>= U\W
M=H-[+VWQC?OEWKUJM_P/4$L! A0#%     @ D(6^6LN]3'V5'0  QI   !T
M             ( !     &4V-C0U-3%?.&LM:6UM=6YI8W!R:6-I;F<N:'1M
M4$L! A0#%     @ D(6^6J>#L%\,M@  2"($ !$              ( !T!T
M &4V-C0U-3%?97@Q+3$N:'1M4$L! A0#%     @ D(6^6N K_CG)1@  @G<!
M !$              ( !"]0  &4V-C0U-3%?97@T+3$N:'1M4$L! A0#%
M  @ D(6^6F&1SXSP20  BZ(! !$              ( ! QL! &4V-C0U-3%?
M97@T+3(N:'1M4$L! A0#%     @ D(6^6HL0PPZ]3P  &L$! !$
M     ( !(F4! &4V-C0U-3%?97@T+3,N:'1M4$L! A0#%     @ D(6^6B[;
MFTJ2"0  KBD  !$              ( !#K4! &4V-C0U-3%?97@U+3$N:'1M
M4$L! A0#%     @ D(6^6CPZR$BS$   L3@  !(              ( !S[X!
M &4V-C0U-3%?97@Y.2TQ+FAT;5!+ 0(4 Q0    ( )"%OEK_EB/4)P,  -8+
M   1              "  ;+/ 0!I;75X+3(P,C4P-3(X+GAS9%!+ 0(4 Q0
M   ( )"%OEKEB#\M_0H  '^&   5              "  0C3 0!I;75X+3(P
M,C4P-3(X7VQA8BYX;6Q02P$"% ,4    " "0A;Y:IQ)?=E,'  #,5P  %0
M            @ $XW@$ :6UU>"TR,#(U,#4R.%]P<F4N>&UL4$L%!@     *
-  H BP(  +[E 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>e664551_8k-immunicpricing_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imux-20250528.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-28" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-28" id="Fact000004">0001280776</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-28" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-28" id="Fact000010">2025-05-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-28" id="Fact000011">IMMUNIC, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-28" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-28" id="Fact000013">001-36201</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-28" id="Fact000014">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-28" id="Fact000015">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-28" id="Fact000016">&#160;Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-28" id="Fact000017">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-28" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-28" id="Fact000019">10036</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="AsOf2025-05-28" id="Fact000020">US</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2025-05-28" id="Fact000021">(332)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-28" id="Fact000022">255-9818</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-05-28" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-28" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-28" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-28" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-05-28" id="Fact000027">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-28" id="Fact000028">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-28" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-28" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
